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 I 
Zusammenfassung 
 
Das Kaposi-Sarkom assoziierte Herpesvirus (KSHV oder auch humanes Herpesvirus 8, HHV-
8) ist kausal an der Entstehung des Kaposi-Sarkoms (KS) sowie zwei menschlicher B-Zell-
Lymphome beteiligt. Es gibt zahlreiche Hinweise darauf, dass neben der latenten 
Virusinfektion auch der lytische, produktive Replikationszyklus von KSHV bei der 
Onkogenese eine bedeutende Rolle spielt. Eine Schlüsselfunktion beim Übergang vom 
latenten zum lytischen Replikationszyklus besitzt das sehr frühe (immediate-early) virale 
Protein RTA, welches die Expression weiterer Virusproteine aktiviert und in der Lage ist den 
vollständigen produktiven Lebenszyklus von KSHV auszulösen. In der vorliegenden Arbeit 
wurde untersucht, welche intrazellulären Signaltransduktionswege unterhalb von RTA 
entscheidend zum Fortschreiten des lytischen Zyklus beitragen. Es konnte eine verstärkte 
Aktivierung von ERK2 und Akt während der frühen und späten Phase der lytischen 
Replikation festgestellt werden. Eine Hemmung der MEK/ERK Signalkaskade durch 
chemische Inhibitoren führte zu einer stark reduzierten Expression später Virusproteine und 
erheblich verminderter Virusproduktion in verschiedenen Zelllinien.  
Um herauszufinden welche Virusproteine an der Aktivierung von ERK und Akt und/oder dem 
stufenweisen Fortschreiten des produktiven Vermehrungszyklus beteiligt sind, wurde die 
Synthese mehrerer aussichtsreicher viraler Proteine mittels inhibitorischer RNA unterdrückt. 
Es zeigte sich, dass ein Mangel an KSHV-eigenem K1-Protein die Bildung infektiöser 
Viruspartikel erheblich verringerte. Untersuchungen mit einer K1-Deletionsmutante eines 
rekombinanten KSHV (BAC36 ΔK1) bestätigten die verstärkende Wirkung von K1 auf den 
produktiven Lebenszyklus von KSHV. In HEK293 Zellen, welche anstelle mit BAC36 
Wildtyp mit BAC36 ΔK1 transfiziert worden waren, wurden die viralen Gene K8/b-ZIP, vIL-
6 und vCCL-1 nicht oder nur in verringertem Ausmaß exprimiert. Die Virusproduktion war 
stark herabgesetzt und auch die Menge an RTA-Protein war deutlich reduziert. Dies ging 
einher mit einer fehlenden oder stark verringerten Aktivierung von ERK und Akt. 
Zusammenfassend weisen diese Ergebnisse auf eine wichtige Rolle des K1-Proteins während 
des lytischen Replikationszyklus von KSHV hin. 
 
 
Schlagwörter: KSHV, Signaltransduktionswege, lytischer Zyklus
 II 
Summary 
 
Lytic (productive) replication of the Kaposi sarcoma herpesvirus (KSHV) promotes 
progression of Kaposi sarcoma (KS), a common malignancy in sub-Saharan Africa and 
patients with AIDS worldwide. Activation of the KSHV lytic pathway is initiated by the viral 
immediate-early protein RTA, which activates the expression of several viral early genes. I 
analysed which signalling pathways and viral proteins are important for the progression of the 
KSHV lytic cycle downstream of RTA. I observed that ERK2 and Akt activation increased 
during the viral lytic cycle following RTA expression and that chemical inhibition of the ERK 
pathway reduced late viral protein expression and virus production in various cell lines. These 
observations suggest an important role for MEK/ERK signalling cascade in the progression of 
the KSHV lytic life cycle. 
In order to identify viral lytic cycle proteins required for the activation of ERK2 and Akt, 
and/or the progression of the lytic cycle, I used RNA interference to down-regulate the 
expression of individual candidate proteins. Knockdown of the KSHV K1 protein 
significantly reduced the production of infectious virus particles in the supernatant of 
reactivated Vero rKSHV.219 and EAhy rKSHV.219 cells. To confirm these results, I deleted 
the K1 open reading frame from a recombinant KSHV genome (BAC36). In HEK293 cells 
transfected with BAC36 ΔK1, expression of the early viral genes K8/b-ZIP, vIL-6, vCCL-1 
was lacking or strongly reduced, protein levels of RTA were diminished and significantly less 
viral progeny was produced. This was accompanied by a lacking activation of ERK and Akt 
in KSHVΔK1 containing cells. These results suggest an essential role of the K1 protein 
during the early stage of the KSHV lytic (productive) replication cycle. 
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Abbreviations used: 
 
Ab, antibody; 
AP-1, activator protein 1;  
cAMP, cyclic adenosine monophosphate; 
BAC, bacterial artificial chromosome; 
CCR, CC-motif chemokine receptor;  
Cox-2, cyclooxygenase-2;  
CREB, cAMP-response element binding protein;  
CBP, CREB binding protein; 
Dscr-1, Down syndrome critical region gene 1;  
EBV, Epstein Barr virus; 
ERK, extracellular signal-regulated kinase;  
FGF-2, basic fibroblast growth factor;  
FKHR, member of the FoxO subfamily of forkhead transcription factors (also known as 
FoxO1a); 
GM-CSF, granulocyte-macrophage colony-stimulating factor;  
Gro-α, growth regulated oncogene alpha;  
GSK3, glycogen synthase kinase 3;  
HHV, human herpesvirus; 
HIF1α, hypoxia induced factor 1 alpha;  
hIL-6, human interleukine 6;  
HSV, herpesvirus saimiri; 
IKK, IkappaB kinase; 
IL, interleukine;  
ITAM, immunoreceptor tyrosine-based activation motif; 
JAK, janus kinase;  
JNK, c-Jun N-terminal kinase;  
KSHV, Kaposi sarcoma herpesvirus; 
MAPK, mitogen activated protein kinase;  
Mdm2, murine double minute 2; 
MKK, MAPK kinase (also called MEK);  
MEF-2, myocyte enhancer factor 2;  
MIP-1, macrophage inflammatory protein 1;  
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MMP, matrix metalloproteinase;  
MSK1, mitogen- and stress-activated protein kinase 1;  
mTOR, mammalian target of rapamycin;  
MSK1/2, mitogen- and stress-activated protein kinase 1/2;  
NFAT, nuclear factor of activated T cells;  
NF-κB, nuclear factor kappa B;  
Oct-2, octamer binding protein 2;  
p70RSK/p90RSK, approximately 70/90-kDa ribosomal protein S6 kinase;  
PDK1/2, PI3K-dependent kinase 1/2; 
PI3K, phosphatidylinositol 3-kinase;  
PKA, protein kinase A (also known as cAMP-dependent kinase); 
PKB, protein kinase B (also known as Akt);  
PKC, protein kinase C;  
PLCγ, phospholipase C-gamma;  
PTEN, phosphatase and tensin homologue;  
RANTES, regulated upon activation, normal T cell expressed and secreted (also known as 
CCL5);  
RasGAP, Ras GTPase activating protein;  
SH2, src homology 2;  
SP-1, specificity protein 1 (transcription factor); 
STAT, signal transducers and activators of transcription;  
Syk, spleen tyrosine kinase;  
TAK1, transforming growth factor-β-activated protein kinase 1;  
VEGF, vascular endothelial growth factor. 
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1 Introduction 
 
1.1 The family Herpesviridae 
 
Herpesviruses are widely distributed in nature and are prevalent in most species 
throughout the animal kingdom. They are highly adapted to their hosts and are thought to 
have coevolved with their hosts for millions of years. Up to date, more than 130 herpesviruses 
have been described, eight of which have been isolated from humans (Wang et al. 2007a).  
All herpesviruses have a characteristic virion morphology, which consists of the 
envelope, tegument, capsid and core (Mettenleiter 2002). The size of the virion varies from 
120 to nearly 300 nm. The viral genomes consist of linear, double-stranded DNA molecules 
that range in size from about 125 to 240 kbp and in the nucleotide composition from 32 to 
75% G+C, depending on the virus species (Honess 1984), and the most extensively 
characterized contain from about 70 to 165 genes. Replication of the viral DNA and capsid 
assembly occurs in the nucleus. All herpesviruses encode a variety of enzymes involved in 
nucleic acid metabolism, DNA synthesis and protein processing. Herpesviruses are able to 
establish a latent infection in their natural hosts. In the latent stage, viral gene expression is 
heavily restricted to a small number of genes (latency associated genes); the viral DNA is 
retained as circular episomes in the nucleus and no progeny virus is produced. Reactivation 
from latency induces expression of a large number of viral (lytic) genes, viral DNA 
replication and production of new infectious progeny, in the course of which the host cell 
dies. 
On the basis of their biological characteristics and genome sequences, human 
herpesviruses (HHV-1 to -8) are classified into three subfamilies: Alpha-, Beta- and 
Gammaherpesvirinae (McGeoch et al. 1995).  
• α-herpesvirinae, which include Simplexvirus herpes simplex virus 1 and 2 (HSV-1 and -
2 or HHV-1 and -2) and Varicellovirus Varizella zoster virus (VZV or HHV-3), have a 
wide host cell range, multiply efficiently and rapidly spread in culture. Primarily, but 
not exclusively, they establish latency in sensory ganglia.  
• β-herpesvirinae show a more restricted host range and grow slowly in cell culture. They 
establish latent infection in lymphocytes, secretory glands and other tissue. 
Representatives of this subfamily are the genera Cytomegalovirus (HCMV or HHV-5) 
and Roseolovirus (HHV-6 and -7).  
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• γ-herpesvirinae are lymphotropic but some are also capable of infecting epithelial, 
eindothelial and/or fibroblast cells. The subfamily contains two genera: 
Lymphocryptovirus (γ-1) (Epstein-Barr virus, EBV or HHV-4) and Rhadinovirus (γ-2) 
(Kaposi sarcoma herpesvirus, KSHV or HHV-8). A striking characteristic of members 
of the γ-herpesvirinae, including EBV and KSHV, is their strong association with 
neoplastic disease. Both EBV and KSHV are associated with different types of cancer 
and also related with lymphoproliferative diseases of B and/or T cells (Damania 2004). 
 
1.2 Kaposi sarcoma herpesvirus (KSHV) 
 
Kaposi sarcoma herpesvirus was discovered in Kaposi sarcoma (KS) lesions in 1994 
(Chang et al. 1994), and soon epidemiologic evidence accumulated showing that KSHV (or 
human herpesvirus 8, HHV-8) is the infectious cause of KS. Before the early 1980s, KS was a 
rare disease restricted to East and Central Africa, the Mediterranean and Eastern European 
regions. However, in the course of the then-emerging HIV-pandemic, KS has evolved into the 
most common malignancy in some African countries, and in patients with AIDS in other parts 
of the world (Dedicoat and Newton 2003). Today, KS is the most common cancer in sub-
Saharan Africa, and poses an important health problem in HIV-infected and uninfected 
individuals worldwide (Orem et al. 2004; Parkin 2006; Greene et al. 2007). In addition to KS, 
KSHV is associated with primary effusion lymphoma (PEL) (Cesarman et al. 1995), a rare 
form of non-Hodgkin’s lymphoma mostly seen in AIDS patients, and the plasma cell variant 
of multicentric Castleman’s disease (MCD) (Soulier et al. 1995).  
Like other herpesviruses, KSHV is able to establish a lifelong infection in its host. The 
viral life cycle is divided into two phases: latent and lytic (Dourmishev et al. 2003). During 
latency, the KSHV genome persists as a circular DNA episome, and protein expression is 
tightly restricted. The lytic (productive) phase is characterized by wide-spread gene 
activation, classically in an ordered cascade of sequential induction, in the course of which 
new infectious progeny virus is produced. In KSHV associated tumours, the vast majority of 
cells are latently infected by KSHV. However, a small percentage of cells (usually in the 
order of 1-5%) spontaneously switch into the lytic replication cycle (Zhong et al. 1996; 
Staskus et al. 1997; Katano et al. 2000; Parravicini et al. 2000). 
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1.2.1 Diseases associated with KSHV 
 
Kaposi sarcoma 
 
Kaposi sarcoma (KS) is an unusual neoplasm which was first described in Eastern 
Europe by the dermatologist Moritz Kaposi in 1872 (Kaposi 1872) but later recognized to be 
endemic in Mediterranian countries and sub-Saharan Africa. The classic form of KS is a rare, 
benign disease seen in elderly males and usually only affecting the skin. Endemic KS can be 
more widely disseminated and occurs in East and Central Africa. An aggressive form of 
endemic KS (also known as lymphadenopathic form) is found in young children in endemic 
regions with high fatality rates (Ziegler and Katongole-Mbidde 1996). AIDS-KS is the most 
common and aggressive variant of KS with the most lymph node/visceral spreading amongst 
all KS subtypes (Mitsuyasu 1987; Friedman-Kien and Saltzman 1990). Another form of KS, 
known as iatrogenic/post-transplant KS, is seen in patients under immunosuppressive therapy 
after solid organ transplantation (Penn 1988).  
Unlike most classical cancers, which arise from the clonal outgrowth of a single cell 
type, KS lesions are histologically complex (Herndier and Ganem 2001). The principal 
proliferating cell in advanced lesions is the so-called spindle cell, named for its dramatically 
elongated morphology. The cellular origin and nature of KS spindle cells have long been 
debated. Evidence indicates a lymphatic endothelial cell origin for KS spindle cells. However, 
recently it has been shown that KSHV can reprogram endothelial cells to express lymphatic 
endothelial markers, which complicates attempts to discern the lineage of these KSHV 
infected cells (Hong et al. 2004; Wang et al. 2004a). All KS lesions also contain significant 
numbers of inflammatory cells (B- and T-cells, plasma cells, and monocytes) and a profusion 
of aberrant, slit-like neovascular spaces. Hence, KS appears to be composed of three parallel 
processes: a proliferative component (involving chiefly spindle cells), an inflammatory 
component, and an angiogenic component. It is likely that these processes are interdependent 
and perhaps mutually reinforcing (Ganem 2006). 
KSHV DNA is present in all KS tumours, irrespectively of clinical type. Viral infection 
selectively targets spindle cells (Boshoff et al. 1995; Staskus et al. 1997; Dupin et al. 1999), 
with little or no infection of other cell types. In situ hybridization studies have shown that 
most KS spindle cells are latently infected; only a small subpopulation of spindle cells (1% - 
3%) display lytic replicative markers (Staskus et al. 1997; Sturzl et al. 1997; Dupin et al. 
1999; Katano et al. 2000; Dittmer 2003). Although latent KSHV infection certainly plays a 
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role in the development of KS and KSHV-associated B-cell lymphomas (Dupin et al. 1999; 
Parravicini et al. 2000), there is also a role for lytic replication. This may involve the 
propagation of infectious virus to new target cells, as well as autocrine and paracrine effects 
induced directly by KSHV-encoded cytokines and regulatory molecules, or indirectly through 
the induction of cellular cytokines (Martin et al. 1999; Goudsmit et al. 2000; Grundhoff and 
Ganem 2004; Schulz 2006). 
 
Primary effusion lymphoma 
 
Primary effusion lymphoma (PEL), sometimes referred to as body cavity-based 
lymphoma (BCBL), is a unique form of non-Hodgkin’s lymphoma found more commonly in 
immunocompromised AIDS patients. PEL is derived from clonally expanded malignant B-
cells and presents as a lymphomatous effusion tumour contained in various body cavities such 
as the pericardium, pleura, and peritoneum. PEL is aggressive and rapidly progressing, and 
rapidly fatal. Unlike KS tumours, which harbour generally less than two viral genome copies 
per cell (this is due to the mixed cellularity of KS lesions – see above – with only endothelial 
and spindle cells being infected by KSHV), KSHV genomes are found in PEL cells at a high 
copy number (50-150 viral genomes per infected cell) (Cesarman et al. 1995; Renne et al. 
1996a; Staudt et al. 2004). In PEL cells, KSHV gene expression is restricted largely to the 
latency locus that encodes LANA-1, v-cyclin and vFLIP, and the kaposin locus. Additionally, 
LANA-2/vIRF-3 expression has been observed in some PEL cell lines (Rivas et al. 2001). 
Lytic gene expression has been detected in a small subset of cells: the viral interleukin 6 
homologue (vIL-6) was detected in two to five percent of tumour cells, whereas other lytic 
transcripts such as K8/bZIP or the late lytic glycoprotein K8.1 were detected in less than one 
percent of PEL cells (Katano et al. 2000; Parravicini et al. 2000). 
 
Multicentric Castleman’s disease 
 
MCD is a lymphoproliferative disorder, characterized by the proliferation of polyclonal 
B-cells. Its plasmablastic variant is highly associated with KSHV; however, the hyaline 
variant of MCD is not. In MCD lesions, the ratio of lytically infected to latently infected cells 
is much greater than in PEL or KS, suggesting that the pathogenic role of KSHV in these 
different diseases might be attributable to different gene expression programs of the virus 
(Dourmishev et al. 2003). Dysregulated IL-6 levels, probably induced by KSHV proteins such 
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as the virally encoded IL-6 (vIL-6) (Parravicini et al. 1997), play a role in the clinico-
pathophysiology of MCD.  
 
1.2.2 Epidemiology 
 
In regions in the world where KS is not endemic, including Northern, Western and 
Central Europe, USA, Canada, as well as Asian countries, the seroprevalence of KSHV is low 
with estimates of < 5% (Bagni and Whitby 2009). The prevalence of KSHV is elevated in 
Mediterranean countries but varies geographically and thereby mirrors the incidence of classic 
KS in different geographical regions. The highest prevalence of KSHV in the Mediterranean 
area is observed in Southern Italy, particularly the Islands of Sicily and Sardinia (24-35%) 
(Bagni and Whitby 2009). In other Mediterranean regions, seropositivity for the virus ranges 
from 8% to 25%. Elevated KSHV prevalence may also be present in parts of Asia (Dilnur et 
al. 2001; Chen et al. 2004). However, by far the highest prevalence of KSHV is found in most 
parts of sub-Saharan Africa where 40-50% of the general population carries KSHV 
antibodies. Higher prevalence estimates are reported for Congo (82%), Botswana (76%), 
Malawi (67%), and the West African country Gambia (75%) (Ariyoshi et al. 1998; Engels et 
al. 2000; DeSantis et al. 2002; Whitby et al. 2004). Lower estimates are reported for South 
Africa (30%) and some West African countries (≤ 25%) (Sitas et al. 1999; Dedicoat et al. 
2004; Volpi et al. 2004; Collenberg et al. 2006; Malope et al. 2007).  
 
1.2.4 Transmission 
 
In KS endemic regions, infection with KSHV occurs in childhood, and prevalence 
increases with age (Mayama et al. 1998; Andreoni et al. 1999; Gessain et al. 1999; 
Plancoulaine et al. 2000; Whitby et al. 2000). Evidence from numerous studies suggests that 
KSHV transmission occurs from mother to child or from sibling to sibling, most likely via 
infected saliva, and it has been shown that mothers with high levels of detectable KSHV DNA 
in saliva are more likely to have KSHV-infected children (Lyall et al. 1999; Plancoulaine et 
al. 2000; Mantina et al. 2001; Andreoni et al. 2002; Mbulaiteye et al. 2003; Dedicoat et al. 
2004; Plancoulaine et al. 2004). Vertical transmission from mother to child might also, albeit 
very rarely, occur in endemic countries (Gutierrez-Ortega et al. 1989; Mantina et al. 2001; 
Brayfield et al. 2003). 
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Horizontal transmission by saliva is believed to be the most common route of infection 
also among high-risk groups in Western countries since viral loads found in vaginal, seminal 
and prostatic secretions are much lower than in saliva (Pauk et al. 2000; Martin 2003; Widmer 
et al. 2006). However, sexual, blood and transplant-related transmission remain a significant 
concern worldwide (Bagni and Whitby 2009). 
 
1.2.5 Tropism of KSHV and virus entry 
 
In vivo, KSHV DNA and transcripts have been detected in human B-cells, 
macrophages, keratinocytes, endothelial cells and epithelial cells. A number of PEL cells have 
been isolated and grown in culture, and have been the main subject to study the KSHV life 
cycle. In PEL cells, the switch from latency to lytic replication can be induced by various 
chemicals such as phorbol esters and sodium butyrate (see below). Virus from induced PEL 
cell lines has been used to infect many cell types in culture, including epithelial and 
endothelial cells, fibroblasts, keratinocytes, B- and CD34+ stem cell precursors of dendritic 
cells. KSHV also infects numerous animal cells such as monkey (Vero, CV-1), hamster 
(BHK-21, CHO) and mouse (Du17, 3T3) cells (Renne et al. 1998; Moses et al. 1999; 
Blackbourn et al. 2000; Akula et al. 2001b; Ciufo et al. 2001; Vieira et al. 2001; Dezube et al. 
2002; Bechtel et al. 2003; Naranatt et al. 2003; Gasperini et al. 2005; Wu et al. 2006; 
Rappocciolo et al. 2008). The broad in vitro cellular tropism of KSHV may be due in part to 
its interaction with the ubiquitous cell surface heparin sulphate (HS-)-like molecule via the 
viral envelope glycoproteins gpK8.1A and glycoprotein B (gB) (Akula et al. 2001a; Akula et 
al. 2001b; Birkmann et al. 2001; Wang et al. 2001a). Subsequently, gB binds via its Arginine-
Glycine-Aspartic Acid (RGD) motif to the α3β1 integrin, which serves as one of the cellular 
receptors for KSHV entry into target cells. Interaction of gB with α3β1 integrin leads to the 
autophosphorylation of focal adhesion kinase (FAK) and subsequent activation of members of 
Src family kinases, phosphatidylinositol-3-kinase (PI3K) and RhoGTPases (Akula et al. 2002; 
Naranatt et al. 2003; Sharma-Walia et al. 2004; Veettil et al. 2006). The induction of 
intracellular signalling pathways may facilitate virus entry through induction of cytoskeletal 
rearrangements and endocytosis and, in the following, may support a suitable environment for 
successful infection of the host cell (Naranatt et al. 2003; Naranatt et al. 2004; Sharma-Walia 
et al. 2004). It has been shown that KSHV infects fibroblasts, epithelial and endothelial cells 
via endocytosis (Akula et al. 2003; Inoue et al. 2003; Naranatt et al. 2005; Greene and Gao 
2009). In fibroblast cells as well as endothelial cells endocytosis was shown to be clathrin-
1 Introduction 
 7
dependent. However, in fibroblast cells endocytosis was suggested to predominantly depend 
on microtubule rearrangements (Naranatt et al. 2005; Raghu et al. 2007), while in endothelial 
cells the process may be primarily regulated through actin dynamics (Greene and Gao 2009).  
A recent study reported that DC-SIGN, a C-type lectin first identified on dendritic cells 
(DC), may serve as an entry receptor for KSHV on DC and macrophages (Rappocciolo et al. 
2006). B lymphocytes from peripheral blood and tonsils were found to express DC-SIGN and 
this expression significantly increased after B-cell activation mediated by CD40 ligand 
(CD40L) and interleukin 4 (IL-4) (Rappocciolo et al. 2006). It was demonstrated that 
activated blood and tonsillar B-cells expressing DC-SIGN can be productively infected with 
KSHV, as determined by an increase in the level of viral DNA, the expression of lytic and 
latency-associated viral proteins, and the production of infectious virus. Furthermore, 
infection could be blocked by the pretreatment of the B-cells with anti-DC-SIGN monoclonal 
antibody (MAb) (Rappocciolo et al. 2008). 
In most infected cell lines, KSHV quickly establishes a latent infection as defined by the 
expression of the latency associated genes and the absence of productive lytic replication. 
Detection of LANA (Orf73) expression two days after infection, has led to the notion that the 
establishment of latency is the default pathway of infection (Schulz et al. 2002; Bechtel et al. 
2003). 
 
1.2.6 Organization and expression of the KSHV genome  
 
Genome structure 
 
KSHV has a double-stranded DNA genome and its size ranges from 165 to 170 kb 
(Renne et al. 1996a; Neipel et al. 1998). The long unique region (LUR) is about 138 to 140.5 
kb in length, contains all of the KSHV open reading frames (orfs) and is flanked by terminal 
repeat (TR) sequences at both ends of the linear viral genome (Figure 2). Each TR is 801 bp 
in length and highly GC-rich (Russo et al. 1996). The number of TRs varies among KSHV 
isolates, ranging from 16 to 75 (Duprez et al. 2007), which accounts for the variations in the 
genome size of KSHV isolates. The KSHV genome shows high similarity to retroperitoneal 
fibromatosis-asociated herpesvirus (RFHV) and rhesus monkey rhadinovirus (RRV) among 
the rhadinovirus genus (O'Connor and Kedes 2007) and shares a somewhat co-linear genetic 
organization with herpesvirus saimiri (HVS). KSHV encodes for over 86 orfs which have 
been given serial numbers from left to right. Although many of the KSHV genes are 
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conserved among the family of herpesviridae, the virus contains a significant number of 
unique orf’s not found in other herpesviruses. These KSHV-specific orfs are named K1 to 
K15, based on their relative locations - from left to right – in the viral genome (Russo et al. 
1996) (see also Figure 1). Moreover, KSHV contains a large number of accessory genes 
including many homologues of cellular proteins. These cellular homologues are believed to be 
captured by the virus from the host cellular genome and are mainly implicated in signal 
transduction, cell cycle control and apoptosis (Neipel et al. 1997; Nicholas et al. 1997). 
 
 
 
Viral gene expression 
 
KSHV genes are broadly classified as latent or lytic genes, reflecting latent and lytic 
replication phases of the virus, respectively. Based on the temporal onset of expression and 
their response to chemical inducers and inhibitors, lytic genes are further divided into 
immediate-early, early and late genes.  
Figure 1: Schematic representation of the KSHV genome. The long unique region comprises nearly 90 
open reading frames (orfs) and is flanked by terminal repeat sequences. Conserved gene blocks within the 
herpesvirus family are labelled by roman numbers (I-IV’’) from left to right. Genes specific to KSHV carry the 
prefix K. Kinetic classes of gene expression are indicated by colours as depicted at the bottom of the figure. 
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KSHV gene expression has been extensively studied by Northern blot analysis and later 
by cDNA arrays and real-time quantitative PCR covering the entire viral genome (Sarid et al. 
1998; Sun et al. 1999; Jenner et al. 2001; Paulose-Murphy et al. 2001; Fakhari and Dittmer 
2002; Dittmer 2003; Nakamura et al. 2003; Lu et al. 2004; Yoo et al. 2005).  
 
Latent gene expression and the major latent protein LANA-1 
 
Viral proteins expressed during latent infection include the latency-associated nuclear 
antigen (LANA-1, encoded by orf73), a viral homologue of a D-type cyclin (vCyc, encoded 
by orf72), a viral homologue of a FLICE-inhibitory protein (vFLIP or K13), kaposin (K12) 
and one of the viral interferon-regulatory factors (vIRFs) LANA-2 (K10.1 or IRF-3) (Sadler 
et al. 1999; Katano et al. 2000; Parravicini et al. 2000; Fakhari and Dittmer 2002; Dittmer 
2003). Except for LANA-2, which is B-cell specific, all other latent genes have been detected 
in all KSHV-associated tumors and experimental models of KSHV latency (Rivas et al. 2001; 
Dittmer 2003). Interestingly, another vIRF, vIRF-1/K9, was found to be expressed during 
latency in primary KS lesions and its transcription profile clustered with LANA-1, vFLIP and 
vCyc (Dittmer 2003). These findings suggests that different vIRFs are important during 
latency in different target cells during latency and/or other stages of viral infection and point 
to an essential role for vIRFs in KSHV pathogenesis. In addition to protein-encoding genes, 
12 KSHV-encoded microRNAs (miRNAs) have been identified in the viral latency region, 
and were shown to be expressed during latent infection in B-cells (Cai et al. 2005; Pfeffer et 
al. 2005; Samols et al. 2005; Grundhoff et al. 2006).  
LANA-1 can be detected in all latently infected cells, and LANA-specific antibodies 
have been found in most infected individuals (Dupin et al. 1999; Zhu et al. 1999). Therefore, 
it is the most widely used marker for KSHV infection (Bagni and Whitby 2009). LANA-1 is a 
large (222-234 kDa), nuclear protein, which has an important function in the establishment 
and maintenance of the viral episome in the nucleus and is required for its replication (Verma 
et al. 2007). The protein tethers the viral episomal DNA to the host chromosomes by directly 
binding to two adjacent 16-bp motifs within the TR region of the KSHV genome through its 
C terminus and to cellular nucleosomes via its N terminus. Tethering to the host chromosomes 
facilitates efficient segregation of the viral episomes during host cell devision (Kedes et al. 
1997; Ballestas et al. 1999; Cotter and Robertson 1999; Hu et al. 2002). Disruptions of 
LANA-1 expression lead to loss of KSHV episomes from latently infected cells, supporting 
its role in persistence of the viral DNA (Ye et al. 2004; Kelley-Clarke et al. 2009). However, 
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viral latent episomes are rapidly lost from infected culture cells in the absence of genetic 
selection (Grundhoff and Ganem 2004). This also applies to short-term cultures of cells 
explanted from KS lesions (Aluigi et al. 1996; Lebbe et al. 1997). Thus, LANA-1 is necessary 
but may not always be sufficient for viral episomal persistence.  
In addition to its role in episome maintenance, LANA-1 acts as a transcriptional 
repressor/activator of both viral and cellular gene expression (Renne et al. 2001; An et al. 
2005; Verma et al. 2006). For example, LANA-1 upregulates expression from its own 
promoter while blocking the expression of RTA protein, which is critical for the switch from 
latency to lytic replication, and thus helps in maintaining viral latency. Furthermore, LANA-1 
can perturb several cellular pathways to contribute to viral oncogenesis. In transfected cells, 
the protein binds to and inhibits p53 function, conferring increased resistance to p53-
dependent apoptosis (Friborg et al. 1999). LANA-1 can also inactivate the tumor suppressor 
retinoblastoma (Rb) gene and release E2F transactivator which induces cells to transit through 
the G1/S cell cycle checkpoint (Radkov et al. 2000). Another potential role for LANA-1 in 
tumorigenesis derives from its interaction with glycogen synthase kinase (GSK)-3β, which 
prevents GSK-3β from complexing with, and degrading, β-catenin in the cytoplasm, and 
ultimately leads to the activation of genes implicated in cell cycle regulation and oncogenesis 
(e.g. cyclin D, c-myc) (Fujimuro and Hayward 2003; Fujimuro et al. 2003). Finally, LANA-1 
was demonstrated to upregulate human telomerase reverse transcriptase (hTERT) gene 
expression, to increase the life-span of primary human umbrilical vein endothelial cells 
(HUVEC), and transgenic mice expressing LANA-1 were shown to develop splenic follicular 
hyperplasia and lymphomas (Watanabe et al. 2003; Verma et al. 2004; Fakhari et al. 2006).  
 
The lytic replication cycle 
 
Reactivation of KSHV from latency and induction of the full lytic cycle leads to an 
ordered sequence of gene expression and viral DNA replication and finally to the production 
and release of new infectious virions. The biological signals that promote lytic cycle induction 
are not fully understood, though proinflammatory cytokines (e.g. IFN-γ) (Monini et al. 1999; 
Chang et al. 2000; Mercader et al. 2000), hypoxia (Davis et al. 2001), and co-infection with 
other viruses (Harrington et al. 1997; Vieira et al. 2001; Lu et al. 2005; Gregory et al. 2009) 
have been implicated. In vitro, KSHV lytic replication can be induced by various chemicals 
such as 12-Ο-tetradecanoyl-phorbol-13-acetate (TPA), or sodium butyrate (Na-butyrate, NaB) 
(Renne et al. 1996b; Miller et al. 1997).  
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The central protein in KSHV lytic replication is the reactivation and transcription 
activater (RTA) encoded by orf50. KSHV RTA alone is sufficient to induce the complete 
lytic cascade (Lukac et al. 1998; Sun et al. 1998; Lukac et al. 1999; Gradoville et al. 2000; 
Bechtel et al. 2003; Zhu et al. 2004; Xu et al. 2005). 
RTA is a potent transcriptional activator. In addition to its own promoter, RTA activates 
a number of genes that are involved in lytic replication, including replication proteins (Orf6, 
K8/bZIP, and Orf21), transcriptional modulators (K8/bZIP, Orf57, and vIRF1), signal 
inducing membrane proteins (vOX2, vGPCR, and kaposins), viral cytokines (vIL-6, vCCL-1), 
immunomodulatory proteins (K5, K3), viral structural proteins (glycoprotein B (gB)), the 
lytic origin of DNA replication (oriLyt), polyadenylated nuclear (PAN) RNA as well as 
latency-associated genes (LANA, vCyclin, vFLIP) (Zhang et al. 1998; Lukac et al. 1999; 
Chen et al. 2000; Deng et al. 2000; Jeong et al. 2001; Lukac et al. 2001; Song et al. 2001; 
Wang et al. 2001b; Chang et al. 2002; Deng et al. 2002; AuCoin et al. 2004; Damania et al. 
2004; Matsumura et al. 2005; Wang and Yuan 2007). The molecular mechanisms of 
transactivation by RTA include direct binding of RTA to specific DNA sequences as well as 
interaction of RTA with cellular proteins (e.g. Oct-1, C/EBPα, SP-1, AP-1, RBP-Jk (also 
known as CSL or CBF-1)) bound to promoter DNA (Zhang et al. 1998; Sakakibara et al. 
2001; Byun et al. 2002; Ueda et al. 2002; Wang et al. 2003a; Wang et al. 2003b; Liang and 
Ganem 2004; Chang et al. 2005b). RTA has also been implicated in induction of some 
cellular genes (Chang et al. 2005a; Zhang et al. 2005), initiation of viral DNA replication 
(AuCoin et al. 2004; Wang et al. 2004c), and was shown to possess ubiquitin E3 ligase 
activity (Yu et al. 2005).  
K8/bZIP (or replication associated protein, RAP) and MTA (Orf57) are two additional 
viral proteins that have been implicated in transcriptional and posttranscriptional regulation, 
respectively. K8/bZIP, a basic region-leucine zipper (bZIP) protein and a positional 
homologue of BZLF1 (also known as ZTA or ZEBRA) in EBV (Gruffat et al. 1999; Lin et al. 
1999), negatively regulates the RTA-mediated activation of the K8, Orf57/MTA and K15 
promoter (Izumiya et al. 2003; Liao et al. 2003; Ellison et al. 2009). Sumoylation and 
phosphorylation of K8/bZIP are critical in regulating this transcriptional repression activity. 
Phosphorylation of K8/bZIP by vPK/Orf36 reduces its repression function (Izumiya et al. 
2005; Izumiya et al. 2007), while sumoylation of K8/bZIP through its cellular interaction 
partner Ubc 9 (E2 SUMO conjugation enzyme) positively influences its repression activity 
(Izumiya et al. 2005). Recent evidence suggests that K8/bZIP may also synergize with RTA 
in the activation of lytic promoters, as the majority of RTA-responsive promoters showed 
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enhanced activity when RTA and K8/bZIP were co-expressed in a reporter assay-based 
system (Ellison et al. 2009). Moreover, Lefort and Flamand (2009) showed that in the absence 
of K8/bZIP expression, expression of orf50, orf57, and orf26 transcripts was highly decreased 
as were the protein levels for RTA and the late lytic glycoprotein K8.1. These findings 
suggest that K8/bZIP may function as a positive regulator of viral lytic gene expression. 
K8/bZIP has also been found to be important for origin-dependent lytic DNA 
replication (Izumiya et al. 2003; Wang et al. 2003a; Wang et al. 2003b; AuCoin et al. 2004; 
Rossetto et al. 2007; Lefort and Flamand 2009; Rossetto et al. 2009) and was shown to be 
involved in cell cycle regulation, inhibition of apoptosis and host antiviral response (Park et 
al. 2000; Izumiya et al. 2007; Lefort et al. 2007).  
The KSHV Orf57 protein, also known as mRNA transport and accumulation protein 
(MTA) and homologue of the EBV SM (MTA, EB2, BMLF1) protein, has been reported to 
enhance several posttranscriptional processes including viral mRNA export, RNA stability 
and pre-mRNA splicing (Conrad 2009; Majerciak and Zheng 2009). Additionally, KSHV 
Orf57 functions as a transcriptional activator or co-activator of several viral genes (Kirshner 
et al. 2000; Malik et al. 2004; Palmeri et al. 2007) and is essential for the production of 
infectious virus (Han and Swaminathan 2006; Majerciak et al. 2007). 
 
1.3 KSHV and signalling pathways 
 
1.3.1 MAPK and PI3K/Akt signalling cascades and Syk protein kinase  
 
Mitogen-activated protein kinase (MAPK) pathways 
 
Mitogen-activated protein kinase (MAPK) cascades are important signalling pathways 
that convert extracellular signals into cellular responses. They regulate proliferation, 
differentiation, cell activation and immune responses. Up to now, four different members 
organized in separate cascades have been identified: (i) ERK (extracellular-signal-regulated 
kinase), (ii) JNK (c-Jun N-terminal kinase), (iii) p38 and (iv) ERK5 (Figure 2). For each 
MAPK different isoforms are known. MAP kinases are activated upon tyrosine and threonine 
phosphorylation within a conserved Thr –Xxx-Tyr motif in the activation loop of the kinase 
domain. This phosphorylation is catalysed by dual-specificity kinases, MAPK kinases 
(MAPKK, MKK or MEK), which again are regulated by serine/threonine phosphorylation 
within a conserved motif in the activation loop, catalysed by MAPKK kinases (MAPKKK or 
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MEKK) (Figure 2). This three layer signalling cascade is activated by various upstream 
activators, including kinases and GTP-binding proteins. 
 
 
 
The Ras/Raf/MEK/ERK pathway has been particularly well studied, because mutations 
in the ras gene occur in many cancers. A wide variety of extracellular stimuli induce 
activation of this signalling cascade including growth factors, phorbol esters and cytokines. 
The canonical ERK MAPK cascade is stimulated by binding of a growth factor to its cell 
surface receptor which leads to the self-phosphorylation of the receptor. The src homology 2 
(SH2) domain of an adaptor protein, Grb2, then binds to the phosphorylated tyrosine residue 
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Figure 2. Schematic depiction of mitogen-activated protein kinase (MAPK) cascades. MAPK 
cascades are induced in response to various extracellular stimuli including among others growth 
factors and cytokines, phorbol esters, stress and G protein-coupled receptors (GPCR). Various 
intracellular upstream activators, including kinases and small GTP-binding proteins then activate a 
characteristic phosphorylation cascade in which a series of three protein kinases phosphorylate and 
activate one another. MAPKs serve as phosphorylation substrate for MAPK kinases (MAPKKs, MKKs 
or MEKs), which in turn are phosphorylated by MAPKK kinases (MAPKKK or MEKKs). Activated 
MAPKs (ERK, JNK, p38, ERK5) translocate to the nucleus, where they phosphorylate and activate 
various transcription factors. ERK1 and ERK2 further phosphorylate multiple cytoplasmic and 
cytoskeletal targets, including p90RSK, that also activates several transcription factors in the nucleus. 
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of the receptor; Grb2 thereby links the activated receptor to the guanine exchange factor SOS 
that regulates the small GTPase Ras. This is followed by the sequential recruitment and 
activation of the kinases Raf, MEK, and ERK. ERK phosphorylates both cytoplasmic and 
nuclear substrates, including many enzymes, cytoskeletal proteins and transcription factors.  
A number of Ras/ERK signalling-related proteins have been identified, such as scaffold 
proteins and inhibitor proteins of this pathway. These proteins provide variations in ERK 
signalling by modulating the duration, magnitude and subcellular compartmentalization of 
ERK activity (Marshall 1995; Ebisuya et al. 2005). Accumulating evidence suggests that such 
differences in ERK activity generate variations in signalling outputs that regulate cell fate 
dicisions. 
ERK1 (also called p44ERK1) and 2 (also called p42ERK2) are highly conserved 
serine/threonine kinases that are 84% identical and share many functions (Lloyd 2006). They 
are activated by MEK1/2 via phosphorylation of both threonine and tyrosine residues within 
the Thr-Glu-Tyr (TEY) sequence in the activation loop. Substrates of ERK1/2 are members of 
the family of ~90-kDa ribosomal S6 kinases (p90RSK), mitogen- and stress-activated protein 
kinase 1/2 (MSK1/2), and transcription factors including Elk-1, c-Fos, c-Myc and Stat1/3 
among others (Figure 2). 
 
Regulation and cellular functions of the PI3K/Akt pathway 
 
The phosphatidylinositol-3-kinase (PI3K)-Akt pathway is activated by several 
hormones, growth factors, cellular stress, signals derived from receptors for extracellular 
matrix molecules (e.g. integrins), and by activation of Ras. The induced signalling cascade 
regulates various cellular processes, such as metabolic regulation, cell growth, proliferation 
and survival (Cantley 2002; Franke et al. 2003; Brazil et al. 2004).  
PI3K consists of regulatory (p85) and enzymatic (p110) subunits and exhibits both a 
protein kinase and a lipid kinase activity (Dhand et al. 1994; Hawkins et al. 2006). The serine-
threonine protein kinase Akt (also known as protein kinase B, PKB) mediates main 
downstream effects of PI3K. Akt exists in three closely related enzymatic isoforms, Akt1 
(PKBα), Akt2 (PKBβ) and Akt3 (PKBγ). They are similar both in structure and size and are 
thought to be activated by a common mechanism (Okano et al. 2000; Gonzalez and McGraw 
2009). The three Akt proteins (in the following refered to as Akt) contain an N-terminal 
pleckstrin homology (PH) domain, a central catalytic domain and a C-terminal regulatory 
region. Activation of Akt is a multi-step process involving both membrane binding and 
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phosphorylation. Briefly, activated PI3K catalyses the conversion of phosphatidylinositol-3,4-
P2 (PIP2) to phosphatidylinositol-3,4,5-P3 (PIP3). Cytoplasmic Akt is recruited to the plasma 
membrane where it binds to PIP3 through its PH domain (Franke et al. 1997), and is then 
phosphorylated by PI3K-dependent kinase-1 (PDK1) at the threonine residue 308, and by 
another PI3K-dependent kinase (PDK2) at the serine residue 473; phosphorylation at both 
sites is required for full induction of Akt activity (Figure 3). The tumour suppressor protein 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) antagonizes the 
PI3K/Akt pathway by dephosphorylating PIP3, resulting in decreased translocation of Akt to 
cellular membranes and subsequent downregulation of the activity of Akt. Active Akt 
phosphorylates a number of substrates both in the cytoplasm and in the nucleus which are 
involved in the regulation of key cellular functions such as cell growth and survival, glucose 
metabolism and protein translation. These targets include GSK3, BAD, caspase 9, forkhead 
and NF-κB transcription factors, mTOR, and p21 (Figure 3). 
The PI3K/Akt pathway is commonly dysregulated in cancer (Liu et al. 2009). In this 
respect, Akt has been recognized as an essential link between the PI3K pathway and the 
mammalian target of rapamycin (mTOR) through the inactivation of the tuberous sclerosis 
complex (TSC) (Manning and Cantley 2003). The TSC complex, formed by hamartin (TSC1) 
and tuberin (TSC2), functions as a GTPase-activating protein (GAP) for Rheb, a Ras-related 
small GTP-binding protein that promotes the activation of mTOR (Garami et al. 2003; Inoki 
et al. 2003; Tee et al. 2003). Phosphorylation of TSC2 by Akt results in its inactivation, 
thereby promoting the accumulation of (active) Rheb-GTP and the induction of mTOR 
activity. mTOR then triggers the phosphorylation of key regulators of the cellular translation 
machinery, including ribosomal p70 S6 kinase (p70S6K) and eukaryote initiation factor 4E 
binding protein 1 (4EBP1) (Gingras et al. 1998; Aoki et al. 2001). Emerging evidence suggest 
that the TSC/mTOR pathway may play a critical role in the development of tumours 
dependent on Akt activation, highlighting its impact on the control of cell growth and 
proliferation and emphasizing its importance in human tumourigenesis (Luo et al. 2003; 
Majumder et al. 2004; Wislez et al. 2005).  
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The protein kinase Syk 
 
Syk (spleen tyrosine kinase) is a small cytoplasmatic non-receptor protein tyrosine 
kinase (PTK) that is widely expressed in haematopoietic cells and has been detected in 
fibroblasts, epithelial cells, breast tissue, hepatocytes, neuronal cells, and vascular endothelial 
cells (Yanagi et al. 2001). In hematopoietic cells, including B- and T-cells, Syk is activated by 
binding of its tandemly arranged SH2 domains to immunoreceptor tyrosine-based activation 
motifs (ITAMs) in immune response receptors (Turner et al. 2000; Sada et al. 2001). In non-
Figure 3. Schematic depiction of Akt signalling. Akt is the major downstream target of 
phosphatidylinositol-3-kinase (PI3K). PI3K activation is achieved by direct or indirect binding of its 
regulatory subunit p85 to an activated receptor. Alternatively, PI3K can be activated through active 
Ras. Activated PI3K then catalyses the phosphorylation of phosphatidylinositol-4,5-bisphosphate 
(PIP2), giving rise to the lipid second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) at 
the cell membrane. This process is antagonized by the tumour suppressor protein PTEN, which 
dephosphorylates PIP3. PIP3 serves as a docking platform for Akt, which is then activated by dual 
phosphorylation through PI3K-dependent kinases 1 and 2 (PDK-1 and -2). Active Akt directly 
phosphorylates and regulates – both positively and negatively – the activity of a wide variety of 
proteins and transcription factors, some of which are represented in this illustration.  
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hematopoietic cells, Syk has been demonstrated to be activated by integrins and G protein-
coupled receptors (Yanagi et al. 1994; Wan et al. 1996; Gao et al. 1997; Woodside et al. 2001; 
Mocsai et al. 2002). Signalling pathways activated by Syk include MAPK (Ras-ERK, JNK) 
and PI3K-Akt cascades, as well as PKC and PLCγ1/2 (Jabril-Cuenod et al. 1996; Law et al. 
1996; Jiang et al. 1998; Craxton et al. 1999; Kawakami et al. 2003; Ruschel and Ullrich 2004; 
Moon et al. 2005) (see also Figure 2). The kinase has been implicated in immunoreceptor 
signalling events that mediate diverse cellular responses including proliferation, 
differentiation, and phagocytosis. In non-hematopoietic tissue, Syk signalling has been 
implicated in several cellular mechanisms such as cell growth, proliferation, differentiation, 
and migration and is assumed to act as a tumour suppressor (Coopman and Mueller 2006). 
 
1.3.2 Viruses and MEK-ERK1/2 and PI3K-Akt signalling cascades  
 
Many viruses activate signalling pathways as a result of cellular response to the 
infection and virus modulation of its environment. For several viruses, including RNA and 
DNA viruses, it has been shown that they largely depend on intact MEK1/2-ERK1/2 
signalling for efficient replication and protein expression (Rodems and Spector 1998; 
Andrade et al. 2004; Lim et al. 2005; Pleschka 2008), while activation of PI3K signalling is a 
strategy of several viruses to facilitate virus entry at early stages of infection and to suppress 
premature apoptosis at later stages of infection (Ehrhardt et al. 2006; Saeed et al. 2008; Soares 
et al. 2009).  
 
1.3.3 Signalling pathways involved in KSHV infection and activation of the lytic 
cycle 
 
Multiple upstream inducers of KSHV lytic cycle share the Raf/MEK/ERK/Ets-1 
pathway to activate the expression of the immediate-early RTA protein and the same pathway 
also mediates spontaneous reactivation in BC-3 cells (Yu et al. 2007). TPA induction of 
KSHV lytic cycle is mediated by various pathways, including calcium-dependent calcineurin 
signalling, protein kinase C (PKC) δ pathway, and MAPK (ERK, JNK, and p38) pathways 
(Zoeteweij et al. 2001; Deutsch et al. 2004; Cohen et al. 2006; Ford et al. 2006; Xie et al. 
2008). MEK/ERK, JNK and p38 mediate lytic cycle induction through their downstream 
target AP-1, which binds to the RTA promoter (Wang et al. 2004c; Xie et al. 2008). All three 
MAPK pathways are also required for productive lytic replication during primary infection 
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(Sharma-Walia et al. 2005; Xie et al. 2005; Pan et al. 2006). Epinephrine and norepinephrine 
efficiently reactivate KSHV from latency via β-adrenergic activation of the adenylyl 
cyclase/cAMP/protein kinase A (PKA) signalling pathway (Chang et al. 2005c). The role of 
NF-kB pathway in lytic replication remains unclear, but there is evidence suggesting that NF-
kB is both a positive and negative regulator of lytic cycle: High level NF-kB inhibits 
immediate-early protein expression and, thus, helps to maintain the latent state of infection 
(Brown et al. 2003; Ye et al. 2008; Izumiya et al. 2009), while the expression of lytic genes 
required for efficient de novo infection seems to depend on NF-kB activity later on during the 
lytic cycle (Sgarbanti et al. 2004). 
 
1.3.4 KSHV lytic proteins involved in signalling 
 
Several lytic proteins of KSHV are capable of inducing signalling pathways. These 
proteins include homologues of cellular cytokines (vIL-6 (K2), vCCL-1 (K6), vCCL-2 (K4), 
vCCL-3 (K4.1)), a homologue of G protein-coupled IL-8 receptor (vGPCR, encoded by 
orf74), two integral membrane signalling proteins (K1 and K15), a serine/threonine protein 
kinase (vPK, encoded by orf36) and a homologue of the cellular glycoprotein CD200/OX2 
(vOX2). Some of them have been shown to contribute to angiogenesis and/or the production 
of cellular mitogenic and survival factors, and thus, as a by-product, to KSHV pathogenesis 
(Schulz et al. 2002; Schulz 2006; Hartmann et al. 2009; Wen and Damania 2009). Some of 
these proteins may also directly modulate the lytic replication cycle. The virus-encoded kinase 
vPK/Orf36 was shown to activate the JNK MAPK pathway, and the cellular transcription 
factor c-Jun. Chemical inhibition of JNK activity resulted in the inhibition of late viral gene 
expression (Hamza et al. 2004). vPK/Orf36 localizes to KSHV replication/transcription 
complexes and interacts with, and thereby modulates, the transcriptional regulator K8/b-ZIP 
in productively infected cells (Izumiya et al. 2007). The KSHV-encoded chemokines vCCL-1 
and vCCL-2 (see also below) promote KSHV lytic replication in endothelial cells and it was 
suggested that this activity involves pro-survival signalling via paracrine as well as autocrine 
mechanisms (Choi and Nicholas 2008). Additionally, two recently published studies have 
shown that vGPCR signalling via Gαq-subunits of heterotrimeric G-protein positively 
regulates the lytic replication cycle (Bottero et al. 2009; Sandford et al. 2009), which may be 
due to the induction of increased promoter activity of Orf50/RTA and other early lytic genes 
(Bottero et al. 2009) (see also below).  
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Viral cytokines 
 
vCCLs 
 
The viral CC-chemokines of KSHV, vCCL-1, vCCL-2 and vCCL-3, are encoded by 
orfs K6, K4 and K4.1, respectively (Russo et al. 1996; Neipel et al. 1997; Nicholas et al. 
1997b). While vCCL-1 and vCCL-2 are structurally most closely related to CCL3 and CCL4, 
vCCL3 has no clear cellular counterpart but is related to CCL2. Functionally, these viral 
chemokines are distinct from their cellular homologues. vCCL-1 and vCCL-2 are agonists for 
CCR8, the receptor for CCL1 (I-309), and vCCL-2 has been reported also to interact 
productively with CCR3 (Boshoff et al. 1997; Dairaghi et al. 1999; Endres et al. 1999). 
vCCL-3 signals through CCR4 and XCR1 (Stine et al. 2000; Luttichau et al. 2007). 
Additionally, vCCL-2 binds as a neutral (non-signalling) ligand to a variety of CC- and CXC 
receptors and to XCR1, thereby acting as an antagonist for cognate ligand signalling (Kledal 
et al. 1997; Shan et al. 2000; Luttichau et al. 2001).  
vCCL-1 as well as vCCL-2 were shown to activate ERK and Akt signalling pathways in 
endothelial cells (Choi and Nicholas 2008). A key property shared by both viral chemokines 
is their anti-apoptotic activity, demonstrated in dexamethasone-treated PEL cells and serum-
deprived primary and telomerase-immortalized human microvascular endothelial cells (Liu et 
al. 2001). CCR8-mediated anti-apoptotic signalling has been noted in murine thymic 
lymphoma cells, BW5147, and Ras/MAPK signalling has been implicated in this function 
(Louahed et al. 2003; Spinetti et al. 2003). CCR8 also mediates vCCL-1 and vCCL-2 induced 
anti-apoptotic signalling in endothelial cells, and it was suggested that this process involves 
the suppression of the proapoptotic Bcl-2 family protein Bim (Choi and Nicholas 2008). In 
addition to Bim, it was shown that Bcl-2 is targeted by v-chemokine signalling, proposing that 
vCCL-1 and vCCL-2 may contribute to prevention of stress-induced apoptosis (Choi and 
Nicholas 2008). The v-chemokines are able to mediate pro-survival signalling in a paracrine 
manner. Thus, their expression in a minority of lytically infected cells within a predominantly 
latent cell population would allow for their contribution to viral pathogenesis via promoting 
the survival of latently infected cells and thereby cooperating with latency functions.  
Recent evidence suggests that vCCL-1 and vCCL-2 also directly promote viral lytic 
replication via both autocrine and paracrine-mediated signalling (Choi and Nicholas 2008). 
Other likely biological functions of the v-chemokines may include immune evasion and virus 
dissemination via Th2 polarization and lymphocyte/monocyte recruitment mediated by their 
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various agonist and neutral agonist activities. Several studies suggest a role in angiogenesis, 
and it is known that vCCL-1 can induce VEGF production in latently infected PEL cell lines 
(Boshoff et al. 1997; Stine et al. 2000). 
 
vIL-6 
 
Cellular (or human) IL-6 (hIL-6), a multifunctional cytokine that acts on a wide variety 
of cell types, had been implicated as a contributing factor in KS and MCD prior to the 
discovery of KSHV. KS lesions showed elevated IL-6 levels and KS cells in culture were 
reported to show increased proliferation rates in response to IL-6; levels of serum IL-6 were 
found to correspond with disease severity in MCD patients and to decrease following excision 
of diseased lymph nodes (Yoshizaki et al. 1989; Miles et al. 1990; Burger et al. 1994; 
Ishiyama et al. 1994). hIL-6 is a known mitogen and survival factor for B-cells, and STAT3, 
the main downstream effector of IL-6 signalling, is found at elevated levels in many cancers. 
The IL-6 homologue encoded by orf K2 shares only 25% amino acid identity with its 
human counterpart but is structurally highly conserved and activates the same downstream 
signalling pathways as hIL-6 (Molden et al. 1997). Both human and viral (v) IL-6 activate 
signalling through the JAK/STAT pathway, specifically activating STAT3 transcriptional 
activity, and induce Ras/MAP kinase pathways (Molden et al. 1997; Osborne et al. 1999; 
Chatterjee et al. 2002). To activate signalling in a cell, human IL-6 requires gp130, a surface 
receptor common to many cytokines, and gp80, an IL-6 specific component. In contrast to its 
cellular homologue, vIL-6 can signal independently of gp80 (Burger et al. 1998). This makes 
the viral IL-6 a more promiscuous activator of signalling since gp130 is present on many cell 
types while gp80 is limited to specific cells (Heinrich et al. 2003). However, gp80 can be 
incorporated into vIL-6-induced signalling complexes, and may contribute to complex 
stability and influence vIL-6 signal transduction (Wan et al. 1999; Boulanger et al. 2004; 
Chen and Nicholas 2006; Hu and Nicholas 2006).  
Another major difference between vIL-6 and hIL-6 is that the viral cytokine is very 
inefficiently secreted, retained largely within the endoplasmic reticulum (ER), where it is able 
to transduce signalling intracellularly (Meads and Medveczky 2004; Kovaleva et al. 2006). 
hIL-6 cannot signal in the ER, even when targeted to this compartment (Chen et al. 2009).  
vIL-6 was shown to be expressed with early kinetics during lytic replication in PEL 
cells and is directly induced by the lytic switch protein RTA (Sun et al. 1999; Jenner et al. 
2001; Paulose-Murphy et al. 2001b; Song et al. 2003). However, vIL-6 also can be expressed 
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independently of other lytic genes (Nicholas et al. 1997c; Chatterjee et al. 2002; Chiou et al. 
2002; Chang et al. 2005a). The cytokine has been found to be expressed in a higher 
percentage of cells than other lytic proteins in KS and PEL tissues and together with latency-
associated nuclear antigen (LANA) in individual cells of KS and MCD (Moore et al. 1996; 
Cannon et al. 1999; Brousset et al. 2001; Chiou et al. 2002), and Chang et al. (2005) identified 
vIL-6 as one of several lytic genes that are specifically induced via Notch signalling, 
independently of RTA (Chang et al. 2005a). vIL-6 may therefore function as an autocrine 
proliferation and survival factor even in the absence of the full lytic replication cycle. In fact, 
it was shown that PEL cells grow with reduced kinetics and display higher rates of aopotosis 
upon shRNA-mediated depletion of vIL-6 when compared to non-transduced cells (Chen et 
al. 2009). Thus, intracellular signalling by vIL-6 may be functional in the autocrine promotion 
of proliferation and survival of latently infected PEL cells.  
vIL-6 could potentially have a role in neoplasia also via paracrine signalling. Effects 
could be exerted directly, for example via mitogenic and survival signalling in surrounding 
latently infected and uninfected cells, and also indirectly via the induction of cellular 
cytokines or other proteins, such as receptors. Examples might include hIL-6, VEGFs and 
other angiogenic factors, which have been demonstrated to be induced by vIL-6 in some cell 
types (Aoki et al. 1999; Mori et al. 2000; Liu et al. 2001), as well as growth factor and 
cytokine receptors. Inflammatory and angiogenic cytokines are known to play a role in KS, 
and VEGF and IL-6 appear to be important for PEL and MCD (Yoshizaki et al. 1989; Burger 
et al. 1994; Ishiyama et al. 1994; Aoki and Tosato 1999). In vitro, both vIL-6 and hIL-6 
support PEL cell growth (Foussat et al. 1999; Jones et al. 1999).  
 
Membrane proteins 
 
The viral G protein-coupled receptor (vGPCR) 
 
The vGCPR of KSHV is a constitutively active (ligand-independent) G protein-coupled 
receptor that is most related structurally to the CXCL8 (IL-8) receptor CXCR2 (Russo et al. 
1996). The receptor is promiscuous in its Gα coupling, activating i, q and 12/13 classes of Gα 
proteins that lead to a broad range of signalling pathway activation (Couty et al. 2001; 
Shepard et al. 2001; Cannon et al. 2003; Liu et al. 2004). Kinases and transcription factors 
activated by vGPCR include MAPK (Erk, p38, Jnk), Akt, NFAT, CREB, NF-κB, AP-1 and 
HIF-1α (Figure 4), and these are relevant to promotion of cell proliferation and survival and to 
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induction of angiogenic responses via cytokine gene activation (Arvanitakis et al. 1997; Bais 
et al. 1998; Sodhi et al. 2000; Montaner et al. 2001; Pati et al. 2001; Schwarz and Murphy 
2001; Shepard et al. 2001) (see below). Although constitutively active, vGPCR activity can be 
modulated both positively and negatively by cellular chemokines such as agonists GROα and 
IL-8 and inverse agonists IP-10 and SDF-1α (Geras-Raaka et al. 1998a; Geras-Raaka et al. 
1998b; Gershengorn et al. 1998). In addition, the KSHV-encoded chemokine vCCL-2 acts as 
an inverse agonist (Geras-Raaka et al. 1998a). Several ‘neutral’ ligands bind to vGPCR 
without affecting signal transduction; these include CC-ligands CCL1 (I-309), CCL5 
(RANTES) and CCL3 (MIP-1a), and CXC-ligands CXCL7 (NAP-2), CXCL5 (ENA-78) and 
CXCL4 (PF-4) (Arvanitakis et al. 1997; Rosenkilde et al. 1999). The biological relevance of 
the vGPCR-chemokine functional and neutral interactions is unresolved. It is known, 
however, that agonist stimulation of vGPCR leads to a switch to predominantly Gαq-initiated 
signalling, and this is likely to be relevant to KS pathogenesis (see below). 
Of all the KSHV-encoded proteins vGPCR is probably the one for which there is most 
evidence for a role in virus neoplasia, specifically KS. Ectopic expression of vGPCR in 
NIH3T3 cells causes oncogenic transformation and leads to the upregulation of VEGF (Bais 
et al. 1998). It has been suggested that vGPCR might participate in KS pathogenesis through 
autocrine and paracrine mechanisms by inducing the secretion of VEGF and by maintaining 
an angiogenic phenotype by signalling via a VEGFR2/VEGF loop (Bais et al. 2003).  
Investigations on vGPCR transgenic mice identified the viral receptor as an inducer of 
KS-like lesions (Yang et al. 2000; Holst et al. 2001; Montaner et al. 2003), and it was shown 
that chemokine stimulation of vGPCR is necessary for efficient induction of KS tumours in 
the murine model (Holst et al. 2001). Additionally, Akt-mediated signalling has been 
identified as important for murine sarcomagenesis in transgenic animals and for 
tumorigenicity of vGPCR-expressing endothelial cells in recipient athymic mice (Sodhi et al. 
2004). In this respect, activation of mTOR via Akt-mediated inactivation of the negative 
regulator TSC2 appears to be centrally important to vGPCR-induced endothelial cell growth 
in culture and to tumorigenesis in the allograft model (Sodhi et al. 2006). 
Recently, two independent studies provided evidence for a functional relevance of 
vGPCR in KSHV biology: Bottero et al. (2009) showed that vGPCR signalling activates the 
Orf50/RTA promoter in a Sp1 and Sp3 transcription factor-dependent manner and decreases 
histone deacetylase (HDAC) activity. This activity was demonstrated to involve the Gαq and 
Gα12 subunits of heterotrimeric G-Protein (Bottero et al. 2009). In agreement with these 
findings, Sandford et al. (2009) suggest that vGPCR promotes KSHV lytic replication 
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through Gαq-mediated activation of MAPK signalling cascades. Thus, vGPCR signalling may 
facilitate sustained expression of Orf50/RTA during the lytic replication cycle, which may 
lead to continued expression of lytic cycle genes and ultimately to the release of new 
infectious virions.  
 
vOX2 
 
The KSHV vOX2 protein shows 36% identity with a cellular protein of the group of 
leukocyte glycoproteins, called CD200 or OX2. The protein is expressed early during lytic 
replication from a bicistronic mRNA containing the orfs 74 (vGPCR) and K14 (vOX2) 
(Kirshner et al. 1999; Talbot et al. 1999; Jenner et al. 2001; Paulose-Murphy et al. 2001). 
CD200-like sequences have been identified in genomes of several evolutionary diverse 
viruses, which include gamma- and betaherpesviruses, yaba- and leporipoxviruses, and small 
viruses such as duck adeno virus (Foster-Cuevas et al. 2004). This apparently independent 
capture of the host CD200 gene indicates a strong selective advantage conveyed by members 
of this family. CD200 is expressed on the surface of a wide variety of cell types including 
endothelial cells, B lymphocytes, T cells, and neuronal cells (Wright et al. 2001) and provides 
immunomodulatory functions. Signal delivery of CD200 occurs through binding to a CD200 
receptor (CD200R). This interaction results in inhibition of CD200R downstream signalling 
(including ERK, JNK and p38 MAPK activity) in monocytes and thus limiting their activation 
(Hoek et al. 2000; Zhang and Phillips 2006). As CD200R expression is restricted to cells of 
the myeloid lineage, it is suggested that CD200-CD200R interaction acts locally to modulate 
inflammatory-cell activity at sites of infection.  
However, studies on vOX2 function have so far pointed in different directions. While 
Chung et al. (Chung et al. 2002) demonstrated that vOX2 stimulates inflammatory cytokine 
production including IL-1β, monocyte chemoattractant protein 1 (MCP-1), and TNF-α from 
primary monocytes, macrophages and dendritic cells, more recent studies by two groups show 
the opposite, suggesting a similar function for vOX2 as for its cellular homologue CD200 
(Foster-Cuevas et al. 2004; Rezaee et al. 2005). Foster-Cuevas et al. (2004) observed that 
vOX2 interacts with almost identical kinetics with human CD200R as shown for CD200, and 
cells expressing vOX2 or CD200 on their surface were able to inhibit secretion of TNF-α 
from activated macrophages. In KSHV biology and tumorigenesis the local inhibition of 
macrophages, which are abundant within KSHV-infected tissue, might be important to 
prevent a host response against lytically-infected cells. Several lytic proteins, of which, 
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notably, the vOX2 co-expressed vGPCR is of major importance, have been shown to induce 
paracrine effects on latently and uninfected cells that may have a role in viral maintenance 
and spread.  
Rezaee et al. (2005) confirmed the immunosuppressive function of vOX2 by 
demonstrating that a fusion protein of vOX2 and the Fc domain of human immunoglobulin 
G1 (vOX2:Fc) downregulated the activity of neutrophils directly and indirectly via inhibiting 
the production of the potent neutrophil chemotactic proteins IL-8 and MCP-1 from monocytes 
and macrophages in vitro. In vivo studies in a carrageen-mouse model of acute inflammation 
demonstrated, that vOX2:Fc reduced cell infiltration (Rezaee et al. 2005), suggesting that 
vOX2 may modulate chemotaxis. 
 
K1 
 
The K1 open reading frame is located at the left end of the KSHV genome. This 
position is equivalent to that of genes in other γ-herpesviruses, which are known to encode 
proteins involved in signalling and transformation. These include the herpesvirus saimiri 
(HVS) transforming protein (STP) (Murthy et al. 1989), the latent membrane protein-1 (LMP-
1) of Epstein Barr virus (Kaye et al. 1993), and the R1 protein of rhesus monkey rhadinovirus 
(RRV) (Damania et al. 1999). Like these proteins, K1 activates intracellular signalling 
cascades and induces proliferative, anti-apoptotic and inflammatory responses. 
Structurally, K1 is a type-I transmembrane protein of 46 kDa. Its extracellular domain 
(228 aa) features regional homology with the immunoglobulin (Ig) superfamily, and consists 
of two conserved regions (C1 and C2) as well as two highly variable regions (V1 and V2). 
The cytoplasmic tail (38 aa) contains an ITAM (Lee et al. 1998a), analogous to motifs within 
the Igα and Igβ chains of the B-cell receptor (BCR). Although the K1 cytoplasmic tail is 
highly variable among different KSHV isolates around the world, the Src homology 2 (SH2) 
binding motifs comprising the ITAM are always conserved (Zong et al. 1999).  
Unlike the BCR, K1 signalling activity is constitutive in the absence of exogenous 
ligands, presumably through multimerization of its cysteine-rich extracellular domain, which 
then results in phosphorylation of the tyrosine residues in the ITAM. The ITAM is necessary 
for phosphorylation and activation of SH2-containing signalling proteins, such as Syk, Lyn, 
Cbl, Vav, and the p85-subunit of phosphatidylinositol-3’-OH kinase (PI3K) as well as for K1-
mediated upregulation of PI3K pathway signalling, and NF-κB and NFAT promoter-
dependent activity (Lee et al. 1998a; Lagunoff et al. 1999; Prakash et al. 2002; Tomlinson and 
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Damania 2004; Prakash et al. 2005). Activation of PLCγ2, RasGAP, SH2 domain-containing 
protein tyrosine phosphatase 1/2 (SH2-PTP1/2), and Grb2 has been observed upon 
stimulation with a monoclonal antibody directed against the extracellular domain of K1 (Lee 
et al. 2005). 
 K1 is expressed as an early gene during the KSHV lytic cycle (Sarid et al. 1998; Jenner 
et al. 2001; Paulose-Murphy et al. 2001; Bowser et al. 2002; Fakhari and Dittmer 2002; 
Nakamura et al. 2003). Although low level expression has been reported in latently infected 
PEL cell lines (Samaniego et al. 2001), this could have been due to a small proportion of cells 
in these cultures that undergo productive (lytic) replication. K1 expression has been observed 
in tumour tissues of KS and MCD (Samaniego et al. 2001; Lee and Merchant 2003) and in KS 
cells expressing K1, the induction of secretion of inflammatory cytokines implicated in KS 
lesion formation, such as IL-6, IL-12, and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), was observed (Samaniego et al. 2001; Prakash et al. 2002).  
First evidence for the ability of K1 to transform cells emerged from studies in rodent 
cells: K1 expression transformed rodent fibroblasts in vitro, and recombinant herpesvirus 
saimiri strains, in which the STP had been replaced with the K1 gene, induced lymphomas in 
vivo (Lee et al. 1998b). Further experiments indicated that a minority of K1 transgenic mice 
develop tumours with features of a spindle-cell sarcomatoid tumour and malignant 
plasmaplastic lymphomas (Prakash et al. 2002). In these mice, IL-12 levels were severely 
decreased and basic fibroblast growth factor (FGF2) expression was upregulated in 
lymphocytes and tumours (Prakash et al. 2002). Interestingly, FGF2 has been described as an 
autocrine growth factor for endothelial cells that promotes growth and angiogenesis of AIDS-
KS cells (Samaniego et al. 1995). 
Lymphocytes isolated from transgenic mice expressing K1 showed constitutive 
activation of transcription factors NF-κB and Oct-2 as well as enhanced Lyn kinase activity 
(Prakash et al. 2002). Biochemical and in vitro studies confirmed that NF-κB-dependent-
promoter activity is mediated by K1, and for B-cells, Prakash et al. (2002) demonstrated that 
this activation further depends on the interaction of the ITAM with Lyn kinase. Additionally, 
the transcription factor NFAT was identified as a downstream target of K1-induced PI3K, Syk 
and PLCγ signalling (Lee et al. 1998b; Lagunoff et al. 1999; Samaniego et al. 2001; Lee et al. 
2005; Prakash et al. 2005), and Wang et al. (Wang et al. 2004b) provided evidence that the 
transcription factor AP-1 is activated by K1-mediated activation of PI3K-MAPK signalling. 
NF-κB and NFAT are known to increase the expression of cytokines associated with 
inflammation and proliferation, and Lee at al. (2005) identified numerous inflammatory 
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cytokines (MDC, IL-8, IL-10, VEGF, IL-1α/β, and RANTES), which all contain NF-κB 
and/or NFAT and/or AP-1 binding sites in their promoter sequences and were induced by K1-
mediated signal transduction. K1 may therefore activate uninfected or latently infected cells in 
a paracrine manner through activation of NF-κB-, NFAT- and AP-1-dependent promoters and 
secretion of inflammatory cytokines. Co-expression of the HIV-1-transactivation gene tat with 
K1 results in an additive effect on NF-κB-dependent transcription, suggesting cooperative 
signal activation of K1 and Tat. It has therefore been postulated that these two proteins might 
converge to reach an enhanced level of inflammation that may underlie progressive KS in 
AIDS patients (Prakash et al. 2000).  
K1 utilizes several mechanisms to prevent cells from undergoing apoptosis and to 
support cell proliferation. These processes are mediated by increased anti-apoptotic and 
survival signalling via direct inhibition of proteins involved in apoptosis, or by expression and 
secretion of growth factors such as VEGF. A role for K1 in the survival of KSHV-infected 
cells was first described by Lee et al. (Lee et al. 2000), who found out that the N-terminal 
extracellular domain of K1 interacts with the µ (heavy) chains of BCR complexes to retain 
them in the endoplasmatic reticulum (ER), resulting in downregulation of their surface 
expression. Later, Tomlinson & Damania (2004) demonstrated that K1 mediated-upregulation 
of the PI3K signalling cascade in B-cells results in the phosphorylation of Akt and PTEN, 
which further leads to increased phosphorylation, and thereby inactivation, of forkhead 
(FKHR) transcription factors. This would enhance cell survival signals and protect cells from 
apoptosis. Wang et al. (Wang et al. 2006) showed, that K1 can immortalize primary human 
umbrilical vein endothelial cells (HUVEC) in culture, and suggested that this is a 
consequence of the activation of the PI3K pathway. In addition to the PI3K downstream 
signals in B-cells, this group observed K1-induced activation of mTOR and inactivation of 
GSK-3 and Bad, which are all events indicative of cell survival. Furthermore, Wang et al. 
(2007) showed that Fas is an interaction partner of K1 in vitro and in vivo (Wang et al. 
2007b), suggesting that K1 may directly inhibit Fas-mediated apoptosis to promote cell 
survival. 
Inhibition of pro-apoptotic factors within the cell represents a direct effect of K1 on the 
infected cell, which may ensure host cell survival during the lytic cycle of KSHV for efficient 
virus production. In addition, paracrine mechanisms apparently mediated by K1 may also 
contribute to KSHV maintenance and pathogenesis. It has been demonstrated, that K1 induces 
the expression of VEGF, matrix metalloproteinase-9 (MMP-9) and basic fibroblast growth 
factor (FGF2) (Prakash et al. 2002; Wang et al. 2004b), and VEGF is secreted in the 
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surrounding matrix (Wang et al. 2004b; Prakash et al. 2005). Angiogenesis is an essential 
feature of KS, and VEGF and FGF2 have been described to be involved in this process 
(Samaniego et al. 1998; Sgadari et al. 2002). Thus, the signalling activity of K1 may play an 
important role in VEGF-mediated angiogenesis in KS tumours.  
 
 
 
Whether K1 plays a role in lytic replication cycle is controversial: Overexpression of a 
CD8/K1 chimera suppressed TPA-induced lytic replication in B-cells (Lee et al. 2002). In 
contrast, a dominant-negative K1 mutant lacking the ITAM motif reduced RTA-induced lytic 
replication in B-cells up to 80 percent (Lagunoff et al. 2001). Furthermore, it was shown that 
K1 inhibits NF-κB activation induced by latently expressed viral FLICE inhibitory protein 
(vFLIP)/K13 and Orf75 when transiently co-expressed in HEK293-T cells (Konrad et al. 
Figure 4. Schematic representation of the intracellular signalling pathways engaged by the 
KSHV transmembrane proteins K1 and vGPCR. Both K1 and vGPCR activate the PI3K/Akt 
cascade, AP-1 and NF-kB transcription factors. In addition, K1 activates members of the Src kinase 
family and Syc kinase in an ITAM-dependent manner, while vGPCR activates MAPK cascades. Their 
downstream effects include the activation of a broad range of inflammatory and angiogenic cytokines, 
particularly VEGF and IL-8 (both K1 and vGPCR), IL-6 (K1), and Groα (vGPCR). 
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2009). In consideration of the finding by others that NF-kB suppresses lytic replication 
(Brown et al. 2003) the authors suggest that K1 may promote the productive replication cycle. 
 
K15 
 
Open reading frame K15 is located at the right end of the KSHV genome, adjacent to 
the terminal repeat region. Multiple and alternative splicing of its eight exons gives rise to a 
family of proteins that share a common C-terminal cytoplasmic domain but vary in the 
number of membrane anchor domains. So far, only the largest K15 protein with predicted 12 
transmembrane domains linked to the cytoplamic region has been shown to activate signalling 
pathways within host cells. Signalling motifs found in the cytoplasmic tail include two 
potential SH2- and one SH3-binding site as well as a TRAF-binding region (Glenn et al. 
1999; Choi et al. 2000; Brinkmann et al. 2003). These motifs are conserved among the two 
highly divergent P (predominant) and M (minor) genotypes of K15 (Glenn et al. 1999; Poole 
et al. 1999), suggesting the conservation of associated functional properties.  
Biochemical studies with a CD8-K15 (C-Tail) chimera expressed in KSHV-negative 
BJAB-cells performed by Choi et al. (2000) showed, that the tyrosine residue (Y481) within 
the putative SH2-B domain Y481EEV is the major site of phosphorylation by cellular tyrosine 
kinases and that this tyrosine phosphorylation is independent of antibody stimulation.  
Structurally and functionally, K15 shows similarities to LMP1 and LMP2A of Epstein-
Barr virus (Nicholas 2003; Brinkmann and Schulz 2006). Like LMP1, K15 interact with 
TRAF-1, TRAF-2, and TRAF-3, activates the MAP kinases ERK2 and JNK as well as the 
transcription factors NF-κB and AP-1 (Glenn et al. 1999; Brinkmann et al. 2003). 
Reminiscent of LMP2A, K15 interacts with members of the Src family of protein tyrosine 
kinases, which phosphorylate the tyrosine residue Y481 in a YEEV SH2-binding domain 
(Brinkmann et al. 2003). In a further parallel to LMP2A, K15 is able to inhibit B-cell receptor 
signalling, as shown by the suppression of tyrosine phosphorylation and intracellular calcium 
mobilization in the B-cell line BJAB (Choi et al. 2000). Inhibition of BCR signalling involves 
the SH2-B (Y481EEV) and the SH3-B domains, as mutants with point mutations in these 
motifs do not suppress mobilization of intracellular free calcium upon anti-IgM stimulation 
(Choi et al. 2000). The second putative SH2-B motif (Y431SI) is not significantly 
phosphorylated and may therefore not serve as a SH2-B domain but provide other functions. 
K15 is expressed during the lytic cycle of KSHV with low expression levels observed in 
unstimulated PEL cells (Glenn et al. 1999; Poole et al. 1999; Choi et al. 2000; Brinkmann et 
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al. 2007). This is reminiscent of the K1 expression pattern (see above), and clustering of gene 
expression array data grouped K15 together with K1, indicating a similar expression pattern 
for these two proteins (Jenner et al. 2001; Paulose-Murphy et al. 2001; Nakamura et al. 2003). 
It was demonstrated that TPA-induced lytic infection and the RTA protein activate K15 
promoter elements (Brinkmann et al. 2003; Wong and Damania 2006). Furthermore, a 45 kDa 
K15-derived protein has been shown to be expressed after the activation of the lytic 
replication cycle in HEK293 cells carrying a recombinant viral genome (Brinkmann et al. 
2007). These findings indicate a predominant role for K15 during the KSHV lytic cycle. 
K15 is capable of inducing the expression of multiple cytokines, including in particular 
IL-8, IL-6, CXCL3 (Gro-γ), which have been shown to play a role in KSHV-associated 
pathogenesis (Brinkmann et al. 2007). While strongly inducing the expression and secretion 
of the angiogenic chemokine IL8, K15 does not, unlike K1, show a marked effect on VEGF 
expression, but activates a number of VEGF target genes directly, e.g. dscr1 and cox-2 
(Brinkmann et al. 2007). Expression of the majority of K15-induced genes depends on an 
intact YEEV SH2 binding site, underlining the importance of this motif, and presumably the 
recruitment of members of the src kinase family, for K15-mediated signalling (Brinkmann et 
al. 2003; Brinkmann et al. 2007).  
Therefore, as suggested for K1, K15 signalling may contribute to the hypothesized 
paracrine effects of lytically infected cells in KS lesions on latently infected or uninfected 
neighbouring cells. In addition, K15 may also have an antiapoptotic role. Sharp et al. (2002) 
observed that K15 interacts with HAX-1 (HS1 associated protein X-1), a protein with anti-
apoptotic functions. A K15 protein and HAX-1 were shown to co-localize in the ER and, 
consistent with apoptotic regulatory activity, in mitochondria (Sharp et al. 2002). However, to 
date there is no functional evidence that K15 association with HAX-1 affects cell survival. In 
addition, K15 has recently been shown to upregulate the expression of anti-apoptotic genes 
such as tnfaip3/A20, bf, birc3, birc2, and bcl2a1, of which, notably, the last shows sequence 
homologies with HAX-1 (Brinkmann et al. 2007). Another interesting factor shown to be 
upregulated through K15-induced signalling pathways is Cox-2 (Brinkmann et al. 2007). Cox-
2 expression after KSHV infection had already been reported (Naranatt et al. 2004) and its 
association with other herpesviruses, including EBV, CMV and HHV-6, has been observed 
(Speir et al. 1998; Murono et al. 2001; Janelle et al. 2002; Zhu et al. 2002). Cox-2 may 
contribute to viral replication by increasing prostaglandin E2 synthesis, which has been shown 
to increase multiple gene products of the KSHV related γ-herpesvirus MHV68 (Symensma et 
al. 2003).  
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Table 1. Characteristics and functional properties of some important KSHV lytic signalling proteins. 
Transmembrane proteins Serine-threonine protein kinase Viral homologues of cellular cytokines 
Characteristics 
K1 K15 vGPCR/Orf74 vPK/Orf36 vIL-6/K2 vCCL-1/K6 vCCL-2/K4 
Expression 
kinetics early lytic early lytic early lytic 
early lytic (3.6 
kb transcript)  
 
early-late lytic 
(4.2 kb 
transcript)  
early lytic early lytic early lytic 
Activated by 
Orf50/RTA 
(molecular 
mechanism of 
transactivation) 
yes (Oct-1) yes yes (RBP-Jk) 
not known; 
 
induced by 
hypoxia 
yes 
(direct 
mechanism); 
 
also RTA-
independent 
regulation via 
Notch signalling 
pathway 
yes (RBP-Jk) not known 
Induction of the 
activation of 
PI3K-Akt, Syk, 
Lyn, Cbl, Vav, 
RasGAP, 
PLCγ2, NFAT, 
NF-kB, AP-1, 
Oct-2 
MAPK (ERK, 
JNK), NF-kB, 
AP-1 
MAPK (ERK, 
p38, JNK), Akt, 
JAK2, NFAT, 
CREB, NF-kB, 
AP-1, HIF-1α, 
SP-1/3 
JNK, MKK4, 
MKK7  
JAK1, 
STAT1/3, Ras-
MAPK 
Agonist of 
CCR8; Akt, 
ERK 
Agonist of 
CCR8 and 
CCR3; Akt, 
ERK 
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Transmembrane proteins Serine-threonine protein kinase Viral homologues of cellular cytokines 
Characteristics 
K1 K15 vGPCR/Orf74 Orf36/vPK vIL-6 (K2) vCCL-1 (K6) vCCL-2 (K4) 
Induction of the 
expression of 
VEGF, FGF-2, 
GM-CSF, MMP-
9, IL-6, IL-8, IL-
10, IL-12, IL-
1α/β; Rantes  
IL-8, Dscr-1, 
Cox-2 
VEGF, IL-6, 
Gro-α, MIP-1α/β not known hIL-6, VEGF VEGF not known 
Role in lytic 
replication cycle 
yes, but both 
positive and 
negative 
regulation of 
KSHV lytic 
replication have 
been described 
not known yes; positive regulator 
yes; involved in 
lytic DNA 
replication 
no 
yes; promotes 
survival 
signalling 
yes; promotes 
survival 
signalling 
 
AP-1, activator protein 1; CCR, CC-motif chemokine receptor; Cox-2, cyclooxygenase-2; CREB, cAMP-response element binding protein; Dscr-1, Down 
syndrome critical region gene 1; ERK, extracellular signal-regulated kinase; FGF-2, basic fibroblast growth fctor; GM-CSF, granulocyte-macrophage colony-
stimulating factor; Gro-α, growth regulated oncogene alpha, HIF1α, hypoxia induced factor 1 alpha; hIL-6, human interleukine 6; IL, interleukine; JAK, janus 
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen activated protein kinase; MKK, MAPK kinase (also called MEK); MEF-2, myocyte enhancer factor 2; MIP-
1, macrophage inflammatory protein 1; MMP, matrix metalloproteinase; MSK1, mitogen- and stress-activated protein kinase 1; mTOR, mammalian target of 
rapamycin; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor kappa B; Oct-2, octamer binding protein 2, PI3K, phosphatidylinositol 3-kinase; PLCγ, 
phospholipase C-gamma; Rantes, regulated upon activation, normal T cell expressed and secreted (also known as CCL5), RasGAP, Ras GTPase activating 
protein; SP-1, specificity protein 1; STAT, signal transducers and activators of transcription; Syk, spleen tyrosine kinase; VEGF, vascular endothelial growth 
factor. 
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1.4 Protein kinase inhibitors 
 
Using protein kinase inhibitors to study cellular signalling pathways 
 
Protein kinase inhibitors represent a powerful tool to study the physiological substrates 
and cellular functions of their target kinases and related signalling pathways. Since their 
discovery in the early 1980s (Cohen 2002), a broad spectrum of small cell permeable 
inhibitors has been developed that exhibit a relatively high degree of specificity for a 
particular protein kinase. The advantage of using these chemical compounds for the study of 
signalling pathways is that (i) they can be used simply and rapidly to assess the physiological 
roles of protein kinases in normal cells and tissue, and (ii) they inhibit the endogenous protein 
kinases, avoiding the need for overexpression of dominant-negative and constitutively active 
protein kinases, which can cause the specificity of signalling to break down.  
Two widely used inhibitors of the MEK-ERK1/2 signalling cascade are PD98059 and 
U0126 (see also Table 3 in Results I). Both inhibitors bind to (inactive) MEK1 and thereby 
prevent its activation by upstream kinases such as c-Raf (Alessi et al. 1995; Dudley et al. 
1995; Favata et al. 1998; Davies et al. 2000). A commonly used inhibitor of PI3K is 
LY294002. Unlike PD98059 and U0126, LY294002 is ATP-competitive and acts by binding 
to the ATP-binding site of its target kinase (Vlahos et al. 1994; Vlahos et al. 1995; Baumann 
and West 1998). Piceatannol (trans-3,4,3’,5’-tetrahydroxystilbene) is a naturally occurring 
stilbene present in sugar cane, berries, peanuts, red wine and the skin of grapes (Cantos et al. 
2003; Rimando et al. 2004), that has been shown to act as a potent inhibitor of the tyrosine 
kinase Syk (Thakkar et al. 1993; Burke 1994) (see also Table 3). 
 
Protein kinases as major drug targets 
 
Dysregulated protein kinases are involved in the development of a variety of human 
neoplastic diseases. Hence, much of the effort to develop drugs that target specific protein 
kinases has been concentrated in the field of cancer. A landmark event occurred in May 2001 
when Gleevec – the first important drug to be developed by targeting a protein kinase 
specifically (the Abelson tyrosine kinase, ABL) – was approved for clinical use (Druker and 
Lydon 2000). In nearly all cases of chronic myelogenous leukaemia (CML), a chromosomal 
rearrangement leads to enhanced activity of ABL, which might cause CML by eliciting 
uncontrolled activation of the MAPK cascade.  
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Today, protein kinases are the second largest group of drug targets after G protein-
coupled receptors, and they account for 20 to 30 percent of the drug discovery programs of 
many companies (Cohen 2002). In cancer therapy, protein kinase inhibitors are proving to be 
well tolerated compared with conventional chemotherapeutic treatments. 
 
1.4.1 Protein kinase inhibitors in the treatment of KSHV-associated diseases  
 
A number of reports have been published describing the effectiveness of rapamycin 
(sirolimus) in the treatment of transplant recipients with (iatrogenic) KS (Gutierrez-Dalmau et 
al. 2005; McCaffrey 2005; Mohsin et al. 2005; Stallone et al. 2005; Zmonarski et al. 2005; 
Kolhe et al. 2006). Rapamycin is widely used as an immunosuppressive agent. It inhibits 
mTOR, which is a target of the PI3K-Akt signalling cascade (see also Figure 3) and has a 
crucial role in cell-cycle progression from G1- to S-phase, as well as in IL-2 stimulated T-cell 
proliferation. It has been demonstrated that in patients undergoing a kidney-transplant, 
rapamycin (sirolimus) inhibited the progression of dermal KS while providing effective 
immunosuppression. In vivo experiments using a cell based (allograft) animal model for KS 
showed that activation of the TSC2/mTOR pathway was sufficient to promote the 
tumorigenic potential of endothelial cells. Furthermore, Sin et al. (Sin et al. 2007) showed that 
mTOR, Akt and p70S6K are phosphorylated in PEL cells and that rapamycin was efficacious 
against PEL in culture and in a murine xenograft model. 
Others found that expression of the proto-oncogene c-Kit, a member of the PDGF 
family of receptor protein tyrosine kinases and receptor for stem cell factor, is upregulated in 
KS tumours and KSHV latently infected endothelial cells (Moses et al. 2002; Pantanowitz and 
Dezube 2004; Pantanowitz et al. 2005). Limited experience with the c-kit inhibitor imantinib 
showed a partial response to the drug in patients with epidemic KS (Koon et al. 2005). 
Clinical trials are currently ongoing to examine the role of other c-kit inhibitors, such as 
sorafenib, in the treatment of KS. 
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1.5  Objectives 
 
Accumulating evidence suggests that ongoing viral lytic replication in a small number 
of cells in KSHV associated tumours significantly contributes to KSHV pathogenesis and is 
necessary to maintain stable viral infection. Identification of the molecular mechanisms that 
regulate the viral lytic life cycle may therefore provide new targets for antiviral and tumour 
therapy. Additionally, understanding virus manipulation of cellular signalling pathways and 
their functional relevance to KSHV biology may contribute to our knowledge and 
appreciation of viral strategies developed during the long co-evolution with their host.  
Previous reports had concentrated on the role of signalling pathways during primary 
infection and reactivation of KSHV from latency and had identified Raf/MEK/ERK and PI3K 
signalling cascades as key regulators of KSHV infection and activation of the RTA promoter. 
I now investigated the activation of these signalling pathways during progression of viral lytic 
replication downstream of RTA expression.  
Since several viral lytic proteins are capable of inducing signalling pathways within 
their host cell, I asked whether these proteins contribute to the activation of signalling 
pathways during KSHV productive phase and analysed their contribution to successful viral 
protein expression and virus production in siRNA-mediated depletion experiments and by 
genetic knockout. 
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2 Materials and Methods 
 
2.1 Reagents and Chemicals 
 
Chemicals were purchased from the following companies: Amersham, AppliChem, 
Biochrom, Biomol, BioRad, Calbiochem, Difco, Fluka, Invitrogene, Life Technologies, 
Merck, New England Biolabs, Pierce, Promega, Riedel-deHaën, Roche, Roth, Santa Cruz, 
Sigma and Stratagene. 
Consumables were obtained from Amersham, Beckman, Biozym, Costar, Eppendorf, Falcon, 
Gilson, Greiner, Hartmann, Kodak, Machery-Nagel, Millipore, Nerbe Plus, Qiagen, Sarstedt 
and Whatman. 
Restriction enzymes came from Amersham, New England Biolabs and Life Technologies. 
Oligonucleotides were purchased from Ambion, Dharmacon, MWG Biotech and Sigma. 
 
2.1.1 Antibodies 
 
Primary antibodies: 
 
α-β-actin 
Chemicon, mouse monoclonal, IgG1κ, used in a 1:2000 dilution, specific for the N-terminal 
two-thirds of the actin molecule near aa residues 50-70 in primary sequence. 
 
α-Akt1  
Cellsignaling, rabbit polyclonal, raised against a synthetic peptide (KLH-coupled) derived 
from the carboxy-terminal sequence of mouse Akt. Antibodies are purified by protein A and 
peptide affinity chromatography, used in a 1:1000 dilution. MW of Akt = 60 kDa. 
 
α-BrdU 
BD Biosciences, mouse monoclonal, IgG1,k , purified, used in a 1:5 dilution. 
 
α-ERK2 D-2 
Santa Cruz, mouse monoclonal, IgG2b, raised against a peptide at the C-terminus of human 
ERK2-encoded MAP kinase, used in a 1:2000 dilution. MW of ERK2 = 42 kDa. 
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α-K1 (2H5) 
(Lee et al. 2003), mouse monoclonal, purified from mouse ascites by affinity chromatography 
on recombinant protein G columns, recognizes an epitope of K1 in the C2 region overlapping 
with the Ig region, used in a 1:500 dilution for Western blotting and a 1:200 dilution for 
immunofluorescence assay;  provided by J.Jung. MW of K1 = 46 kDa. 
 
α-K8 
(Wu et al. 2001), rabbit polyclonal, the antibody was generated by immunization with the N-
terminal peptide (16-DNSEKDEAVIEED-28) bounded by N-Y and C-CS residues, used in a 
1:200 dilution; provided by G. S. Hayward. K8 is a 237-aa nuclear protein. 
 
α-K8.1 A/B 
Advanced Biotechnologies (ABI), mouse monoclonal, IgG1, originated from serum-free 
hybridoma cell culture medium, purified by protein G agarose affinity chromatography. K8.1 
is highly glycosylated, used in a 1:1000 dilution. A 37 kDa- and a 25 kDa-K8.1 protein are 
detected by Western blotting in most KSHV lytic infected cell lines. 
 
α-c-myc 9E10 
Biomol, mouse monoclonal, IgG1; raised against a synthetic peptide corresponding to residue 
408-439 of the human p62c-myc protein and recognizes an epitope located in the aa residue 
410 to 419; used in a 1:500 dilution. 
 
α-Orf50/RTA 
(Lukac et al. 1998), rabbit polyclonal, raised against a recombinant Orf50/RTA fragment (aa 
484 to 691), rabbit serum, used in a 1:1000 dilution, provided by D. M. Lukac. MW of RTA: 
predicted: 73.7 kDa. However, the expressed protein when anlysed by Western blot appears to 
be about 110 kDa, suggesting post-translational modification (Lukac et al. 1999). 
 
α-Orf59 
Advanced Biotechnologies (ABI), mouse monoclonal, IgG, originated from ascites fluid and 
is purified by protein A agarose affinity chromatography, used in a 1:2000 dilution. MW of 
Orf59 = 50 kDa. 
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α-phospho Akt (Ser473) (193H12) 
Cellsignaling, rabbit monoclonal, IgG, detects endogenous levels of Akt only when 
phosphorylated at serine 473, used in a 1:1000 dilution. MW of Akt = 60 kDa. 
 
α-phospho p42/44 MAPK (Thr202/Tyr204) (E10) 
Cellsignaling, mouse monoclonal, detects endogenous levels of p42 (ERK2) and p44 (ERK1) 
MAP kinase dually phosphorylated at threonine 202 and tyrosine 204, used in a 1:2000 
dilution. MW of ERK1 = 44 kDa and of ERK2 = 42 kDa. 
 
α-Vimentin 
Chemicon, mouse monoclonal, IgG1, used in a 1:1000 dilution, recognizes the 57-60 kDa 
vimentin protein. 
 
Secondary antibodies: 
 
α-goat, HRP-conjugated  
DakoCytomation, rabbit monoclonal, IgG, used in a 1:2000 dilution. 
 
α-mouse, Cy5-conjugated 
Jackson ImmunoResearch, goat polyclonal, IgG, used in a 1:200 dilution for 
immunofluorescence and 1:50 for FACS analysis. 
 
α-mouse, HRP-conjugated 
DakoCytomation, rabbit polyclonal, IgG, used in a 1:1000 dilution. 
 
α-mouse, Rhodamine X-conjugated 
Jackson ImmunoResearch, goat polyclonal IgG, used in a 1:200 dilution. 
 
α-rabbit, HRP-conjugated 
Cellsignaling, mouse polyclonal IgG, used in a 1:2000 dilution. 
 
α-rabbit, Rhodamine X-conjugated 
Jackson ImmunoResearch, goat polyclonal, IgG, used in a 1:200 dilution. 
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2.2 Vectors, primers, inhibitor peptide and small inhibitory RNAs (siRNAs) 
 
2.2.1 Expression vectors 
 
Eukaryotic expression vectors 
 
pcDNA3 
T7 and SP6 promoter for in vitro transcription, CMV promoter for expression in mammalian 
cells; bovine growth hormone polyadenylated signal; Ampicillin and Neomycin resistance 
gene. Invitrogen. 
 
pcDNA3.1(-)/Myc-His 
Derived from pcDNA3.1. With a C-terminal peptide containing the c-myc epitope and a 
polyhistidine metal binding tag. Invitrogen.  
 
pcDNA4/myc-His B 
CMV promoter for expression in mammalian cells; three reading frames with a C-terminal 
peptide encoding c-myc epitope and a polyhistidine (6xHis) metal-binding tag; Zeocin 
resistance gene for selection. Invitrogen.  
 
pK1 
K1 expressing plasmid, the cDNA sequence of K1 was cloned between the BamHI-HindIII 
restriction sites into pcDNA3.1(-)/Myc-His. Provided by M. Stürzl. 
 
pOrf74 
vGPCR (Orf74) expressing plasmid; Orf74 was cloned by EcoRI and SacII digestion of 
pcDNA4/myc-His B. Provided by M. Stürzl. 
 
pTpl-2 wt.MT 
Tpl2 expressing plasmid. Provided by A. Kieser. 
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Prokaryotic expression vector 
 
pKD46 
(Datsenko and Wanner 2000); Red recombinase expression plasmid, includes 2.154 nt 
(31088-33241) of phage λ (GenBank accession no. J02459). 
 
2.2.2 Primers and probes 
 
Primer pair for K1-knockout construction 
 
K1 ko-forward  
Target position: nt 44-104 of KSHV genome sequence (Russo et al. 1996) and nt 1-24 
(underlined) of the rpsL-neo cassette (GeneBridges).  
Sequence: 5’-TTC TGG CGG CCC TTG TGT AAA CCT GTC TTT CAG ACC TTG TTG 
GAC ATC CTG TAC ATC AAG GGC CTG GTG ATG ATG GCG GGA TCG-3’. 
 
K1 ko-reverse  
Target position: nt 971-1034 of KSHV genome sequence (Russo et al. 1996) and nt 1298-
1319 of the rpsL-neo cassette sequence (GeneBridges). 
Sequence: 5’-TAA ACA TAA AAC ACA TTA CAA TTA TGT TAT AGA GAA TAT TTA 
GAT TAT CTT ACC TGA ATG TCA GAA GAA CTC GTC AAG AAG GCG-3’. 
 
Primer pairs used for verification of BAC36 ΔK1: 
 
neo1 (forward) 
Targets position nt 541-560 in the rpsL-neo cassette (GeneBridges). 
Sequence: 5’-GAT TGC ACG CAG GTT CTC CG-3’. 
 
neo2 (reverse) 
Targets position nt 1298-1319 in the rpsL-neo cassette (GeneBridges). 
Sequence: 5’-TCA GAA GAA CTC GTC AAG AAG G-3’. 
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K1 ko transitional region right forward 
Target position: nt 981-1000 of the rpsL-neo cassette (GeneBridges). 
Sequence: 5’-GTC GAT CAG GAT GAT CTG GA-3’. 
 
K1 ko transitional region right reverse 
Target position: nt 1084-1104 in the KSHV genome sequence (Russo et al. 1996). 
Sequence: 5’-CTG TAA CAT ATT GGC ACG ATG-3’. 
 
 
Table 2: Primers used to quantify transcripts of KSHV early lytic proteins by reverse 
transcription real-time quantitative PCR (qPCR). 
 
a 
Based on the coding sequence of K1 derived from BC-1 cells (GenBank accession no. KSU86667). 
b 
Based on the genomic sequence of a KSHV P-type (GenBank accession no. NC_009333). 
c Glyceraldehydes-3-phosphate dehydrogenase primer pair was used as an internal control. 
d All taqman probes were labelled with 6-FAM at their 5’ end and with TAMRA at their 3’ end. 
 
 
2.2.3 Inhibitor peptide 
 
ERK Activation Inhibitor peptide I 
Purchased from Calbiochem; alternate name: Ste-MEK113 or Ste-MPKKKPTPIQLNP-NH3; a 
cell-permeable, stereated, 13-aa peptide corresponding to the N-terminus of MEK; acts as a 
specific inhibitor of ERK activation and blocks transcriptional activity of Elk1; selectively 
binds to ERK2 and prevents it interaction with MEK (IC50=2.5 µM according to the 
primer pair target position product size (bp) forward primer sequence (5’-3’) reverse primer sequence (5’-3’) 
K1 152-256a 104 TATTAAGCCTTTATGTGCTATCGTCTC CCAGGATATTGGCAAGGATGAATC 
K2/vIL-6 17709-17841b  132 CCCATAGCATCCAATTGAGTCTC ATGCGCTGGTTCAAGTTGTG 
K6/vCCL-1 27358-27445b  87 ACGCCCTCGCTTGGTCAG CCGCCCGTCCAAATTCTAAAAG 
K8/bZIP 75142-75278b  137 AATTCCACATCCCCGATCCTTC CTTAGTGCATAAGCGTTCCTCTTC 
GAPDHc   GAAGGTGAAGGTCGGATGC GAAGATGGTGATGGGATTTC 
Probe length (nt) Sequence (5’-3’)d 
K1 25 [6FAM]TGTGCCCTGGAGTGATTTCAACGCC[TAM] 
K2/vIL-6 25 [6FAM]CTATCTTGCTGGTCGGTTCACTGCT[TAM] 
K6/vCCL-1 23 [6FAM]CGTCCCCAGCGTGCCCAAAACCC[TAM] 
K8/bZIP 25 [6FAM]CACACACCACCAAGAGGACCACACA[TAM] 
GAPDH 20 [6FAM]CAAGCTTCCCGTTCTCAGCC[TAM] 
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manufacturer). MW: 1757.3. Reconstituted in ddH2O (2.5 mM stock solution). Aliquotted and 
stored at -20°C. 
 
 
2.2.4 siRNAs 
 
siRNAs targeting early-lytic transcripts of KSHV 
 
siRNAs K1 
siRNA1 was purchased from Ambion, siRNA2 and siRNA3 were purchased from 
Dharmacon. siRNA1 and 3 were designed based on a K1 sequence obtained from a patient 
with classic KS (GenBank accession no. AF148805); siRNA2 was designed with the use of a 
K1 sequence derived from JSC-1 cells (PEL cells) (GenBank accession no. DQ984721). 
siRNA1: Targets position nt 319-339 in the K1 transcript; 
  sequence: 5’-GUCACUUGUGGUCAGCAUGTT-3’ 
siRNA2: Targets position nt 111-131 in the K1 transcript; 
sequence: 5’-CCAUUGUGCUCGAAUCCAAUU-3’. 
siRNA3: Targets position nt 403-423 in the K1 transcript; 
sequence: 5’-GAAACCGUGUCACAAACUAUU-3’. 
 
siRNAs K2 (vIL-6) 
Purchased from Ambion; siRNA design was based on the coding sequence for K2/vIL-6 
derived from a PEL cell line, published by Nicholas et al. (Nicholas et al. 1997) (GenBank 
accession no. U67774).  
siRNA1: Targets position nt 234-254 in the K2 transcript; 
sequence: 5’-CGAUACUGAUCACUGCGGGUU-3’ (K2_1),  
siRNA2: Targets position nt 426-444 in the K2 transcript; 
sequence: 5’-GCUGACUAAGACGCACUACUU-3’ (K2_2). 
 
K4 (vCCL-2) 
Purchased from Ambion; designed based on the K4 sequence from a KSHV P-type complete 
genomic sequence (GenBank accession no. NC_009333). 
 
siRNA1: Targets position nt 147-167 in the K4 transcript; 
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sequence 5’-GCACCUGUGGUAAUGGUCUU-3’. 
siRNA2: Targets position nt 19-39 in the K4 transcript; 
sequence: 5’-UAAUUGCUGCAUCAGCUUCUU-3’. 
 
K6 (vCCL-1) 
Purchased from Ambion; designed based on the coding sequence of K6 published by Sun et 
al. (1996) (GenBank accession no. U50138). 
 
siRNA1: Targets position nt 131-149 in the K6 coding sequence;  
sequence: 5’-CACCGCCCGUCCAAAUUCUUU-3’. 
siRNA2: Targets position nt 153-171 in the K6 coding sequence; 
sequence: 5’-AGAGUGGUAUCCCACGUCCUU-3’. 
 
K14 (vOX2) 
Purchased from Ambion; designed based on the K14 mRNA sequence published by Nador et 
al. (Nador et al. 2001) (GenBank accession no. AF367766). 
siRNA1: Targets position nt 225-543 in the K14 transcript;  
sequence: 5’-CCUUGCAGUGGAUGAUGAGUU-3’.  
siRNA2: Targets position nt 104-122 in the K14 transcript;  
sequence: 5’-CUGAAGAAGGCGUGUCUGCUU-3’. 
 
K15 siRNA 
Purchased from Dharmacon; targets exon 8 of the K15 transcript. 
Sequence: 5’-CAACCACCUUGGCAAUAAU-3’. 
 
Orf36 (vPK) 
Purchased from Ambion; designed based on the Orf36 coding sequence from a KSHV P-type 
complete genomic sequence (GenBank accession no. NC_009333). 
siRNA1: Targets position nt 362-380 in the Orf36 transcript; 
sequence: 5’-UUGCCAACGACCUGAUGCAUU-3’. 
siRNA2: Targets position nt 109-129 in the Orf36 transcript;  
sequence: 5’-CUCCCUAAGGCUACCCGGAUU-3’. 
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Orf74 (vGPCR) 
Purchased from Ambion (siRNA1) and Dharmacon (siRNA2 and siRNA3); designed based 
on the Orf74 sequence published by Nador et al. (Nador et al. 2001) (GenBank accession no. 
AF367766). 
siRNA1: Targets position nt 638-656 in the Orf74 transcript;  
sequence: 5’-CCGUGUCAGUUACUGCAGGUU-3’. 
siRNA2: Targets position nt 191-209 in the Orf74 transcript;  
sequence: 5’-GAAAUGGAUUGGUCACCUAUU-3’. 
siRNA3: Targets position nt 276-294 in the Orf74 transcript;  
sequence: 5’-CUCGCUGUGUCUUAGCAUAUU-3’. 
 
Control siRNA 
 
siCONTROL Non-Targeting siRNA#1 
Dharmacon; negative control siRNA with at least four mismatches to any human gene. 
Sequence: 5’-UAGCGACUAAACACAUCAA-3’. 
 
 
2.3 Eukaryotic cell culture methods 
 
2.3.1 General components for cell culture 
 
DMEM (Gibco)   + 4.5 g/l glucose, L-glutamine, pyruvate 
MEM (Cytogen)   + Eagle’s BSS, NEAA, L-glutamine, 2.2 g/l NaHCO3 
RPMI 1640 (Gibco)   + L-glutamine 
Grace’s Insect medium (Gibco) + L-amino acids 
L-Glutamine (Cytogene)  200 mM 
NEAA (Gibco)   100x 
β-Mercaptoethanol (Gibco) 50 mM 
PBS,10x (Gibco)   without CaCl2 and MgCl2 
Trypsin/EDTA (Cytogen)  0.05/0.02% in PBS 
Trypsin/EDTA (Biochrom)  0,25/0.02% in PBS 
FCS (Gibco)    heat-inactivated for 30 min. at 56°C 
FCS (PAA)    heat-inactivated for 30 min. at 56°C 
2 Materials & Methods 
44 
Hygomycin B (Signal)  50 mg/ml in PBS 
Puromycin (Sigma)   5 mg/ml 
DMSO (AppliChem)   cell culture grade 
 
 
Protein kinase inhibitors 
 
MEK inhibitors 
U0126  Purchased from Calbiochem, MW: 380.5, reconstituted in DMSO just prior to 
use (25 mM stock solution). 
PD98059 Purchased from Calbiochem, MW: 267.3, reconstituted in DMSO (25 mM 
stock solution), stored at -20°C. 
 
U0124, the non-active analogue of U0126, was purchased from Biomol; MW: 226.3, 
reconstituted in DMSO (25 mM stock solution), stored at -20°C. 
 
PI3K inhibitor 
LY294002 Purchased from Biomol, MW: 307.4, reconstituted in DMSO (25 mM stock 
solution), stored at -20°C. 
 
Syk inhibitor 
Piceatannol Purchased from Biomol and Calbiochem; MW: 244.2, reconstituted in DMSO 
(25 mM stock solution), stored at -20°C.  
 
After reconstitution, all kinase inhibitors were aliquotted and stored for up to six months. All 
inhibitors were handled under low-light conditions. 
 
 
2.3.2 Eukaryotic cell lines 
 
Adherent cell lines 
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HEK293 
human embryonic kidney cell line; adherent fibroblastoid cells which were established from a 
human primary embryonal kidney transformed by adenovirus type 5 (Ad 5). ACC 305 
(German Collection of Microorganisms and Cell Cultures (DSMZ)). 
 
EAhy926 
(Edgell et al. 1983); derived by fusing human umbrilical vein endothelial cells (HUVEC) with 
the permanent human lung carcinoma cell line A549. Provided by P. Ojala. 
Vero 
African green monkey kidney cell line; adherent-elongated, fibroblast-like cells, which were 
established from the kidney of a normal adult African green monkey (Cercopithecus 
aethiops). ACC 33 (DSMZ). 
 
Insect cells SF9 
Cells isolated from Spodoptera frugiperda (ATCC CRL-1711). 
 
Adherent cell lines carrying a recombinant KSHV genome 
 
Vero rKSHV.219 
Vero cells stably infected with a recombinant KSHV (rKSHV.219) containing the red-
fluorescent protein (RFP) gene under the control of the viral lytic PAN promoter, the green-
fluorescent protein (GFP) gene expressed by the human elongation factor 1-α (EF-1α) 
promoter, and the pac gene for resistance to puromycin expressed by the RSV promoter. The 
RFP/GFP/PURO cassette is inserted between ORF K9 and ORF 57 at a site that sequence 
data indicated does not contain a gene (Vieira and O'Hearn 2004). Provided by J. Vieira. 
 
EAhy rKSHV 
EAhy926 cells were stably infected with rKSHV.219 produced from Vero rKSHV.219 cells 
(see 2.3.6). 
 
HEK293 BAC36 
HEK293 stably transfected with recombinant bacterial artificial chromosome (BAC) KSHV 
(BAC36) containing hygromycin resistance and GFP markers. The BAC vector/Hyg/GFP 
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cassette is integrated into the PmeI site between orf18 and orf19 in the long unique region of 
the viral genome (Zhou et al. 2002). 
 
Suspension cells 
 
TREx BCBL-1-pcDNA5/FRT/TO-RTA/myc/his (TREx BCBL-1-RTA) 
PEL cell line (BCBL-1) stably transfected with a vector containing myc/his-tagged RTA 
cDNA downstream of the CMV promoter and tetracycline operator sequences. The vector 
further contains the hygromycin resistance gene as selectable marker (Nakamura et al. 2003). 
Provided by J. Jung. 
 
 
2.3.3 Cell culture conditions 
 
Vero:    MEM with 10% FCS 
HEK293, EAhy926:  DMEM with 10% FCS 
SF9:    Grace’s insect medium with 10% FCS 
 
Vero rKSHV.219:  MEM with 10% FCS, puromycin 5 µg/ml 
EAhy rKSHV:  DMEM with 10% FCS, puromycin 1 µg/ml 
HEK293 BAC36:  DMEM with 10% FCS, hygromycin B 150 µg/ml 
TREx BCBL-1-RTA  RPMI 1640 with 20% FCS, hygromycin B 100 µg/ml 
 
Cells were kept in humidified air with 5% CO2 at 37°C. Adherent cell lines were split at 80-
90% confluency at a ratio of 1:6 to 1:10. BCBL-1 cells were usually split every three days at a 
ratio of 1:5. Insect cells were cultured at 27°C and split at 100% confluency at a ratio of 1:10. 
 
 
2.3.4 Cryoconservation 
 
For conservation, cells were resuspended in 1 ml of the appropriate cell culture medium 
with 20% FCS and 10% DMSO, transferred to a cryo tube and frozen in a polystyrene box or 
an isopropanol-jacketed freezing box at -80°C. After two days, the cells were transferred to 
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liquid nitrogen. For recovery, cells were thawn in handwarm water, washed once in 10 ml 
pre-warmed medium and transferred to a tissue culture flask. 
 
 
2.3.5 Amplification of baculovirus Orf50/RTA in SF9 cells 
 
Baculovirus (BV) Orf50/RTA was provided by J. Vieira. For production of new BV 
Orf50/RTA, SF9 insect cells were grown in 125 ml suspension culture flasks up to a cell 
density of 1,6x106 cells/ml. The cells were then infected with SF9 cell supernatant containing 
high titer BV Orf50/RTA. The added amount corresponded to 5% of the final volume. When 
a cytopathic effect was observed – usually two to three days after infection - the culture was 
aliquoted to 50 ml-falcon tubes and centrifuged at 1500 rpm for 10 minutes at 4°C to remove 
cells and cell debris. Supernatant was filtered through a 0.45 µm- filter, transferred to fresh 
tubes, and stored at 4°C for later use. 
 
 
2.3.6 Lytic cycle induction 
 
Lytic cycle induction in Vero rKSHV.219 cells 
 
For reactivation of KSHV from latency, Vero rKSHV.219 cells were subcultured to 
1.5x105 cells per well in 6-well plates (Greiner) in medium without puromycin over night. 
The next day, lytic cycle was induced using baculovirus (BV) Orf50/RTA in combination 
with 1 mM sodium (Na-) butyrate (NaB, Sigma-Aldrich). For inhibition of signalling 
pathways during lytic replication, Vero rKSHV cells were incubated with protein kinase 
inhibitors at a final concentration of 12.5 and 25 µM one hour prior to reactivation (if not 
indicated otherwise). Subsequently, BV Orf50/RTA and NaB were added without medium 
change. After 48 h, the supernatant was collected, and the number of newly produced 
infectious virions (infectious units (IU)/ml) was determined by infectivity assay. Cells were 
washed once in PBS, lysed, subjected to Western blot analysis or stored at -20°C for later use. 
To investigate the activation pattern of the ERK and Akt kinases during the KSHV lytic 
cycle, Vero rKSHV.219 cells were lysed 4, 8, 12, 16, 20, 24, 28, and 40 h after induction of 
the lytic replication cycle (h.p.i.). Supernatants were collected 20, 24, 28, and 40 h.p.i..  
To inhibit viral DNA replication during the KSHV lytic cycle, phosphonoacetic acid 
(PAA, 98%, Sigma-Aldrich) was applied at a final concentration of 1 mM at the time of 
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inducing the lytic cycle. To inhibit viral lytic protein synthesis, cycloheximide (CHX, Sigma-
Aldrich) was applied at 50 µg/ml 4, 8, 10, 12, 13, 14, or 16 h.p.i.. 
 
 
 
Generation and reactivation of EAhy rKSHV 
 
To establish EAhy rKSHV cell lines, EAhy926 cells (see 2.3.2) were plated at 1.5X105 
cells per well on 6-well plates (Greiner) and grown over night. The next day, the medium was 
removed, cells were infected with supernatant of reactivated Vero rKSHV.219 cells (1ml/ 
well), incubated for 2 h while rocking at room temperature (RT), the volume of the medium in 
each well was adjusted to 2 ml with fresh cell culture medium, and cells were transferred to 
37°C. The medium was exchanged the next day. The infection efficiency was monitored by 
expression of GFP. 48 hours after infection (h.p.i.), cells were split 1:3 in medium containing 
1 µM puromycin for selection. In the following, medium was exchanged every two days, and 
when foci developed, individual clones were picked and transferred to 96-well (Greiner) 
under selection of puromycin. Cell lines were established from 12 individual clones which 
Figure 5: (A) Schematic diagram of the structure and insertion site of the RFP/GFP/PURO construct in 
the recombinant KSHV.219 genome. rKSHV.219 was constructed by insertion of a gene cassette 
between orf K9 and orf 57, that comprises the RFP genetic marker under the control of the lytic PAN 
promoter, along with the GFP gene expressed by the human elongation factor 1-α promoter (EF-1α p), 
and a gene for resistance to puromycin (PURO) expressed by the RSV promoter. pA, poly A. (B) GFP 
expression (upper picture) and RFP expression (lower picture) in Vero rKSHV.219 cells 32 h after 
induction of the lytic replication cycle using baculovirus Orf50/RTA in combination with sodium butyrate 
[1 mM]. 
 
A Vero rKSHV.219,
32 hours post induction
(Viera J. & O‘Hearn P.M. [2004])
RSVp
RFP GFP PUROpApA pAPANp EF-1αp
K9orf57K8.1orf50/RTA K8/bZIP
rKSHV.219 in Vero cells
B
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were resistant to puromycin, expressed GFP to nearly 100 %, and produced infectious virions 
after induction of lytic replication using BV Orf50/RTA and Na-butyrate.  
To induce the KSHV lytic cycle, EAhy rKSHV cells were subcultured at 1*105 cells/ml 
in 6-well plates in medium without puromycin. After 24 h, the medium was removed, and 
cells were incubated with BV Orf50/RTA (1ml/well) for 2 h while rocking at RT. Then, the 
supernatant baculovirus was replaced with 2 ml of fresh medium containing 1 mM Na-
butyrate. 48 h after reactivation from latency, culture supernatants were collected in 2 ml-
reaction tubes (Eppendorf), centrifuged for 10 minutes at 2.000 rpm, and transferred to new 
tubes. Virus titer (IU/ml) was determined by infectivity assay on HEK293 cells. Cells were 
washed once in PBS, lysed, analysed by Western blotting or stored at -20°C for later use.  
 
 
2.3.7 Infectivity assay 
 
For determination of virus titer (IU/ml) in supernatant of cells undergoing KSHV lytic 
infection (see 2.3.6), HEK293 cells were seeded to 70% confluency in a 96-well plate. The 
next day, cells were infected in triplicates with 25 µl/well of culture supernatant diluted 1:2; 
1:5, and 1:10. Total volume per well was adjusted to 100 µl with fresh medium. After 
incubation for 2 h at RT, plates were centrifuged at 450x g for 25 min at 30°C, the culture 
volume per well was adjusted to 200 µl with fresh medium, and plates were incubated at 
37°C. After 48 h, the plates were examined on a Nikon Eclipse TS100 fluorescence 
microscope with a 10x objective for GFP-expressing cells. For counting, we chose the 
dilution that gave between 100 and 400 GFP-positive cells per well. These numbers were then 
converted to GFP-positive cells per ml to reflect the virus titer (IU/ml).  
To relatively quantify the number of infectious virions in supernatant of inhibitor-
treated and reactivated cells, HEK293 cells were plated at 2x105 cells per ml on black-bottom 
96-well plates (Nunc), and infected 24 h later with 50-100 µl supernatant as described above. 
48 hours after infection, the overall fluorescence intensity of GFP in each well was measured 
at a BioTek plate reader. Data was processed using Gen5 software and analysed in Excel. 
 
Entry control assay for kinase inhibitors 
 
To ensure that inhibitors applied during reactivation of KSHV in Vero rKSHV.219 or 
EAhy rKSHV cells no longer interfered - under the experimental conditions used - with 
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KSHV entry into HEK293 cell in infectivity assay, inhibitors were incubated for 48 h at 37°C 
in normal culture medium supplemented with 10% FCS, BV Orf50/RTA, and 1 mM NaB. 
These pre-incubated inhibitors were then mixed with virus inoculum, which was subsequently 
used to infect HEK293 cells as described above. After 48 h, infected (GFP-positive) cells 
were counted and virus titers were calculated. The titers obtained for pre-treated virus 
inoculum were compared to those determined for non-treated and DMSO-treated virus 
inoculum. 
 
 
2.3.8 Transient transfection 
 
Transient expression of K1 in HEK293 cells 
 
pcDNA 3.1(-)-K1/myc/His, and pcDNA4-Orf74/myc/His were kindly provided by M. 
Stuerzl. Tpl-2 wt.MT (myc-tagged) (Patriotis et al. 2001) was a kind gift of A. Kieser. 
HEK293 cells were plated at 2x105 cells per well of 6-well plates, and grown over night. The 
cells were transiently transfected with 1 µg of DNA per well using FuGENE 6 transfection 
reagent (Roche) at a ratio of 1:3 (DNA to transfection reagent) according to the 
manufacturer’s protocol. The cells were incubated in complete medium. Protein samples were 
taken 24 h and 48 h posttransfection to be assayed by immunoblotting for activation of ERK 
signalling. Expression of K1, Orf74/vGPCR, and Tpl-2 was analysed using myc-specific 
antibodies. 
 
Transfection of siRNAs to downregulate lytic gene expression 
 
Expression of KSHV early-lytic proteins was downregulated using RNA interference. 
Therefore, Vero rKSHV.219 or EAhy rKSHV cells were transfected with individual siRNAs 
targeting viral early-lytic transcripts using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s protocol. Briefly, Vero rKSHV.219 or EAhy rKSHV cells were seeded to 40-
50 % confluency on 6-well plates one day prior to transfection. Each siRNA (160 pmol) was 
diluted with 5 µl Lipofectamine 2000 in 500 µl reduced serum medium (OptiMEM I, Gibco), 
incubated for 20 min at RT, and then added to the cells. Medium was replaced after 6-8 h, and 
lytic cycle was induced simultaneously using BV Orf50/RTA in combination with Na-
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butyrate as described in 2.3.6. 48 h after reactivation, culture supernatant was collected for 
infectivity assay, and protein extracts were taken for Western blot analysis.  
 
 
2.4 Prokaryotic culture methods 
 
2.4.1 Culture media and growth conditions 
 
Luria Bertani (LB) -medium: 
1% (w/v) Trypton (Becton Dickinson) 
0.5% (w/v) Yeast extract (Difco) 
1% (w/v) NaCl 
pH 7.0 with NaOH 
 
Agar plates: 
LB medium with 1.5% (w/v) Bacto-Agar (Becton Dickinson) 
 
Overnight cultures were usually grown in LB medium at 37°C and 220 rpm. The 
medium was inoculated with bacteria kept on agar plates at 4°C or from cryoconserved 
cultures. The medium/agar plates were supplemented with antibiotics according to the 
properties of the plasmid being introduced. Antibiotics were used in the following final 
concentration:  
Ampicillin:  100 µg/ml 
Kanamycin:  15 µg/ml 
Chloramphenicol: 15 µg/ml 
 
2.4.2 Bacterial strains 
 
E. coli TG-2 
supE hsdΔ5 thiΔ(lac-proAG)Δ(srl-recA)306::Tn10(tetr)F΄[traD36 proAB+ laclq lacZΔM15]. 
 
E.coli DH10B 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 
Δ(ara,leu)7697 araD139 galU galK nupG rpsL λ- (Durfee et al. 2008). 
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2.4.6 Cryokonservation of bacteria 
 
500 µl of a bacterial overnight culture were mixed with 500 µl glycerol in a cryo tube 
and stored at -80°C. 
 
 
2.4.7 Preparation of competent cells and transformation 
 
Competent cells were prepared using the rubidium chloride method. An overnight 
culture was diluted 1:100 in LB medium and grown at 37°C and 200 rpm to an OD600 
between 0.6 and 0.8. In the following, all steps were performed at 4°C and buffers were ice 
cold. Cells were incubated on ice for 15 min, centrifuged at 1000 x g for 10 min, cell pellets 
were resuspended gently and thoroughly in 20 ml RF1 buffer per 50 ml of starting culture, 
cells were again incubated on ice for 15 min, centrifuged as before, resuspended in 2 ml RF2 
per 50 ml of starting culture and aliquotted to 200 µl. After 15 min incubation on ice, the now 
competent cells were used for transformation or stored at -80°C. 
For each transformation, 200 µl of competent bacteria were mixed with DNA (e.g. 100 
ng plasmid DNA) in a 1.5 ml tube, incubated on ice for 1 h, heat-shocked for 45 sec at 42°C 
and kept on ice for 5 min. LB medium (800 µl, pre-warmed to 42°C) was then added and cells 
were incubated at 37°C and 200 rpm for 45 min. 100 µl of the cell suspension was 
subsequently plated onto LB agar plates containing the appropriate antibiotic for selection and 
plates were incubated at 37°C over night. 
 
RF1:  100 mM RbCl2    RF2:  10 mM MOPS 
  30 mM K-acetate      75 mM CaCl2 
  10 mM CaCl2       10 mM RbCl2 
  50 mM MnCl2      15% (v/v) glycerol 
  15% (v/v) glycerol      pH 6.5 with KOH 
  pH 5.8 with acetic acid 
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2.5 Molecular biology methods 
 
2.5.1 Isolation of plasmid and BACmid DNA 
 
Plasmid and small amounts of BACmid DNA were isolated from 5-10 ml overnight 
cultures with the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s 
instructions. Large DNA preparations of BAC36 wild types or mutants were obtained from 
500 ml bacterial cultures and isolated with the Nucleobond BAC 100 Kit (Machary-Nagel, 
Germany) following the manufacturer’s protocol. 
 
 
2.5.2 Enzymatic modification of DNA 
 
Digestion of DNA with specific restriction endonucleases and ligations were performed 
with enzymes and suitable provided buffers from Roche, New England Biolabs of Life 
Sciences according to the manufacturer’s instructions. 
 
2.5.3 PCR amplification of DNA 
 
Generation of the rpsL-neo PCR product flanked by homology arms 
 
To generate the rpsL-neo counter selection cassette PCR product flanked by 60 or 63 
nucleotides homologous to the region immediately upstream of the KSHV K1 start codon or 
downstream of the K1 stop codon, respectively, PCR reactions were carried out in a final 
volume of 100 µl using the following components: 20 ng of rpsL-neo template DNA, 1x Pfu 
polymerase buffer, 200 µM dNTPs, 0.2 µM of each K1 ko forward and reverse primer, 9 µl 
DMSO, 10 units Pfu-polymerase and H20 (PCR grade). PCR reactions were carried out in a 
Perkin Elmer GeneAmp PCR system 2400 thermocycler with the following cycling 
parameters: 95°C for 5 min (initial denaturation), followed by 35 cycles of 94°C for 1 min 
(denaturation), 50°C for 1 min (annealing) and 72°C for 4 min (elongation), and was 
completed with 72°C for 10 min.  
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Colony-PCR 
 
PCR reactions were carried out in a final volume of 50 µl. The reaction mixture 
contained 1x  PCR buffer (10x stock), 2.5 mM MgCl2, 500 µM dNTPs, 0.3 µM of each 
forward and reverse primer, 3 units/50 µl Taq DNA polymerase, 1 µl/50 µl DMSO and H20 
(PCR grade). A small amount of bacteria of individual bacterial clones grown on an agar plate 
substituted for DNA template. PCR reactions were performed in a Perkin Elmer GeneAmp 
PCR System 2400 thermocycler or in a ABI Gene Amp PCR System 9700. To verify the 
insertion of the rpsL-Kan/neo cassette into the genome of BAC36, we used primers - neo1 
(forward) and neo2 (reverse) - located in the rpsL-neo cassette and the following cycling 
parameters: 95°C for 7 min (initial denaturation), followed by 35 cycles of 94°C for 1 min 
(denaturation), 55°C for 1 min (primer annealing) and 72°C for 1.5 min (elongation).  
 
 
2.5.4 Preparation of RNA and quantification by qPCR 
 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s instructions. Residual DNA was digested using RNase-free DNase I (rDNase 
I, Ambion). RNA concentration was measured using a NanoDrop 1000 spectrophotometer. 1 
µg of the DNA-free RNA was reverse transcribed for 1 h at 43°C in 20 µl reaction buffer 
containing 50 units Expand Reverse Transcriptase (Roche), 1x Expand Reverse Transcriptase 
buffer, 12.5 µM oligo-dT’s, 10 mM DTT, 1mM deoxynucleoside triphosphates, and 20 U 
RNasin (Promega). A control experiment without reverse transcriptase was conducted in 
parallel. qPCR was performed with the cDNA. Primers and probes used for the quantification 
of K1, K8, K2/vIL-6, K6/vCCL-1, and GAPDH are listed in Table 1 (see 2.2.2 Primers and 
probes). Taqman probes were labeled with 6-FAM at their 5’ end and with TAMRA at their 
3’ end.  
qPCR was carried out in a total volume of 25 µl containing 1x JumpStart Taq 
ReadyMix (Sigma), 5 mM MgCl2, 1x reference dye (Sigma), 500 nM of each primer, 250 nM 
probe, and 4 µl cDNA at 500 ng/µl. Thermal amplification was performed in a Stratagene 
MX3000P and using the following linked profile: 94°C for 2 min for initial denaturation 
followed by 40 amplification cycles, each with denaturation (94°C for 15 sec), and annealing 
(60°C for 1 min) periods. Fluorescence data were viewed and analysed using MxPro QPCR 
software. The cycle threshold (CT) value shows the number of cycles required for the 
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fluorescent signal to cross the threshold (i.e. exceed background level), and was set 
automatically by the program. Each sample was assayed in duplicates. cDNA extracted from 
transiently K1-expressing HEK293 cells (see 2.3.8 Transient expression of K1 in HEK293 
cells) was amplified as positive control for K1 expression. 
 
 
2.5.5 Electrophoresis of DNA and extraction from agarose gels 
 
DNA loading buffer (5x; 100 mM Tris-HCl, pH 7.4, 100 mM EDTA pH 8.0, 45 % (v/v) 
glycerol, orange G) was added to DNA fragments and the DNA was separated 
electrophoretically with 1 % agarose gels in TAE running buffer (1x; 40 mM Tris-acetate, 1 
mM EDTA). Restriction-enzyme digested BAC36 DNA was separated electrophoretically 
with large 0.4 % agarose gels in TBE running buffer (0.5x; 45 mM Tris-borate, 1 mM EDTA, 
pH 8.5) for 14-20 h at 2.5 V/cm. 
DNA fragments were purified with the QIAquick Gel Extraction Kit (Qiagen) according to 
the manufacturer’s protocol. The 1 kb plus DNA ladder (Invitrogen) was used for molecular 
weight marker. 
 
 
2.5.6 DNA sequencing 
 
DNA fragments were sequenced with the BI Prism dRhodamine terminatof cycle 
sequencing ready reaction kit (Applied Biosystems). Per sequencing reation, 500 ng of DNA 
were added to 4 µl terminator ready reaction mix and 1.6 pmole specific primer and the total 
reaction volume was adjusted to 10 µl with H2O. Thermal cycling was performed with the 
following parameters for 25 cycles with the annealing temperature depending on the specific 
sequencing primer: 96°C for 10 sec (denaturation), 56°C (variable) for 10 sec (annealing) and 
60°C for 4 min (elongation). Excess of dye terminators was then removed by ethanol 
precipitation as follows: 10 µl of the PCR product was added to 37 µl precipitation mix (70 % 
EtOH, 0.5 mM MgCl2) in a 1.5 ml high yield nucleic acid recovery tube (Robbins), vortexed 
and incubated for 15 min at RT. After centrifugation (14.000 x g, 15 min) the supernatant was 
removed and the pellet was dried at 95°C for 1 min. The sample pellet was resuspended in 6 
µl of template suppression reagent, heated for 2 min at 95°C, cooled on ice, centrifuged and 
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transferred to a 0.5 ml sequencing sample tube (Applied Biosystems). Sequencing was carried 
out with the ABI Prism 310 Genetic Analyser. 
 
 
2.5.7 Generation of BAC36 ΔK1 
 
The BAC36 ΔK1 mutant was generated by ET-cloning (Gene Bridges) following the 
manufacturer’s protocol. Briefly, BAC36 (Zhou et al. 2002) was transformed into E. coli 
strain DH10B, and selected with chloramphenicol to generate DH10B-BAC36. A Red/ET 
expression plasmid (pkD46; Datsenko and Wanner 2000), was transformed into DH10B-
BAC36. The rpsL-neo cassette carrying 60 nucleotides upstream of the K1-start codon, and 
63 nucleotides downstream of the K1-stop codon was obtained by PCR using the primers K1 
ko-Forward and K1 ko-Reverse (see 2.2.2). To insert the rpsL-neo cassette into BAC36, a 
liquid overnight culture of DH10B BAC36 containing the pKD46 plasmid was induced with 
0.2% L-arabinose for 1 h at 37°C to allow expression of the recombination enzymes. Bacteria 
were washed three times with ice-chilled water to render them electrocompetent. After 
electroporation with the homology-arms carrying rpsL-neo cassette (2.5 KV and 25 µF in a 2 
mm-cuvette), DH10B BAC36 were incubated for 70 min at 37°C to allow recombination. The 
resulted mutant was selected by kanamycin-resistance on LB-agar plates. Colony PCR was 
performed to verify the presence of the rpsL-neo cassette in each bacterial clone (see above). 
BAC plasmid DNA was isolated from 10-ml overnight cultures by the alkaline lysis method 
and analysed by restriction digestion. Large DNA preparations of BAC36 wild types or 
mutants were used for direct sequencing (see 2.5.1). To reconstitute infectious virus, purified 
BAC36ΔK1 DNA was transfected into HEK293 cells using Lipofectamine 2000 (Invitrogene) 
according to the manufacturer’s instructions. Individual cell colonies were selected by 
hygromycin-resistance and GFP-expression, and cells stably harbouring the BAC36ΔK1 
DNA were propagated in culture medium containing 150 µg/ml hygromycin B. 
 
 
2.5.8 One-colour microarray-based gene expression analysis 
 
The Agilent Whole Human Genome Oligo Microarray is provided in a 4x44 k format 
and covers more than 41.000 validated unique human genes and transcripts. The length of 
each oligonucleotide probe is 60-mer. 
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Cellular gene expression in HEK293 BAC36 wt and ΔK1 cell lines was measured using 
the one-colour protocol. Therefore, HEK293 BAC36 wt and ΔK1 cell lines as well as non-
infected parental HEK293 cells were seeded to 6-well plates at 1.5 to 2x105 cells/well and 
grown for 24 h. Susequently, cells were treated with baculovirus Orf50/RTA and 1 mM Na-
butyrate in order to induce KSHV lytic replication and total RNA was purified 48 h after 
reactivation from lytic cycle-induced as well as latently infected cells using the RNeasy Mini 
Kit (Qiagen) according to the manufacturer’s instructions followed by on-column DNaseI-
digestion (Qiagen). cRNA was synthesized following the Agilent Quick Amp one-colour 
protocol version 5.7. Briefly, a total of 0.5 µg RNA used to generates fluorescent cRNA by 
oligo(dT)-T7-primed cDNA synthesis followed by in vitro transcription with T7 RNA 
polymerase. The T7 RNA polymerase simultaneously amplifies target material and 
incorporated Cy3-labeled CTP. cRNA yields were measured photometrically using a 
NanoDrop ND 1000. 1 µg of Cy3-labeled cRNA of every experimental and control sample 
was fragmented, repurified and hybridized to individual microarrays for 17 h at 65°C. 
Subsequently, arrays were washed according to the manufacturer’s protocol using provided 
Gene Expression (GE) Wash buffers 1 and 2.  
Hybridized arrays were scanned on a Microarray Scanner 62505 B at XDR 100 and 5 
(photomultiplier set to 100 or 5 % intensity). Data were processed using Agilent’s Feature 
Extraction software version 9.5.3.1 and normalized according to an "inter-array" 
normalization approach (global linear scaling to reference array “non-infected, non-induction 
mixture-treated parental HEK293 cells” according to 75th percentiles of intensity 
distribution). Additionally, a lower intensity threshold of 39 was used as surrogate value for 
all measurements that fall below the intensity threshold. Data were analysed Genedata 
Expressionist and Excel software. Ratios of gene expression were calculated using Excel 
macros and. Additional information on the microarrays and methodology used can be 
obtained at http://www.agilent.com. 
 
 
2.6 Biochemical and cell biology methods 
 
2.6.1 Preparation of cell lysates 
 
Cells were washed once with PBS and lysed on ice in 1 x SDS sample buffer (62.5 mM 
Tris-HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% bromphenol blue) for 5 
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min. Afterwards, lysates were either directly analysed by Western blot or stored at -20°C for 
later use.  
To analyse the expression of KSHV membrane proteins, cells were lysed in RIPA 100 
buffer (20 mM Tris, pH 7.5, 1 mM EDTA, pH 7.5, 10 mM NaCl, 1% Triton X-100, 0.5 % 
sodium deoxycholate (DOC), 0.1 % SDS) for 10 min on ice. RIPA 100 also contained 
proteinase inhibitors that were added just prior to use giving the following final 
concentrations: 1 mM phenylmethylsulfonyl fluoride (PMSF), 50 µM leupeptin, 100 U/ml 
aprotinin, 200 µM benzamidine and 1 µM pepstatin A (in DMSO). Lysates were cleared from 
cell debris by centrifugation at 14.000 rpm for 10 min at 4°C. Protein concentration in each 
sample was determined by Bradford analyses using the Bradford reagent (Biorad) according 
to the manufacturer’s instructions. This analysis is based on binding of Coomassie brilliant 
blue G-250 to proteins, which alters the maximum of absorbance of the dye from 465 nm 
without protein to 595 nm with protein (Bradford 1976). Protein concentrations of different 
cell lysates that should be analysed by Western blot and compared with each other were 
adjusted to the lowest protein concentration of all samples with H2O.  
 
 
2.6.2 SDS polyacrylamide gelelectophoresis (SDS-PAGE) 
 
Whole cell lysates were sonicated for 10 sec on ice, boiled at 100°C for 5 min, cooled 
on ice, and shortly centrifuged. Protein samples in RIPA 100 buffer were not boiled, when 
expression of KSHV membrane proteins should be determined. Cell lysates obtained using 1x 
SDS sample buffer were loaded directly on SDS polyacrylamide gels at 20 µl per lane, while 
lysates obtained using RIPA 100 buffer were diluted with 5x protein loading buffer prior to 
analysis by SDS-PAGE. Accoding to the size of the protein of interest, the separation gel 
contained 10-15% and the stacking gel 3-4% polyacrylamide. Gels were run at 25 mM in a 
Hoefer mighty small electrophoresis chamber (Amersham). To determine the size of 
separated proteins we included a prestained 10-200 kDa-molecular weight standard (Biorad) 
on every SDS-polyacrylamide gel during electrophoresis.  
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Protein loading buffer (1x)    Electrophoresis buffer 
50 mM Tris-HCl, pH 6.8    25 mM Tris-Base 
10 % (v/v) glycerol     250 mM glycine 
2 % (w/v) SDS     0.1 % (w/v) SDS 
100 mM DTT      pH 8.3 
0.05 % (w/v) bromphenolblue 
 
 
2.6.3 Western blot analysis 
 
Proteins separated by SDS- PAGE were electrophoretically transferred onto 
nitrocellulose membranes in cold blotting buffer (25 mM Tris-Base, 230 mM glycine, 20 % 
v/v methanol, pH 8.3) for 1.5 h at 350 mA using a Mini Trans Blot Cell (Biorad). 
To analyse the activation status of cellular protein kinases Western blotting was 
performed with phosphospecific primary antibodies, i.e. phospho-p44/42 (Thr202/Tyr204) 
mAb and phospho-Akt (S473) mAb (both purchased from Cell Signaling Technology) 
following the manufacturer’s instructions. Briefly, membranes were incubated in blocking 
buffer (1X TBS, 0.1% Tween-20 with 5% w/v nonfat dried milk) for 1 h at RT, incubated first 
over night at 4°C with primary antibody specific for the phosphorylated forms of ERK1/2 or 
Akt, followed by HRP-conjugated secondary antibody for 1 h at RT. Immunoreactive bands 
were visualized using a standard enhanced chemiluminescence (ECL) reaction kit (Perkin 
Elmer). After detection, membranes were stripped and reprobed with antibodies specific to 
total ERK2 (p42 MAP kinase), or total Akt1.  
For detection of K8.1 A/B, c-myc, or β-actin, membranes were blocked in PBS with 
0.1% v/v Tween 20 (PBS-T) and 5% nonfat dried milk for 1 h at RT, incubated for 1 h at RT 
with primary antibody diluted in blocking buffer, washed three times for 10 min each in PBS-
T, incubated with a HRP-conjugated secondary antibody diluted in blocking buffer for 30 min 
at RT, washed twice in PBS-T and once in PBS for 10 min each, and immunoreactive bands 
were visualized by chemiluminescence. For detection of Orf50/RTA membranes were 
blocked and antibodies diluted in PBS-T supplemented with 3% BSA and 1% glycine.  
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10X TBS (1 liter)     Stripping buffer 
50 mM Tris      100 mM β-mercaptoethanol 
150 mM NaCl      2% w/v SDS 
adjust to pH 7.6 with HCl    62.5 mM Tris, pH 6.8 
 
 
2.6.4 Immunofluorescence assay 
 
HEK293 BAC36 wt and HEK293 BAC36 ΔK1 cells were seeded at 70% confluency on 
poly-L-lysine -coated glass coverslips in 6-well plates one day prior to reactivation. The lytic 
cycle was induced using baculovirus Orf50/RTA in combination with Na-butyrate (1 mM). 72 
h after induction, cells were washed with PBS, fixed with 4% paraformaldehyde in PBS for 
20 min at RT, washed three times with PBS for 5 min each, quenched with 50 mM NH4Cl for 
10 min at RT, permeabilized with 0.2% Triton X-100 in PBS for 10 min at RT, washed once 
with PBS, and blocked with 10% goat serum in PBS for 10 min at RT. Then, cells were first 
incubated with rabbit anti-K8 pAb, mouse anti-Orf59 mAb, or rabbit anti-K8 pAb in 
combination with mouse anti-K1 mAb for 1 h in a damp and wet chamber at 37°C. 
Afterwards, cells were washed three times with 0.5% goat serum in PBS for 5 min each, and 
incubated with Rhodamine X-conjugated goat-anti-mouse IgG, or Rhodamine X-conjugated 
goat-anti-rabbit IgG and Cy5-conjugated goat-anti-mouse IgG (Jackson ImmunoResearch) for 
45 min in a damp and wet chamber at 37°C. Cells were washed twice with 0.5% goat serum 
in PBS, and twice with PBS for 5 min each. DNA was stained using DAPI (1:1000 in PBS) 
for 30 min at RT. As controls for cross-reactions and background staining, cells were stained 
with secondary antibody only, or cells, which were stained with primary antibodies specific 
for K8, were incubated with secondary antibody for K1, and vice versa. Immunofluorescence 
was examined with a Zeiss AxioObserver Microscope. 
 
 
2.6.5 Flow cytometry-based cell cycle analysis 
Vero rKSHV.219 cells were seeded at 5x105 cells per well of a 6-well plate. The next 
day, the KSHV lytic replication cycle was induced as described in 2.3.5 in the presence or 
absence of the MEK inhibitor U0126 (20 µM). 32 to 36 hours after induction, 5-bromo-2’-
deoxyuridine (BrdU) was added to the medium of the growing population of cells to a final 
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concentration of 10 µM and incubated for 1 h at 37°C. Cells were then trypsinized, washed in 
PBS, and washed twice with PBS containing 1% w/v bovine serum albumin (BSA). Cells 
were fixed with 4% paraformaldehyde, pH 7.4, for 15 min, permeabilized with 0.1% Triton X-
100 in PBS 1% BSA at RT for 10 min, washed once in PBS 1% BSA, resuspended in 1 ml 
PBS containing 20 µg/ml DNase-free RNase A and incubated at 37°C for 30 min. Cells were 
then subjected to acidic DNA denaturation with 1 ml 2 N HCl containing 0.5 % Triton X-100 
for 30 min at RT, followed by a neutralization step with 1 ml of 0.1 M Na2B4O7, pH 8.5. 
Subsequently, cells were labeled with a α-BrdU antibody (final concentration: 500 ng/ml) in 
950 µl of PBS containing 0.5% Tween 20 (v/v) and 1% BSA (w/v) for 30 min at RT, followed 
by incubation with a secondary Cy5-conjugated antibody (final concentration: 15 µg/ml) in 
100 µl of PBS containing 0.5% Tween 20 and 1% BSA for 30 min at RT. After two washing 
steps with PBS 1% BSA, cells were resuspended in PBS containing 100 µg/ml propidium 
iodide to stain DNA. Flow cytometric cell cycle analysis with a total number of 105 events per 
sample was performed on a BD FACSCalibur. Raw data were recorded and analyzed using 
the software Windows Multiple Document Interface for Flow Cytometry 2.8 (WinMDI2.8) 
available at http://facs.scripps.edu/software.html. For cell cycle analysis, the BrdU content of 
the whole cell population was quantified in relation to its DNA content. Thereby, the 
percentage of cells in each phase of the cell cycle can be determined. 
 
3.1 Results I 
 62
3 Results 
 
3.1 Results I: The MEK/ERK Signalling Cascade Contributes to 
Successful KSHV Lytic Replication Downstream of RTA 
Expression. 
 
ERK and Akt signalling are activated, respectively, during the early and late 
stages of the KSHV lytic cycle.  
In earlier work, it was shown that PI3K and the MAP kinases ERK, JNK and p38 are 
activated early during KSHV primary infection, and have important functions in virus entry 
and/or subsequent viral gene expression (Naranatt et al. 2003; Sharma-Walia et al. 2005; Xie 
et al. 2005; Pan et al. 2006). Furthermore, it was shown that signalling cascades involving 
MEK/ERK, JNK and p38 mediate TPA-induced reactivation of KSHV from latency and 
activation of the immediate-early RTA promoter (Cohen et al. 2006; Pan et al. 2006; Yu et al. 
2007; Xie et al. 2008). Two studies further suggest an impact of all three MAP kinases on the 
production of new infectious KSHV virions, as inhibition of MEK, JNK and p38 reduces the 
yield of progeny virus during lytic replication (Pan et al. 2006; Xie et al. 2008). The aim of 
the current study was to investigate the role of cellular signalling pathways during the 
progression of the lytic replication cycle and to identify additional viral proteins required for 
the completion of viral productive replication.  
To investigate which signalling pathways are activated during the KSHV productive 
cycle, I induced lytic replication using baculovirus (BV) Orf50/RTA in combination with Na-
butyrate (NaB) in Vero rKSHV.219 cells, a cell line stably infected with recombinant KSHV 
expressing green-fluorescent protein (GFP) from the EF-1α promoter and red-fluorescent 
protein (RFP) from the lytic PAN promoter (Vieira et al. 2004, Figure 5). Cells were lysed 4, 
8, 12, 16, 20, 24, 28, and 40 hours post induction (h.p.i.), and whole protein extracts were 
immunoblotted with anti-phospho p42/44 (ERK2/1), and anti-phospho Akt-S473 antibody. 
ERK activation strongly increased around 8 h.p.i., while activation of Akt was first seen at 4 
h.p.i. and strongly increased around 20-24 h.p.i. (Fig. 6 A). To exclude the possibility that the 
activation of the ERK pathway could have been the result of the baculoviral infection, I 
infected Vero rKSHV.219 cells with baculovirus expressing the Orf73 protein of murine 
herpesvirus 68 (baculovirus (BV) MHV68 Orf73). As shown in Fig. 6 B, ERK activation was 
not induced when the cells were infected by this irrelevant baculovirus. 
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Furthermore, I exposed uninfected (i.e. KSHV-negative) Vero cells to BV Orf50/RTA and 
Na-butyrate as above, and no activation of the ERK pathway was seen in this experiment. 
Figure 6. ERK and Akt signalling pathways are activated during the KSHV lytic cycle. (A) Lytic 
replication was induced in Vero rKSHV.219 cells using baculovirus Orf50/RTA (BV Orf50/RTA) in 
combination with Na-butyrate (NaB) [1mM]. Cells were lysed 4, 8, 12, 16, 20, 24, 28, and 40 hours 
post induction (h.p.i.), subjected to Western blot analysis. Equal amounts of proteins were separated 
by SDS-PAGE, transferred to nitrocellulose, probed with phosphospecific antibody to Akt (S473), or 
p42/44 (ERK 2/1), respectively, stripped and reprobed with antibody that recognized total Akt levels, or 
ERK 2 levels, respectively. The membranes were stripped a second time and reprobed with antibody 
to β-actin. (B) Expression of the viral late lytic protein K8.1 was detected 24 h.p.i. and was strongly 
increased 32 and 48 h.p.i., indicating successful viral DNA replication and the progression of the lytic 
replication cycle. A baculovirus expressing the Orf73 protein of murine herpesvirus 68 (BV MHV68 
Orf73) only very weakly induced ERK activation in Vero rKSHV.219 cells. (C) BV Orf50/RTA and NaB 
did not activate ERK signalling in uninfected (KSHV negative) Vero cells. 
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(Fig. 6 C). Therefore, I concluded that new viral protein synthesis is necessary for lytic cycle-
induced ERK activation and that this activation may be mediated by KSHV early genes.  
To investigate whether activation of the ERK signalling pathway during lytic replication 
of KSHV occurs independently of the infected cell type and the induction system used in our 
experiments, I reactivated KSHV in a PEL cell line (BCBL-1) that harbours a tetracycline-
inducible RTA expression system (TREx BCBL-1-RTA (Nakamura et al. 2003)). To induce 
the lytic replication cycle, TREx BCBL1-RTA were stimulated with 1 µg of tetracycline/ml 
for 2, 4, 8, 10, 16, 20, 24, 27, 32, or 48 h. Whole cell lysates were analysed by 
immunoblotting with phospho-specific antibodies for ERK1/2. As shown in Fig. 7, activation 
of ERK was detected after 4 h of tetracycline treatment, and strongly increased after 20 h of 
tetracycline treatment. These findings suggested that activation of ERK during the lytic 
replication cycle is independent of both cell type and the method used to reactivate KSHV 
from latency. 
 
 
Activation of ERK is independent of KSHV genome replication while activation of 
Akt may depend on successful replication of viral DNA.  
The temporal pattern of ERK and Akt activation suggests activation of ERK and Akt 
pathway during the early or late stages of the lytic replication cycle. To investigate, if 
activation of ERK and Akt signalling depends on viral genome replication, I reactivated 
KSHV from latency in the presence of phosphonoacetic acid (PAA), an inhibitor of 
herpesviral DNA polymerase (Chang and Ganem 2000). Vero rKSHV.219 cells were pre-
incubated with PAA one hour prior to induction of lytic replication, lytic cycle was induced 
using baculovirus Orf50/RTA in combination with Na-butyrate, and cells were lysed at 4, 8, 
10, 12, 16, 20, 24, and 48 h.p.i.. 
Figure 7. The ERK signalling pathway is activated during lytic replication in the
tetracycline-inducible PEL cell line TREx BCBL1-RTA. KSHV lytic replication was induced in 
TREx BCBL1-RTA by stimulation with 1 µg/ml tetracycline. Cells were lysed at different time 
points after induction of the lytic cycle (h.p.i.), and protein extracts were analysed by Western 
blotting with phosphospecific antibodies to p42/44 (ERK2/1). Membranes were stripped and 
reprobed with antibody to total ERK2. 
0     2     4     8   10   16   20    24  27   32   48
Tetracycline 1 µg/ml
37
37
kDa
α-phospho p42/44
α-ERK2
h.p.i.
3.1 Results I 
 65
Lysates were immunoblotted with anti-phospho Akt and anti-phospho p42/44. The inhibition 
of viral DNA synthesis by PAA was checked indirectly by immunoblotting with antibody for 
Figure 8. Effect of chemical manipulation of the KSHV lytic replication cascade on ERK and 
Akt activation. (A) Akt activation may depend on viral DNA replication, while ERK activation does 
not. Lytic replication was induced in Vero rKSHV.219 cells in the presence (right panel) or absence 
(left panel) of phosphonoacetic acid (PAA, 1 mM). Cells were lysed 4, 8, 12, 16, 20, 24, and 48 hours 
after induction (h.p.i.). Lysates were analysed by Western blot analysis with phosphospecific 
antibody to Akt, or ERK2/1 (p42/44), or antibody to K8.1 A/B. Membranes were stripped and 
reprobed with antibody to total Akt 1, or total ERK2, or antibody to β-actin. (B) Activation of ERK 
requires de novo protein expression in the first 10 h post induction of lytic cycle. Vero rKSHV.219 
cells were reactivated from latency using baculovirus (BV) Orf50/RTA in combination with Na-
butyrate (NaB, 1 mM). Cycloheximide (CHX) [50 µg/ml] was added to individual wells 4, 8, 10, 12, 
13, 14, or 16 h.p.i.. 32 h.p.i., expression of red-fluorescent protein (RFP) from the lytic PAN promoter
was visualized by fluorescence microscopy, cells were lysed and analysed by Western blot with 
phosphospecific antibodies to ERK2/1 (p42/44). The membrane was stripped and reprobed with 
antibodies to total ERK2 levels. 
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the late lytic protein K8.1, which should not be expressed in the absence of KSHV DNA 
replication (Chang and Ganem 2000). As shown in Fig. 8 A, K8.1 was not expressed in the 
presence of PAA, indicating that PAA efficiently blocked KSHV genome replication. 
Whereas activation of ERK was not affected by PAA, Akt activation – although relatively low 
also in the non-PAA-treated control experiment (Fig. 8 A, left panel) - was reduced in the 
presence of the viral polymerase inhibitor (Fig. 8 A, right panel); suggesting that activation of 
ERK is independent of viral DNA replication, while activation of Akt signalling at least 
partially depends on successful KSHV genome replication. 
To narrow down to the time point of initial ERK activation, I reactivated rKSHV in 
Vero cells in the presence of cycloheximide (CHX), which is traditionally used to distinguish 
between the immediate-early (independent of de novo protein synthesis) and early (requiring 
synthesis of viral proteins) stages of the herpesviral replication cycle. I induced lytic 
replication in Vero rKSHV.219 cells and added CHX 4, 8, 10, 12, 13, 14, or 16 h.p.i.. I found 
that ERK activation during lytic replication was completely inhibited, if CHX was added in 
the first 10 h after induction, and was still reduced, if CHX was added between 12 and 16 h 
after reactivation from latency (Fig. 8 B). The present but strongly reduced expression of RFP 
from the lytic PAN promoter in Vero rKSHV.219 cells in the presence of CHX shows that the 
KSHV lytic cycle was induced in all samples, but widely inhibited at the early phase by CHX 
(Fig. 8 B). From this experiment I concluded that new viral protein synthesis is necessary for 
lytic cycle-induced ERK activation and suggest that activation of ERK may be mediated by 
KSHV early genes. 
 
Chemical inhibition of MEK reduces late lytic protein expression, and the 
production of infectious progeny virus.  
To determine whether efficient KSHV lytic replication and virus production depend on 
the activation of ERK and Akt signalling cascades, I induced the KSHV lytic cycle in Vero 
rKSHV.219 cells in the presence of chemical inhibitors of these pathways (Table 3). Cells 
were pretreated with the inhibitors for one hour prior to reactivation. KSHV lytic cycle was 
induced as described above. Cells were lysed 48 h.p.i., and protein extracts were 
immunoblotted with antibodies for Orf50/RTA, and for the late lytic protein K8.1. 
Supernatants were collected, filtered, and used to infect HEK293 cells. After two days, the 
number of GFP-positive (i.e. infected) HEK293 cells was counted to determine the number of 
infectious virions released from Vero rKSHV.219 cells during the productive cycle.  
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Table 3. Protein kinase inhibitors used to study the role of signalling pathways during KSHV 
lytic cycle. 
 
Inhibitor name Target kinase 
Mode of 
action/description 
Target signalling 
pathway 
Signalling pathway 
involved in 
U01261 
PD980592 
MEK1/2 
Non-ATP-competitive; 
prevent the activation of 
MEK1/2 
Ras-Raf-MEK1/2-ERK1/2 Cell growth, differentiation 
ERK Activation 
Inhibitor Peptide I3 MEK/ERK1/2 
prevents the interaction of 
ERK1/2 and MEK1/2 Ras-Raf-MEK1/2-ERK1/2 Cell growth, differentiation 
LY2940024 PI3K ATP-competitive PI3K-Akt Anti-apoptotic processes, cell survival 
Piceatannol5 Syk 
trans-3 ,4 ,3 ’,5’-
tetrahydroxystilbene (plant 
metabolite) 
MAPK pathways; NFAT 
activation Proliferation, differentiation 
 
 
After induction of the KSHV lytic cycle, RTA was strongly expressed in Vero 
rKSHV.219 cells, except in the presence of PD98059 at a concentration of 25 µM (Fig. 9 A). 
In contrast, expression of the late lytic protein K8.1 was strongly reduced by both MEK1/2 
inhibitors, U0126 and PD98059, in a dose dependent manner (Fig. 9 A). For PD98059 at a 
concentration of 25 µM it is assumed that at least part of the reduced amounts of K8.1 protein 
was due to less efficient RTA expression. The inhibiton of the PI3K-Akt pathway by 
LY294002 and inhibiton of Syk kinase by Piceatannol affected neither RTA nor K8.1 
expression (Fig. 9 A).  
To confirm that the inhibitors used in these experiments exerted the expected effects on 
their kinase targets, Vero rKSHV.219 cells were pre-incubated with U0126, PD98059, 
LY294002 and Piceatannol for one hour prior to reactivation, induced lytic replication as 
above, lysed the cells 30 h.p.i., and immunoblotted lysates with phosphospecific antibodies 
(Fig. 9 E). ERK phosphorylation was more strongly inhibited by U0126 than by PD98059, 
while Akt phosphorylation was not affected by either MEK inhibitor (Fig. 9 E). LY294002 
inhibited lytic cycle-induced Akt phosphorylation as expected (Fig. 9 E). Inhibition of Syk by 
Piceatannol also reduced Akt phosphorylation, while ERK phosphorylation was not 
negatively affected by Piceatannol (Fig. 9 E) 
 
1 DeSilva et al. 1998; Duncia et al. 1998; Favata et al. 1998; Davies et al. 2000 
2 Kültz et al. 1998; Dudley et al. 1995; Langlois et al. 1995; Davies et al. 2000 
3 Kelemen et al. 2002 
4 Baumann and West, 1998; Vlahos et al. 1995; 1994; Davies et al. 2000 
5 Oliver et al. 1994; Geahlen et al. 1989 
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Inhibition of the MEK-ERK signalling cascade by U0126 and PD98059 also reduced 
late-lytic K8.1 expression in the endothelial cell line EAhy rKSHV (see Materials and 
Methods) (Fig. 10 A). However, the effect of both inhibitors on K8.1 expression was weaker 
than observed in Vero rKSHV.219 cells, although U0126 completely abolished lytic cycle-
induced ERK activation in EAhy rKSHV cells, when applied at a final concentration of 25 or 
20 µM (Fig 10 A).  
Figure 9. Inhibition of MEK/ERK signalling during KSHV lytic cycle reduces expression 
the viral late lytic K8.1 protein and virus production. (A) Expression of the late lytic protein 
K8.1 and is reduced by inhibition of MEK1/2 signlling. Vero rKSHV.219 cells were incubated with 
chemical kinase inhibitors at two concentrations 1h prior to induction of lytic replication. DMSO 
(i.e. solvent of all inhibitors) was applied for negative control. Lytic cycle was induced using 
baculovirus (BV) Orf50/RTA in combination with Na-butyrate (NaB, 1mM). 48h after induction
(h.p.i.), cells were lysed and analysed by Western blotting with antibodies to Orf50/RTA, K8.1 
A/B, and β-actin. (B) Inhibition of MEK1/2-ERK signalling reduces the yield of infectious progeny 
virus from Vero rKSHV.219 cells. Vero rKSHV.219 cells were incubated with chemical inhibitors
or ERK activation inhibitor peptide I (ERK activ. inhibit. pep.) and the lytic replication cycle was 
induced as above. 48 h.p.i., culture supernatants were collected and used to infect HEK293 
cells. Two days after infection, the number of infected (i.e. green-fluorescent) HEK293 cells was 
counted, and virus titers (infectious units (IU)/ml) were calculated. Results represent the 
averages and standard deviations from one experiment carried out in triplicates. (C) U0126 
inhibits virus production in a dose-dependent manner. Shown are the results of an infectivity 
assay on HEK293 cells with supernatant of Vero rKSHV.219 cells. (D) MEK inhibitors have no 
significant effect on virus entry in infectivity assay. U0126, its inactive analogue U0124, 
PD98059, and the ERK activation inhibitor peptide I were incubated with BV Orf50/RTA and 
NaB for 48h at 37°C. These pre-incubated inhibitors were then applied at their indicated final 
concentrations to HEK293 cells, which were then infected with rKSHV. The number of infected 
target cells was determined after two days, and virus titers were calculated. Bars represent 
average virus titers and standard deviations of one experiment carried out in triplicates. (E) 
Chemical kinase inhibitors reduce lytic cycle-induced activation of ERK and Akt in Vero 
rKSHV.219 cells. Vero rKSHV.219 cells were incubated with chemical kinase inhibitors and the 
lytic cycle was induced as described above. 36 h.p.i., cells were lysed and analysed by Western 
blot with phosphospecific antibodies to Akt (S473) and p42/44 (ERK2/1). The membrane was 
then stripped, and reprobed with antibody that recognized total ERK2 levels.  
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The infectivity assay showed similar results. Inhibition of MEK1/2 by U0126 or 
PD98059 drastically reduced the titer of infectious virus released from treated Vero 
rKSHV.219 cells in a dose-dependent manner (Fig. 9 B, C). In accordance with the reduction 
in KSHV K8.1 protein expression (Fig. 9 A), U0126 showed a more pronounced inhibition 
than PD98059. In addition, peptide-based inhibition of ERK activation also reduced virus 
production (Figure 9 B). Since inhibition of ERK by this peptide is thought to be specific 
because of its ability to compete with the MEK-ERK2 interaction (Kelemen et al. 2002), these 
findings provide strong evidence for a role of MEK/ERK pathway during the progression of 
the lytic replication cycle. No effect on virus production from Vero rKSHV.219 cells was 
seen after inhibition of PI3K using LY294002, nor after inhibition of Syk kinase using 
Piceatannol (Fig. 9 B).  
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In contrast, when EAhy rKSHV cells were used in a similar experiment, inhibition of 
PI3K by LY294002 consistently produced an enhancement of virus production (Fig. 10 C,), 
while inhibition of Syk kinase by Piceatannol reduced the yield of infectious progeny virus 
from EAhy rKSHV cells by 30-50 % in a dose-dependent fashion. Western blot analysis 
showed that also expression of the RTA and the K8.1 protein was enhanced in the presence of 
LY294002 during the lytic replication cycle in EAhy rKSHV cells (Fig. 10 B), whereas 
Piceatannol had no effect on RTA and K8.1 protein levels (Fig. 10 B). 
Figure 10. Inhibition of MEK/ERK signalling during KSHV lytic cycle reduces late lytic 
K8.1 protein expression in EAhy rKSHV cells. (A) Expression of the late lytic protein K8.1 
and is reduced by inhibition of MEK1/2 signal transduction. The MEK inhibitors U0126 and 
PD98059 were applied individually at different concentrations to EAhy rKSHV cells. DMSO (i.e.
solvent of all inhibitors) was applied for negative control. After 1h, the lytic replication cycle was 
induced using baculovirus (BV) Orf50/RTA in combination with Na-butyrate (NaB, 1mM). 48 
hours after induction (h.p.i.), cell lysates were analysed by Western blotting with antibodies to 
Orf50/RTA, K8.1 A/B, and a phosphospecific antibody to p42/44. Membranes were stripped and 
reprobed with antibodies to β-actin and total ERK2. (B) Inhibition of Akt and Syk signalling does 
not reduce K8.1 expression in EAhy rKSHV cells. EAhy rKSHV cells were incubated with 
LY294004, which targets PI3 kinase, or with Piceatannol, which targets Syk kinase, at different 
final concentrations 1h prior to reactivation. Lytic cycle was induced as in A, cells were lysed 48
h.p.i., and analysed by Western blotting with antibodies to Orf50/RTA, K8.1 A/B, and a 
phosphospecific antibody to Akt. Membranes were stripped and reprobed with antibodies to β-
actin and total Akt1. (C) Inhibition of the MEK/ERK pathway reduces virus production in EAhy 
rKSHV cells, while inhibition of PI3K by LY294002 enhances the yield of infectious progeny 
virus. EAhy rKSHV cells were treated with individual kinase inhibitors and the lytic replication 
cycle was induced as described above. Culture supernatants were harvested 48 h.p.i., 
centrifuged, and used to infect HEK293 cells. The number of infected (i.e. green-fluorescent) 
293 cells was determined after 2 days, and virus titers were calculated. Bars represent averages 
and standard deviations of one experiment carried out in triplicates. 
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To exclude the possibility that the reduced numbers of GFP-positive target HEK293 
cells in our infectivity assay in the presence of ERK inhibitors were simply due to inhibition 
of virus entry (Pan et al. 2006), mediated by carry-over of MEK inhibitors, I incubated 
U0126, its inactive analogue U0124, PD98059, and the ERK activation inhibitor peptide I at a 
concentration of 25 µM and 10 µM together with baculovirus Orf50/RTA and Na-butyrate in 
regular growth medium for two days at 37°C (i.e. the duration of the incubation phase used in 
Figs. 9 and 10). The inhibitors were then transferred to HEK293 cell cultures, which were 
subsequently infected with newly produced rKSHV. In this experiment I did not observe a 
significant reduction of infectivity by U0126, PD98059 and the ERK activation inhibitor 
peptide that had been pre-incubated at 37°C for two days (Fig. 9 D). 
Since ERK activity during the lytic cycle did not considerably increase before eight 
hours after reactivation from latency (Fig. 6 A), the effect of U0126 on late lytic protein 
synthesis and virus production was investigated when the inhibitor was applied at different 
time points after induction of the lytic replication cycle. Lytic replication in Vero rKSHV.219 
cells was induced using baculovirus Orf50/RTA, and U0126 was applied at a final 
concentration of 25 µM at 0 (t0), 1 (t1), 2 (t2), 4 (t3), 8 (t4), 16 (t5), or 24 (t6) hours after 
induction. 48 hours after induction, cells were lysed and protein extracts were subjected to 
Western blot analysis. Culture supernatants were used to infect HEK293 cells. Although the 
level of K8.1 expression and virus production varied slightly in a non-specific order among 
the different samples (Fig. 11 A, B), I found that U0126 severely inhibited K8.1 protein 
expression and virus production when added until eight hours after reactivation from latency 
(Fig. 11 A, B). When the inhibitor was applied later than eight hours after induction of the 
lytic replication cycle, the reducing effect on K8.1 protein expression and virus production 
was less prominent but still significant even when U0126 was applied at 16 or 24 hours after 
reactivation (Fig. 11 A, B). Since U0126 is unstable in solution, I analysed, if the inhibitor 
was still fully active at t5 and t6 (i.e. 16 and 24 hours after its reconstitution). Therefore, 
U0126 was applied at t5 and t6 to Vero rKSHV.219 cells, in which KSHV lytic replication was 
just then induced. Cells were lysed and culture supernatant was harvested 48 hours after 
reactivation. As shown in Fig. 11 A and B, U0126 completely blocked late-lytic K8.1 
expression and virus production 16 or 24 hours after its reconstitution when applied to freshly 
reactivated cells, indicating that the activity of the inhibitor had not deteriorated at t5 and t6. 
These findings suggest that inhibition of ERK activity after eight and even after 16 hours 
postreactivation sufficiently blocks KSHV lytic replication.  
3.1 Results I 
 73
 
Figure 11: U0126 still reduces expression of the K8.1 protein and virus production when 
applied at the early or late phase of the lytic replication cycle. Vero rKSHV.219 cells were 
reactivated with baculovirus (BV) Orf50/RTA and treated with U0126 (25 µM) at 0 (t0), 1 (t1), 2 (t2), 
4 (t3), 8 (t4), 16 (t5), or 24 (t6) hours after induction (h.p.i.) of the lytic replication cycle. 16 h.p.i. (t5) 
and 24 h.p.i. (t6), U0126 was applied in parallel to Vero rKSHV.219 cells, which were just then 
reactivated from latency. 48 h after reactivation, the cells were lysed and supernatants were 
harvested. (A) Protein extracts were analysed by Western blotting with an antibody to late lytic 
K8.1 glycoprotein. Membranes were stripped and reprobed with an antibody to vimentin. (B) 
Culture supernatants were centrifuged and used to infect HEK293 cells. Infected cells were 
counted after two days, and virus titers were calculated. By analysing the effect of the inhibitor on 
K8.1 expression and virus production at postponed t0, we determined the remaining activity of 
U0126 16 or 24 hours, respectively, after its reconstitution. A baculovirus expressing the Orf73 
protein of murine herpesvirus 68 (BV MHV68 Orf73) did not induce lytic replication in Vero 
rKSHV.219 cells. DMSO (i.e. solvent of U0126) was used for negative control. Bars represent 
average titers and standard deviations of one experiment carried out in triplicates. 
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The effect of the two MEK inhibitors U0126 and PD98059 on late lytic protein 
expression was also determined in the tetracycline-inducible PEL cell line TREx BCBL1-
RTA. To induce the lytic replication cycle, TREx BCBL1-RTA cells were stimulated with 0.5 
µl tetracycline/ml. U0126 and PD98059 were applied at a final concentration of 20 µM or 25 
µM, respectively, one hour prior to reactivation (t-1) or together with tetracycline (t0). 48 
hours after reactivation, the cells were lysed, and expression of the K8.1 protein was 
determined by immunoblotting. Both MEK inhibitors efficiently blocked K8.1 expression 
during tetracycline-induced lytic replication in TREx BCBL1-RTA cells (Fig. 12). However, 
when I additionally stimulated the cells with baculovirus Orf50/RTA, the block in late lytic 
K8.1 expression mediated by inhibition of MEK was overcome (Fig. 12). Accordingly, when 
the cells were stimulated with high concentrations of tetracycline, i.e. ≥ 1 µg/ml, U0126 and 
PD98059 were not sufficient to significantly reduce K8.1 expression (data not shown). 
Therefore, I suggest that (i) U0126 and PD98059 are less efficient MEK inhibitors in BCBL-1 
cells, or (ii) strong stimulation of KSHV reactivation induces other factors, e.g. other 
signalling pathways, which can substitute for the role of MEK signalling for efficient lytic 
replication in this cell line.  
 
 
 
Together, these findings suggest that activation of MEK1/2-ERK1/2 signalling is 
important for KSHV lytic replication downstream of RTA expression, and that inhibition of 
MEK1/2 strongly reduces KSHV lytic protein expression and virus production, even when 
Figure 12. Inhibitors of MEK/ERK signalling reduce expression of K8.1 protein in the 
tetracycline-inducible PEL cell line TREx BCBL1-RTA. U0126 (20 µM) and PD98059 (25 µM) 
were applied individually to TREx BCBL1-RTA cells one hour prior (t-1) or simultaneously (t0) to 
stimulation with 0.5 µg/ml tetracycline or to combined treatment with 0.5 µg/ml tetracycline and 
baculovirus (BV) Orf50/RTA. Cells were lysed 48 h after reactivation, and protein extracts were 
analysed by immunoblotting with antibody to K8.1. Membranes were stripped and reprobed with 
antibody to β-actin. 
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RTA is abundant in the cell. In contrast, activation of the Akt pathway appears dispensable for 
efficient lytic replication of KSHV and may even suppress KSHV lytic replication in certain 
cell types (e.g. endothelial cells). 
 
U0126 does not inhibit cell cycle progression from G0/G1 to S phase. 
The Ras/ERK signalling pathway is known to regulate various cellular responses. In 
particular, its role in cell cycle progression in G1 phase and cell proliferation is well 
established (Massague 2004; Torii et al. 2006; Yamamoto et al. 2006). It has been shown that 
PD98059 inhibits stimulation of cell growth in fibroblast (Dudley et al. 1995), and that 
PD184352 (CI-1040), another inhibitor of the MEK-ERK signalling cascade, inhibits serum-
stimulated cyclin D1 expression and DNA synthesis in an ERK 1/2-dependent manner 
(Squires et al. 2002). Therefore, I tested the possible effect of U0126 on cell cycle 
progression.  
Since it was shown that BCBL-1 cells are most susceptible to induction of lytic 
replication during S-phase (McAllister et al. 2005), a block of S-phase entry mediated by 
U0126 might create unfavourable conditions for efficient KSHV lytic replication. To 
determine the proportion of cells in each phase of the cell cycle, I used a bromodeoxyuridine 
(BrdU) incorporation assay, and analysed U0126-treated and non-treated Vero rKSHV.219 
cells in a fluorescence-activated cell sorter (FACS)-based cell cycle assay. BrdU is an 
analogue of thymidine and commonly used in the detection of proliferating cells in living 
tissues. It works by substituting for thymidine during DNA replication and incorporating itself 
into the newly synthesized DNA (during S-phase). Antibodies specific for BrdU can then be 
used to detect the incorporated chemical, thus indicating cells that were actively replicating 
their DNA. Propidium iodide was used to stain the total amount of DNA in the cells. Vero 
rKSHV.219 cells were seeded at 1x105 cells/well on six-well plates. The lytic replication 
cycle was induced after 24 h using baculovirus Orf50/RTA in the presence or absence of 
U0126 at a final concentration of 25 µM. 48 hours after reactivation, cells were identified at a 
proportion of ~ 50% in G1/G0 phase, ~ 18% in S phase, and ~ 7 % in G2/M phase (Fig. 13 A, 
cells located in region (R) 1, 2, and 3, respectively; Fig. 13 B). The remaining percentages 
laid outside the regions that were set for each cell cycle phase for analysis (Fig. 13 A, upper 
panel). U0126-treated cells showed cell cycle distributions similar to those of non-inhibitor 
treated cells (Fig. 13 A, B), implying that the inhibitor does not affect the cell cycle 
distribution of Vero rKSHV.219 cells. 
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Figure 13. U0126 does not induce G0/1 cell cycle arrest in Vero rKSHV.219 cells. (A, B) Cell 
cycle analysis of U0126-treated and non-treated Vero rKSHV.219 cells. Briefly, Vero rKSHV.219 
cells were incubated with U0126 at a finl concentration of 25µM one hour prior to reactivation using 
baculovirus (BV) Orf50/RTA. 48 hours after induction, cells were BrdU pulsed for 45 min by adding 
BrdU to a final concentration of 10 µM. Subsequently, cells were paraformaldehyde fixed, 
permeabilized, and labeled with a primary BrdU-specific antibody and a secondary Cy5-conjugated 
antibody. Finally, cells were resuspended in PBS containing propidium iodide (PI) and flow 
cytometric analysis was performed. A total of 105 cells were measured in each sample by using a 
BD FACSCalibur. Data were analyzed using the software Windows Multiple Document Interface for 
Flow Cytometry 2.8 (WinMDI2.8). (A, upper panel) Cells were analyzed for BrdU positivity (y axis, 
log scale) in relation to their DNA content (x axis, linear scale) depicted as dot plot. Cells with a 
DNA content of 2n (diploid) and negative for BrdU are shown in region R1 (i.e. cells in G0/1 
phase); cells with a DNA content of ≥2n and ≤4n (tetraploid) and which were positive for BrdU are 
shown in region R2 (i.e. cells in S-phase); cells with a DNA content of 4n and which were negative 
for BrdU are found in region R3 (G2/M phase). The lower panel shows the distribution of all cells 
counted (y-axis, linear scale) to individual cell cycle phases (DNA content, x-axis, linear scale). 
Control = uninduced, no inhibitor. (B) Percentage of cells in each individual cell cycle state. 
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A systematic screen of chemical compounds to identify new inhibitors of KSHV 
lytic replication. 
In order to identify novel kinase inhibitors that could interfere with the production of 
infectious virions we screened 486 chemical compounds from the core validation library of 
the biotech research company VICHEM CHEMIE (Budapest, Hungary) in a virus reactivation 
assay. The screen was conducted in Vero rKSHV.219 cells in a 96-well format. Figure 14 
shows a schematic illustration of the screening system and representative results from the 
initial screening phase. Briefly, 486 kinase inhibitors were applied individually at final 
concentrations of 10 µM and 5 µM to Vero rKSHV.219 cells. After one hour of incubation, 
the lytic replication cycle was induced using baculovirus Orf50/RTA in combination with Na-
butyrate. Culture supernatants were harvested 48 hours after induction, centrifuged, and used 
to infect HEK293 cells. The relative number of infected (i.e. green fluorescent) target 
HEK293 cells was determined after two days by measuring the overall fluorescence intensity 
in the wells using a Biotek plate reader. Diminished fluorescence intensity in comparison to 
controls (i.e. infection with supernatant of non-inhibitor-treated cells) reflected fewer rKSHV-
infected cells, suggesting that virus production had been inhibited during lytic replication in 
Vero rKSHV.219 cells in the presence of the respective compound. To exclude toxic 
compounds, reactivated and inhibitor-treated Vero rKSHV.219 cells were fixed with 
paraformaldehyde (PFA), stained with crystal (Gentiana) violet, and total absorbance was 
measured using a Biotek plate reader. Reduced absorbance in comparison to non-inhibitor 
treated controls reflected reduced cell numbers, indicating toxicity of the compound that had 
been applied to the respective well. Toxic compounds were excluded from the list of potential 
“hits” identified in the first round of the screen, but were further titrated in a second round of 
reactivation assay to identify non-toxic concentrations and analyse their effect on lytic 
replication.  
To differentiate between true inhibitors of the lytic replication cycle and inhibitors of 
virus entry, we tested compounds with inhibitory activity in a virus-entry assay. Therefore, 
target HEK293 cells were incubated with fresh inhibitors one hour prior to infection with an 
rKSHV virus preparation and the number of infected cells was determined after two days as 
described above. Figure 14 C shows representative results of the first screening round. 
Compounds 3617 and 4550 were identified as “hits” in reactivation assay and were subjected 
to further analysis and titrations (Fig. 14 D, not shown for 3617). Compound 5802 was toxic 
to the cells when applied at a final concentration of 10 or 5 µM, and was therefore further 
titrated in a second screening round (data not shown). 
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Figure 14. Schematic illustration of the screen system and primary results.  
(A, B) Overview of the reactivation assay and the virus-entry assay. (A) Vero rKSHV.219 cells were 
incubated with individual kinase inhibitors at two different concentrations one hour prior to reactivation 
using baculovirus Orf50/RTA in combination with Na-butyrate (1mM). Culture supernatants were 
harvested after 48 hours, centrifuged, and used to infect 293 cells. Two days after infection, the overall 
fluorescence intensity was measured in each well using a Biotek plate reader. Inhibitor-treated and 
reactivated Vero rKSHV.219 cells were fixed, stained with crystal violet, and absorbance at 590 nm was 
measured using a Biotek plate reader. Inhibitors of lytic viral replication reduce the number of infectious 
virus in culture supernatant, which is reflected by reduced numbers of infected target 293 cells i.e. 
reduced fluorescence intensity in the respective wells. Toxic compounds induce increased cell death of 
Vero rKSHV.219 cells, which is reflected by reduced absorbance in the respective well. All experiments 
were carried out in triplicates. (B) Potential inhibitors of KSHV lytic replication identified in the 
reactivation assay (“hits”) were analysed in a virus-entry assay for their effect on virus infectivity. 
Therefore, 293 cells were incubated with fresh inhibitors one hour prior to infection with an rKSHV virus 
preparation. The overall fluorescence intensity in each well was measured 48 hours postinfection using 
a Biotek plate reader. Reduced fluorescence intensity indicated that the respective compound reduced 
virus infectivity and was therefore classified as virus entry inhibitor. All experiments were carried out in 
triplicates. (C) Histogram of representative results from the reactivation assay. The reference value for 
all fluorescence intensities is represented by the fluorescence intensity of the DMSO control (i.e. solvent 
of all compounds). The arrows indicate the signals and respective inhibitors that showed significantly 
reduced fluorescence intensity in comparison to DMSO control. Compound 5802 had toxic effects on 
Vero rKSHV.219 cells during reactivation assay and could therefore not be classified as a “hit”. (D) 
Further analysis of compound 4550. Entry assay shows that the inhibitor had no effect on KSHV 
infectivity (upper right panel). Therefore, we classified compound 4550 as a lytic cycle inhibitor. Further 
titration of 4550 in the reactivation assay demonstrated that the inhibitor reduced virus production during 
lytic replication in a dose-dependent manner with an IC50 ≤ 1µM (left panel), while the inhibitor only 
showed some toxicity to the cells when applied at a concentration of 10 µM (lower right panel). Bars 
represent average fluorescence (or absorbance, respectively) and standard deviations of one 
experiment carried out in triplicates. Similar results were obtained for compound 3617 (data not shown). 
D 
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After setting up the system and protocol for the screen with 20 initial compounds, 
screening of all further compounds as well as all entry assays and further titrations were 
carried out by a technician. In summary, we identified 13 compounds that appeared to 
specifically target the production of new infectious virus. These are currently being 
investigated for their cellular and viral targets. 
 
Table 4. Total number of inhibitors of the KSHV lytic replication cycle and virus entry identified 
by systematic screening. 
Total number of compounds Inhibitors of KSHV lytic replication Inhibitors of virus entry 
486 13 33 
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3.2 Results II: Essential Role of Kaposi Sarcoma Herpesvirus K1 
Protein During the Progression of the Lytic Replication Cycle. 
 
SiRNA-mediated depletion of K1 reduces the yield of new infectious virions.  
Transient transfection of several early lytic proteins of KSHV has been reported to 
induce the activation of signalling pathways. Among them are transmembrane proteins such 
as the viral G-protein coupled receptor (vGPCR, encoded by orf74), the K15 and the K1 
protein. Kinases and transcription factors activated by vGPCR include MAPK (ERK, JNK, 
and p38), Akt, NF-kB, NFAT, CREB, AP-1, and HIF-1α (Sodhi et al. 2000; Couty et al. 
2001; Shepard et al. 2001; Cannon et al. 2003; Liu et al. 2004) (see also Fig. 4). K15 induces 
ERK and JNK signalling as well as activation of the transcription factors NF-kB and AP-1 in 
HEK293 cells (Brinkmann et al. 2003; Brinkmann et al. 2007). The K1 protein interacts 
among others (see also Fig. 4) with PLC-γ2, and the p85 subunit of PI3K, and induces 
activation of Akt signalling and the transcription factors NFAT, Ap-1 and NF-kB in B-cells 
and endothelial cells (Lagunoff et al. 1999; Prakash et al. 2002; Tomlinson and Damania 
2004; Wang et al. 2004b; Lee et al. 2005). Activation of signalling pathways has further been 
shown for viral homologues of cellular cytokines including the viral interleukin 6 (vIL-6, 
encoded by orf K2), which activates STAT3, JAK1 and the Ras-MAPK pathway (Molden et 
al. 1997; Osborne et al. 1999; Hideshima et al. 2000), and the viral CC-chemokines 1 and 2 
(vCCL-1/K6 and vCCL-2/K4), that are capable to induce Akt and MAPK signalling in 
endothelial cells (Choi and Nicholas 2008) (see also Table 1).  
To test whether any of these candidate proteins contribute to ERK and Akt activation 
during the early phase of KSHV lytic cycle, I designed at least two distinct siRNAs for each 
of these genes. I also included two siRNAs each for the viral serine/threonine protein kinase 
(vPK) encoded by Orf36 (Park et al. 2000) and for viral OX2 (vOX2). Orf36 activates JNK 
MAPK signalling, and was shown to have an important function in KSHV DNA replication 
and progression of lytic cycle (Hamza et al. 2004; Izumiya et al. 2007). vOX2 is expressed 
from the same transcript as vGPCR and has been shown to possess immunomodulatory 
functions (Foster-Cuevas et al. 2004; Rezaee et al. 2005). These siRNAs were then 
transfected into Vero rKSHV.219 cells, induction of lytic replication was initiated eight hours 
after transfection, cells were lysed 48 h after induction of lytic cycle, and supernatants were 
collected.  
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Immunoblots of cellular lysates were performed with antibodies to phospho-p42/44 and 
phospho-Akt, and supernatants were transfered to HEK293 cells to measure infectivity. None 
of the siRNAs tested showed a reproducible and significant inhibition of phospho ERK or 
phospho Akt levels. Results from one experiment are shown in Figure 15 B.  
Only siRNA-mediated silencing of K1 resulted in a more than 50 % reduction of 
infected HEK293 cells in all experiments. Representative results of one experiment are shown 
in Figure 15 A (K15 siRNA was not included in this experiment). Downregulation of Orf36 
also consistently and strongly reduced the number of GFP-positive HEK293 cells, while 
transfection of non-target siRNA did not lower the yield of infectious virions during lytic 
cycle in Vero rKSHV.219 cells (Fig. 15 A). In most experiments I also observed reduced 
numbers of rKSHV-infected HEK293 cells in infectivity assay after RNA interference with 
other early lytic transcripts of KSHV, e.g. the viral CC-chemokines and vGPCR. This was in 
line with the findings by others, who showed that vCCL-1, vCCL-2 and vGPCR contribute to 
the progression of the lytic replication cycle (Choi and Nicholas 2008; Bottero et al. 2009; 
Sandford et al. 2009). However, downregulation of K1 expression had the most consistent 
effect on KSHV reactivation. I repeated the siRNA silencing experiments in EAhy.926 
endothelial cells that had been stably infected with rKSHV.219 (see Materials and Methods) 
and obtained similar results (Figure 15 C). Again, the highest and most consistent reduction in 
virus yield was seen, if expression of Orf36 (i.e. positive control) or of K1 was downregulated 
by siRNA interference (Fig. 15 C). These observations indicated that the early-lytic protein 
K1 may contribute significantly to successful KSHV lytic replication in endothelial cells. 
 
Figure 15. SiRNA-mediated downregulation of early-lytic protein expression reduces 
production of new infectious virions. Vero rKSHV.219 cells or EAhy rKSHV cells were 
transfected with individual siRNAs targeting the KSHV early-lytic proteins K1, K2 (vIL-6), K4 
(vCCL-2), K6 (vCCL-1), K14 (vOX2), Orf36 (vPK) and Orf74 (vGPCR) or K1, Orf36 and Orf74, 
respectively. Non-target siRNA (N) was used for negative control. Six to eight hours after
transfection, the lytic cycle was induced using baculovirus (BV) Orf50/RTA in combination with Na-
butyrate (NaB). Culture supernatants were collected 48 h after reactivation from latency, 
centrifuged, and used to infect HEK293 cells. After two days, the number of infected (i.e. green 
fluorescent) target HEK293 cells was counted using fluorescence microscopy, and virus titers 
(infectious units (IU)/ml) were calculated. (A) Infectivity assay with culture supernatant of siRNA-
transfected and reactivated Vero rKSHV.219 or (C) Eahy rKSHV cells. Experiments were carried 
out independently six times in Vero rKSHV.219 cells, and four times in EAhy rKSHV cells, each in 
triplicate. Bars represent the average and standard deviation from one experiment. (B) siRNA-
transfected and reactivated Vero rKSHV.219 cells were lysed 48 h after induction of the lytic 
replication cycle and analysed by Western blotting with phosphospecific antibodies to Akt and 
p42/44 (ERK2/1). Afterwards, the membranes were stripped and reprobed with antibodies 
detecting total levels of Akt1 and ERK2. For each KSHV protein targeted, siRNAs were transfected 
in the following order (from left to right): siRNA1, siRNA2, combination of siRNA1 and 2.  
U, uninduced; I, induced; L, lipofectamine.  
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Generation of a KSHV mutant with a deletion of orf K1.  
In order to corroborate the role of K1 during the lytic replication cycle of KSHV and to 
the activation of the ERK and Akt signalling pathway, I constructed a K1 deletion mutant in a 
recombinant KSHV genome cloned into a bacterial artificial chromosome (BAC36, Zhou et 
al. 2002). To delete the complete orf K1 (i.e. nt 105 – 974, Russo et al. 1996) from the BAC36 
genome, I induced homologous recombination with a bacterial double selection cassette, rpsL-
kan/neo, flanked by sequences homologous to 60 nt upstream of the K1 start codon and 63 nt 
downstream of the stop codon of orf K1 at two ends, in E. coli DH10B-cells carrying BAC36 
wt (Figure 16; see Materials and Methods). Transformants were selected by kanamycin 
resistance. DNA was isolated from kanamycin-resistant colonies, checked by colony PCR for 
integration of the rpsL-kan/neo cassette, digested with restriction enzymes, and analysed on 
0.4% agarose gels. EcoRI, KpnI, NotI, and SalI digestion of episomal DNA from mutant 
clones showed that they had all the restriction bands observed in wildtype BAC36 (Fig. 16 B 
and data not shown). To confirm the correct insertion of the rpsL-kan/neo cassette, I 
sequenced the 3’-transitional region by placing one primer (forward) in the rpsL-kan/neo 
cassette and a second primer (reverse) in the flanking KSHV genomic region on the right. 
Nucleotide alignment of the sequences of BAC36 ΔK1 clones to the predicted sequence in the 
transitional region showed that the rpsL-kan/neo counter selection cassette was inserted at its 
correct target position (Fig. 16 A). To verify the integrity of the rest of the KSHV genome, 
one BAC36 ΔK1 clone (bacterial clone 6) was completely sequenced using 454 technology 
(not shown). 
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A 
B 
Figure 16. Schematic illustration of the generation of a KSHV mutant with a deletion of the 
K1 gene. (A) BAC36ΔK1 was generated by ET-cloning. The K1 gene was replaced with a 
Kan/Neo cassette (rpsL-neo) PCR product flanking sequences from outside the area to be 
knocked out by homologous recombination in E. coli strain DH10B, which had been previously 
transformed with wildtype BAC36. The correct insertion of the rpsL-neo cassette was verified by 
sequencing of a PCR fragment spanning the 3’ end of the rpsL-neo cassette and the flanking 
KSHV sequence, as well as by complete sequencing of one BAC clone (ΔK1 clone 6) using 454 
technology. Gaps indicate missing nucleotides. (B) EcoRI-digested BAC DNA from bacterial 
colonies was resolved on a 0.4% agarose gel. All restriction bands present in the wild type BAC36 
were also present in the K1-deletion mutant clones.  
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K1 promotes KSHV lytic replication in BAC36-infected HEK293 cells and 
contributes to lytic cycle-induced activation of ERK and Akt signalling. 
BAC36 ΔK1 DNA from two independent clones (bacterial clone 6 and 21), verified by 
restriction profiling and PCR, was transfected into HEK293 cells, which were then subjected 
to hygromycin selection. Of each KSHV ΔK1 DNA, 15 to 25 individual GFP-expressing cell 
clones were isolated, and amplified under hygromycin selection.  
 
 
Figure 17. Production of infectious virions is reduced in HEK293 BAC36 ΔK1 cells. (A) Lytic 
replication was induced in BAC36 wt-infected and BAC36 ΔK1-infected HEK293 cells in parallel 
using baculovirus Orf50/RTA in combination with Na-butyrate [1mM]. Three days after reactivation, 
culture supernatants were harvested, centrifuged, and used to infect HEK293 cells. After two days, 
the number of infected target HEK293 cells was counted using fluorescence microscopy, and virus 
titers were calculated. B: Average virus titers of BAC36 wt and BAC36 ΔK1 clones depicted in Fig. 
17 A were calculated. Two individual experiments were carried out, each in triplicate. Results 
represent averages and standard deviations from one experiment.  
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I examined ten cell lines derived from BAC36 ΔK1 clone 21 and two cell lines derived 
from BAC36 ΔK1 clone 6 for production of infectious virus and activation of ERK and Akt 
signalling after induction of lytic replication using baculovirus Orf50/RTA in combination 
with Na-butyrate. In parallel, I generated and analysed ten individual HEK293 cell lines 
harbouring the BAC36 wt genome. In all cell lines, KSHV lytic replication was induced at 
low cell passage number (between p4 and p10), and using the same batches of baculovirus 
Orf50/RTA and Na-butyrate. Cells were lysed at 5, 12, 24, 48, and 72 h.p.i., and protein 
extracts were immunoblotted with anti-phospho p42/44 and anti-phospho Akt antibody. 
Supernatants were collected, and used to infect HEK293 cells to determine the yield of 
infectious progeny virus. Production of infectious virus was clearly reduced in all BAC36 
ΔK1 clones (Fig. 17). Virus titers in BAC36 ΔK1 culture supernatant ranged in all cell lines 
from 23 infectious units (IU)/ml (clone 21_2) to 273 IU/ml (clone 6_3) with an average 
number of 144 IU/ml, compared to titers of 760 IU/ml (clone 2) to 1816 IU/ml (clone 10 B) 
for BAC36 wt culture supernatant (average 1148 IU/ml). Therefore, in spite of marked 
variations in the yield of infectious progeny virus among individual BAC36 wt or BAC36 
ΔK1 lines, the average number of infectious virions produced from BAC36 ΔK1 lines was 
eight-times lower than the average number produced from BAC36 wt lines (Fig. 17 B). These 
results confirm the importance of the K1 protein for successful KSHV lytic replication.  
 
KSHV lytic gene expression is reduced in K1-deficient HEK293 BAC36 cells.  
I next investigated the expression of KSHV lytic genes in KSHV wt and ΔK1 cell lines. 
I induced KSHV reactivation in three individual clones of each BAC36 wt and BAC36 ΔK1, 
and measured the accumulation of the viral proteins K8/-bZIP and Orf59. The early-lytic 
protein K8/-bZIP is the proposed homologue of Epstein-Barr virus (EBV) Zta, and it has been 
suggested that K8/K-bZIP modulates RTA function (Izumiya et al. 2003; Kato-Noah et al. 
2007). Orf59 expresses the KSHV homologue of other herpesvirus polymerase accessory 
proteins, and is expressed with delayed early kinetics (Chan et al. 1998). Both K8/K-bZIP and 
Orf59 are nuclear proteins. Additionally, I measured the expression of K1, and analysed the 
correlation of K1 expression to the expression of K8 and Orf59. 72 h after induction of the 
lytic cycle, cells were fixed in 4% paraformaldehyde (PFA), permeabilized with 0.2% Triton 
X-100, and stained with either anti-Orf59 antibody or anti-K8 antibody alone, or double-
stained with anti-K8 and anti-K1 antibody. Cells were then analysed by fluorescent 
microscopy.  
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Figure 18. K8 expression was not detected by immunofluorescence assay in BAC36 ΔK1-
infected HEK293 cell lines. (A) Three individual lines of each BAC36 wt- (two top rows) and 
BAC36 ΔK1-infected (bottom row) HEK293 cells were stained for K8 protein expression 72 h after 
reactivation from latency. DNA was stained by DAPI. Among BAC36 wt clones, ten to fifteen 
percent of the cells expressed K8 three days after induction of lytic cycle, while no K8 expression 
was detected in cells that were infected with K1-deletion mutant. Pictures show representative 
results from one wildtype-infected line and one K1-deletion mutant-infected line. (B) Seven to ten 
percent of K8-expressing BAC36 wt-infected HEK293 cells also show K1 expression. BAC36 wt-
infected HEK293 cells were double stained for K8 and K1 protein expression at 72 h after
reactivation from latency. DNA was stained by DAPI. Pictures show representative results from 
BAC36 wt clone 8 G-infected HEK293 cells. 
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A 
3.2 Results II 
 89
For BAC36 wt, 15 ± 3 % of the cells of each clone (10 B, 8 G, and 8) expressed K8 
after activation of the lytic cycle (Fig. 18 A, B). Similar percentages were obtained for Orf59 
expressing cells (data not shown). Five to ten percent of the K8-expressing cells also 
expressed the K1 protein (Fig. 18 B). As expected, K1 was not expressed in HEK293 BAC36 
ΔK1 cells, nor did I detect K8 or Orf59 expression in any of the three K1-deletion mutant 
clones analysed (21_7, 21_9, 6_2) (Fig. 18 A and data not shown).  
In addition I measured the level of K8/bZIP transcripts by quantitative real-time PCR in 
four independent BAC36 wt lines and five independent K1-deletion mutant lines after 
reactivation from latency. I further determined the transcript levels of the KSHV chemokines 
vIL-6 and vCCL-1 in the same BAC36 wt and BAC36 ΔK1 lines. GAPDH was amplified in 
parallel as an internal control and the expression of RTA in the same BAC36 wt and ΔK1 
clones was monitored by immunoblotting. For HEK293 BAC36 wt lines, the average cycle 
threshold (CT) value for K1 was in the range of 23 to 24 (Fig. 7 A), indicating that 72 hours 
post reactivation of KSHV from latency K1 is highly expressed in all BAC36 wt clones. In 
contrast, the fluorescent signal for K1 detection in samples of induced HEK293 BAC36 ΔK1 
lines did not exceed background levels within 40 qPCR cycles, confirming the absence of K1 
expression in all HEK293 BAC36 ΔK1 clones (Fig. 19 A). For K8/bZIP, the CT value was in 
the range of 20 to 22 for BAC36 wt lines with an average CT value of 21, and varied from 27 
(clone 21_9) to greater than 40 (clone 6_3) for BAC36 ΔK1 (Fig. 19 B). To calculate the 
average CT value for K8 for BAC36 ΔK1, I set the CT value for clone 6_3 to 40, and thereby 
obtained an average CT value of 31. Thus, 72 hours after induction of the KSHV lytic cycle, 
expression of K8/bZIP in BAC 36 ΔK1 lines is approx. 500 to 1000 fold lower than in 
BAC36 wt lines. These expression levels are probably too low to be detected by 
immunofluorescent staining.  
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Expression of vIL-6 and vCCL-1 after induction of the lytic cycle was constitutively 
high in all KSHV wt lines (CT values of 17 to 22) but varies markedly in the four KSHV ΔK1 
lines (Fig. 19 B). The average CT value for vIL-6 was 32 for BAC36 ΔK1 and 21 for BAC36 
wt lines equivalent to an approx. 500 to 1000 fold lower expression of vIL-6 in ΔK1 cell 
lines, while the average CT value for vCCL-1 was 25 for the K1-deletion mutant and 18 for 
the wild type-virus (approx. 100 fold difference in expression).  
Figure 19 C shows the RTA expression for two HEK293 BAC36 wt lines and two 
HEK293 BAC36 ΔK1 lines 72 h after induction of the KSHV lytic cycle. Expression of RTA 
is reduced in both HEK293 BAC36 ΔK1 clones compared to the two KSHV wt lines (Fig 19 
C). Similar results were obtained, when cells were lysed two days after induction (data not 
shown). As RTA was not expressed in uninfected HEK293 cells, which were treated with 
baculovirus Orf50/RTA and Na-butyrate in parallel (Fig. 19 C), the levels of RTA seen in this 
experiment reflect RTA expression from the KSHV genome and not the baculovirus RTA 
vector. Therefore, expression of the early-lytic proteins K8/bZIP, vIL-6, and vCCL-1, as well 
as of the immediate-early protein RTA is reduced in HEK293 BAC36 ΔK1 compared to 
BAC36 wt cells. These findings suggest the expression of early lytic genes is reduced in the 
absence of K1 expression and that K1 promotes KSHV early lytic gene expression.  
Figure 19. Expression of KSHV early lytic genes is reduced in HEK293 BAC36 ΔK1 cells. 
Lytic replication was induced in BAC36 wt- and BAC36 ΔK1-infected HEK293 cells. 72 h after
reactivation, total RNA was isolated, treated with DNase I, reverse transcriped, and subjected to 
real-time quantitative PCR with specific primers and Taqman probes to early-lytic proteins. GAPDH 
was used as internal control, and was strongly detected in all samples. Each reaction was done in 
duplicate, and each bar represents the average and standard deviation of one experiment. CT = 
cycle threshold. (A) K1 is highly expressed in BAC36 wt-infected cells. cDNA from K1-transfected 
HEK293 cells was used as a positive control. As expected, K1 expression was not detected in 
BAC36 ΔK1-infected HEK293 cells at 72 h after induction of lytic cycle up to cycle 40 of the real-
time quantitative PCR run. (B) K8, vIL-6, and vCCL-1 protein expression is reduced in HEK293 
BAC36 ΔK1 cell lines. Ct values of K8, vIL-6, and vCCL-1 were compared among individual BAC36 
wt lines and BAC36 ΔK1 lines. (C) RTA expression is reduced in HEK293 BAC36 ΔK1 cell lines. 
Two independent lines of each BAC36 wt-infected and BAC36 ΔK1-infected HEK293 cells were 
reactivated using baculovirus (BV) Orf50/RTA in combination with Na-butyrate (NaB). 48 h after 
induction, cells were lysed. Proteins were separated by SDS-PAGE, blotted to nitrocellulose, and 
probed with antibodies to Orf50/RTA and antibodies to β-actin. Expression of RTA was not 
detected in uninfected HEK293 cells after treatment with BV Orf50/RTA in combination with NaB in 
parallel, indicating that the RTA detected by Western blotting reflects RTA expressed from the 
KSHV genome and not from the baculovirus RTA vector. 
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Figure 20. Reduced activation of signalling pathways in K1-deletion mutants. (A) Lytic cycle-
induced activation of ERK is reduced in BAC36 ΔK1-infected HEK293 cell lines. Akt activation, 
although constitutively high in many K1-deletion mutant lines, does not increase during lytic 
replication. BAC36 wt-infected and BAC36 ΔK1-infected HEK293 cells were reactivated using 
baculovirus (BV) Orf50/RTA in combination with Na-butyrate (NaB). 5, 12, 24, 48, and 72 h after 
induction (h.p.i.), cells were lysed. Proteins were separated by SDS-PAGE, blotted to 
nitrocellulose, probed with phosphospecific antibodies to Akt or ERK2/1 (p42/44), stripped and 
reprobed with antibodies to total Akt1 or total ERK2 levels. (B) Expression of the late lytic 
glycoprotein K8.1 in BAC36 wt 8 G-infected HEK293 cells after induction of lytic replication using 
BV Orf50/RTA in combination with NaB. (C) BV Orf50/RTA and Na-butyrate do not induce ERK or 
Akt signalling in uninfected (KSHV-negative) parental HEK293 cells. Uninfected HEK293 cells were 
treated with BV Orf50/RTA in combination with NaB, cells were lysed in parallel to BAC36-infected 
HEK293 cells, and analysed by Western blot analysis for activation of ERK and Akt. (C) K1 does 
not directly induce ERK activity. HEK293 cells were transfected with pcDNA3.1-K1/myc/his, 
pcDNA4-vGPCR/myc/his, pCMV5-Tpl2/myc, or pcDNA3.1. 48 h after transfection, cells were lysed 
and assayed for ERK activation by Western blotting with phosphospecific antibodies to ERK2/1 
(p42/44). Protein expression of K1, vGPCR, and Tpl2 was analysed using anti-myc antibody. 
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Having shown that the absence of K1 leads to an inefficient activation of the lytic 
replication cycle, I investigated the activation of the ERK and Akt pathways in the absence of 
K1. I observed activation of both ERK2 and Akt kinase in all BAC36 wt-infected HEK293 
cell lines similar to Vero rKSHV.219 cells (Fig. 20 A and data not shown), although ERK2 
activation occurred somewhat later in HEK293 BAC36 wt cells as activation was not detected 
before 24 h.p.i., and both ERK and Akt activation were prolonged up to 72 after reactivation, 
the last time point measured in our experiments (Fig. 20 A). I also did not detect expression of 
the late lytic protein K8.1 in BAC36 wt cell lines nor infectious virions in culture supernatant 
before 48 h after reactivation from latency (Fig. 20 B and data not shown), while first viral 
progeny appeared around 24 h.p.i. in culture supernatant of Vero rKSHV cells (data not 
shown). Baculovirus Orf50/RTA and Na-butyrate alone did not induce ERK2 or Akt 
signalling in the cells, as phospho p42/44 ERK was not found, and pAkt did not increase in 
non-infected HEK293 cells incubated with the induction cocktail (Fig. 20 C). Interestingly, 
ERK2 activation was strongly reduced in all K1 deletion mutants, and activation of Akt, 
although constitutively high in the majority of HEK293 BAC36 ΔK1 clones, did not increase 
after induction of KSHV lytic cycle (Fig. 20 A and data not shown).  
While this result suggests that the presence of K1 is required for the activation of ERK 
and Akt in KSHV-infected cells, K1 does not appear to activate ERK directly. Transfection of 
a K1 expression vector did not result in an increased ERK phosphorylation in HEK293 cells, 
whereas transfection of vGPCR did (Fig. 20 D). From these results I conclude that K1 is 
required at an early point in the lytic replication cycle which precedes the activation of the 
ERK and Akt pathways. 
 
Differential regulation of cellular gene expression in HEK293 BAC36 wt and 
HEK293 BAC36 ΔK1 cell lines. 
In order to explore the cellular targets of K1 signalling, I performed high-density (HD) 
DNA microarrays (Agilent Whole Human Genome Oligo Microarrays) on HEK293 BAC36 
wt and HEK293 BAC36 ΔK1 lines with latently as well as with productively (lytically) 
infected cells. The Agilent microarray design is based on sources such as RefSeq, 
Goldenpath, Ensembl, Unigene and the Human Genome Build 33, and covers more than 
41.000 unique genes and transcripts which have been verified and optimized by alignment to 
the human genome assembly and by Agilent's Empirical Validation process. The lytic 
replication cycle was induced in each three individual lines of BAC36 wt- and BAC36 ΔK1-
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containing HEK293 cells using baculovirus Orf50/RTA in combination with Na-butyrate 
[1mM].  
 
 
 
Non-infected, parental HEK293 cells were exposed to the induction cocktail in parallel 
to analyse the impact of the baculovirus infection and Na-butyrate on the cellular transcription 
profile. 48 hours after induction of the lytic cycle, reactivated and non-induced cells were 
lysed for RNA extraction, and cDNA was prepared as described in Materials and Methods. 
Overall, 14 Agilent arrays were hybridized using the one-colour protocol and analysed in 
order to find genes that are differentially regulated between BAC36 wt and BAC36 ΔK1 
lines. Since K1 is a lytic gene, which is strongly induced after reactivation from latency 
(Paulose-Murphy et al. 2001; Fakhari and Dittmer 2002; Nakamura et al. 2003), I analysed 
the differential induction of cellular genes after reactivation from latency. Therefore, the data 
were clamped to a minimal intensity of 39, and each analysis pair (induced/non-induced) was 
Figure 21: Differentially regulated genes in BAC36 wildtype (wt) and BAC36 delta K1 lines 48 
h after induction of the lytic replication cycle. Each three HEK293 BAC36 wt and HEK293 
BAC36 ΔK1 cell lines were reactivated from latency using baculovirus (BV) Orf50/RTA in 
combination with Na-butyrate (NaB, 1mM). 48 h after reactivation, RNA was harvested. High density 
(HD) microarray experiments were performed as “one-colour hybridizations”. For each cRNA 
population generated from reactivated cells, we hybridized cRNA of non-induced cells in parallel. 
Additionally, we hybridized cRNA that was generated from BV Orf50/RTA and NaB-treated and non-
treated parental (KSHV-negative) HEK293 cells. Thus, 14 HD microarrays were hybridized 
altogether. After hybridization and data extraction, the whole data set was clamped to a minimal 
intensity threshold of 39, each analysis pair (induced/non-induced) was normalized by pointwise 
division, i.e. the “induced” expression values were divided by the “non-induced” values. The 
resulting ratios were grouped according to the experimental background (wt and ΔK1 lines), and 
these groups were analyzed for genes that were differentially regulated at least threefold in the 
BAC36 ΔK1 group compared to the BAC36 wt group. Depicted are manually selected probes from a 
total number of 17 probes with a fold change larger three that were separated in up- and down-
regulated profiles by k-means clustering. The profile with a label starting with ‘A_’ is not annotated 
with a Gene Symbol. Therefore, the Agilent ID is displayed instead. wt 8 grün = BAC36 wt 8 G. 
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then normalized by point-wise division, i.e. the induced expression values were divided by the 
non-induced values. By this the cell clone effect and a possible hybridization date effect on 
the cellular transcription profile should be removed. The resulting ratios were then subdivided 
into a wildtype and a K1-deletion group. For each group the median was calculated, and the 
ΔK1 value was then divided by the wt value calculating the ratio and analyzed by fold change 
analysis and t-test. 
Filtering for a fold change of larger two resulted in 171 probes, among which 17 probes 
showed a fold change of more than three. However, t-test analysis with a p-value cutoff of 
4E-4 showed no overlap with the fold change analysis, indicating a rather low significance for 
these results. Setting the p-value cutoff to 0.05 resulted in 41 genes, which are depicted in 
Table 5. Among the genes that were upregulated in the BAC36 wt group compared to the 
BAC36 ΔK1 group was a G protein-coupled receptor (GPR6, 3.6-fold upregulated), while 
genes with a lower expression in BAC36 wt lines compared to BAC36 ΔK1 lines included 
two members of the family of tripartite motif-containing (TRIM) proteins, namely TRIM15 
and TRIM10 (4-fold and 2.8-fold downregulated, respectively) and a suppressor of cytokine 
signalling (SOCS3, 3.6-fold downregulated) among others (Table 5).  
Absolute data was also analysed (i.e. the gene expression values of induced cells were 
compared without setting an intensity threshold of 39 and without normalization to the 
expression values of non-induced cells) by fold-change analysis and t-test, and thereby 273 
genes were identified with a fold-change of larger two, among which 55 genes showed a fold-
change of larger three and nine genes of larger five (data not shown). The genes identified in 
this analysis partially overlapped with those from the ratio data above, including GPR6, 
which was found to be upregulated by 4.6-fold in wt cell lines compared to K1-deletion cell 
lines (not shown).  
I further compared the non-induced experiments of ΔK1 and wt cell lines to get an 
impression on the impact of K1 deletion on latently infected cells. Filtering for a fold-change 
of ≥ three resulted in 73 genes (not shown). A p-value cutoff of 4E-4 resulted in 53 items, but 
showed no overlap with the fold change analysis (not shown). Nevertheless, a significant 
difference between the BAC36 wt and BAC36 ΔK1 group during latency seemed probable. In 
summary, I found a rather high number of genes differentially regulated between ΔK1 and wt 
cell lines. However, t-test analysis did not allow to statistically verify the fold change results 
because of high variance in the profile and the low number of experiments. 
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Table 5. Identification of differentially regulated genes between HEK293 BAC36 wt and ΔK1 lines after induction of the lytic replication cycle.a 
Identifier Gene symbol Gene name Gene expression (Ratio of Medians)b 
T-Test: 
   P-Value           BH q-Value 
NM_005284 GPR6 G protein-coupled receptor 6 3.6 0.0069 0.77 
BP871540 NA NA 3.0 0.0114 0.8 
NM_000444 PHEX phosphate regulating endopeptidase homolog, X-linked (hypophosphatemia, vitamin D resistant rickets) 2.77 0.0084 0.78 
AK002200 SMC4 structural maintenance of chromosomes 4 2.75 0.00198 0.69 
ENST00000369158 NA NA 2.61 0.0134 0.81 
NR_003003 SCARNA17 small Cajal body-specific RNA 17 2.56 0.0216 0.83 
A_32_P169383 NA NA 2.4 0.0389 0.89 
AB067523 SMYD4 SET and MYND domain containing 4 2.27 0.0293 0.86 
NM_004302 ACVR1B activin A receptor, type IB 2.25 0.0469 0.89 
BC065547 GUSBL2 glucuronidase, beta-like 2 2.22 0.0268 0.86 
AL137653 CTBP1 C-terminal binding protein 1 2.2 0.0101 0.79 
NM_013305 ST8SIA5 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 2.08 0.0131 0.80 
THC2498220 NA NA 2.08 0.0066 0.77 
NM_197941 ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 2.07 0.0082 0.78 
THC2685727 NA NA 2.01 0.0399 0.89 
A_24_P565503 NA NA 2.01 0.0478 0.89 
NM_007021 C10orf10c chromosome 10 open reading frame 10 0.20 0.0019 0.69 
NM_022454 SOX17 SRY (sex determining region Y)-box 17 0.23 0.0296 0.86 
NM_014624 S100A6 S100 calcium binding protein A6 0.24 0.0010 0.69 
NM_033229 TRIM15 tripartite motif-containing 15 0.25 0.0040 0.72 
NM_003955 SOCS3 suppressor of cytokine signaling 3 0.28 0.0088 0.78 
NM_004510 SP110 SP110 nuclear body protein 0.32 0.0147 0.82 
NM_007021 C10orf10c chromosome 10 open reading frame 10 0.33 0.0016 0.69 
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Identifier Gene symbol Gene name Gene expression (Ratio of Medians)b 
T-Test: 
   P-Value           BH q-Value 
NM_079422 MYL1 myosin, light chain 1, alkali; skeletal, fast 0.34 0.0495 0.90 
NM_052828 TRIM10 tripartite motif-containing 10 0.35 0.0085 0.78 
NM_152403 EGFLAM EGF-like, fibronectin type III and laminin G domains 0.40 0.0234 0.84 
NM_177403 RAB7B RAB7B, member RAS oncogene family 0.43 0.0260 0.86 
L33930 CD24 CD24 molecule 0.43 0.0085 0.78 
NM_000204 CFI complement factor I 0.44 0.0273 0.86 
NM_002928 RGS16 regulator of G-protein signalling 16 0.45 0.0028 0.72 
NM_174936 PCSK9 proprotein convertase subtilisin/kexin type 9 0.46 0.0434 0.89 
NM_015085 GARNL4 GTPase activating Rap/RanGAP domain-like 4 0.47 0.0009 0.69 
NM_001037582 SCD5 stearoyl-CoA desaturase 5 0.48 0.0406 0.89 
NM_001012984 LOC388284 hypothetical gene supported by BC032064; BC041612 0.48 0.0470 0.89 
NM_002318 LOXL2 lysyl oxidase-like 2 0.48 0.0375 0.88 
NM_005756 GPR64 G protein-coupled receptor 64 0.48 0.0420 0.89 
NM_000204 CFI complement factor I 0.49 0.0156 0.82 
THC2586092 NA NA 0.49 0.0329 0.87 
NM_022124 CDH23 cadherin-like 23 0.49 0.0084 0.78 
AB075837 KIAA1957 KIAA1957 0.5 0.0250 0.85 
NM_013369 DNMT3L DNA (cytosine-5-)-methyltransferase 3-like 0.5 0.0356 0.88 
a cDNA of latently infected and reactivated cells of each three individual HEK293 BAC36 wt and ΔK1 cells lines was analysed by Agilent Whole Human Genome 
Oligo Microarrays, which were performed as “one-colour hybridizations”. Gene expression values of reactivated cells were divided by the respective values of 
non-induced cells. The resulting ratios were then grouped into “wt-lines” and “K1-deletion lines”, and for each group the median expression values for all 
individual probes were calculated. The median expression values of the wt group were divided by the median expression values of the ΔK1 group.  
b The ratio of medians describes the fold expression of the respective gene in BAC36 wt cell lines in relation to BAC36 ΔK1 cell lines. Marked in red are the 
values which indicate a higher expression of the respective gene in BAC36 wt cell lines (ratio of medians >1), while values marked in green show a lower gene 
expression in the wt group compared to the K1-deletion group (ratio of medians <1). 
c The gene C10orf10 was identified by hybridization to two different oligonucleotide sequences on the microarrays. 
NA=not available.
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4 Discussion 
 
4.1 Role of MEK/ERK and PI3K/Akt signalling pathways during the KSHV 
lytic replication cycle. 
 
As obligate intracellular parasites, viruses exploit diverse cellular signalling 
machineries during infection of their host. Many viruses, including herpesviruses, have 
evolved to depend on specific modulations of signalling pathways for efficient primary 
infection and viral DNA replication (Rodems and Spector 1998; McLean and Bachenheimer 
1999; Johnson et al. 2001a; Johnson et al. 2001b; Pleschka et al. 2001; Jiang et al. 2004; 
Rahaus et al. 2006; Schumann and Dobbelstein 2006; Rahaus et al. 2007). Previous studies 
showed that PI3K signalling and MAPK (ERK, JNK, p38) pathways play an important role 
during KSHV primary infection. All three MAPK pathways modulate the expression of RTA, 
the key transactivator of KSHV lytic replication, during both primary infection and TPA-
induced reactivation from latency (Cohen et al. 2006; Pan et al. 2006; Yu et al. 2007; Xie et 
al. 2008). 
In the present study, I have shown that KSHV induces the ERK pathway at a point 
downstream of RTA expression during the early stage of lytic replication (Fig. 6, 7). As 
shown in Figs. 6 C and 19 C, activation of the ERK pathway requires the presence of the 
KSHV genome in Vero or HEK293 cells, and is therefore not the result of infection with the 
recombinant baculovirus used here to transduce Orf50/RTA. Furthermore, the ERK pathway 
was also activated after tetracycline-mediated induction of the lytic replication cycle in PEL-
cells (Fig. 7), suggesting that activation of ERK during lytic replication occurs independently 
of the infected cell type. 
Inhibition of the ERK pathway by the specific MEK inhibitor U0126, and by a second 
MEK inhibitor, PD98059, reduced late lytic protein expression (Fig. 9 A) and virus 
production in a dose-dependent manner (Fig. 9 B, C). U0126 did not affect RTA expression, 
suggesting that its inhibitory effect on late viral glycoprotein expression and virus production 
occurred downstream of RTA expression. As shown in Fig. 19 C, the RTA expression in the 
experiments shown here occurs from the KSHV genome in all cell lines used in this study, not 
from the baculovirus RTA vector, which was used at a concentration below that needed to 
express Western blot-detectable RTA. Activation of the ERK pathway was not susceptible to 
an inhibitor of the viral DNA polymerase, but to cycloheximide treatment and therefore 
occurred during the early phase of the lytic replication cycle. However, since expression of 
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K8.1 and virus production were also reduced when ERK activity was inhibited not until the 
delayed-early or late phase of the lytic replication cycle (Fig. 11), intact ERK signalling may 
be crucial also for progression and successful completion of the lytic cycle at subsequent 
phases.  
Activation of ERK pathway has been implicated in viral DNA replication and gene 
expression during productive primary infection of several herpesviruses (Johnson et al. 1999; 
Johnson et al. 2001a; Jiang et al. 2004; Xie et al. 2005; Xie et al. 2008). For example, 
chemical inhibition of ERK activity reduced viral DNA synthesis and immediate-early protein 
synthesis during permissive primary infection of the γ-herpesvirus bovine herpesvirus 4 
(BHV-4) (Jiang et al. 2004). Further analysis showed that ERK regulated the promoter 
activity of immediate-early IE-2 protein expression of BHV-4, and thereby influenced the 
expression of early-lytic proteins involved in viral DNA replication (Jiang et al. 2004). For 
human cytomegalovirus (HCMV) it was shown that U0126 inhibited increased expression of 
the early genes UL44 and UL84, which are required for viral DNA replication (Johnson et al. 
2001a). These findings suggest that regulation of viral gene expression might be a common 
feature of ERK signalling pathway during the herpesviral productive phase. ERK activity may 
promote viral DNA replication and virus production during the lytic cycle downstream of 
RTA expression by modulating the expression of lytic proteins which are involved in 
transcriptional activation and/or viral DNA replication. 
I also observed an activation of the Akt pathway during the late phase of the KSHV 
productive replication cycle (Fig. 6 A, 20 A). A specific PI3K inhibitor, LY294002, strongly 
reduced lytic cycle-induced Akt activation (Fig. 9 E, 10 B), but did not reduce lytic protein 
expression or KSHV virus production (Fig. 9 A and B, 10 B and C). On the contrary, 
inhibition of PI3K by LY294002 resulted in increased expression of RTA and K8.1 protein 
(in an inverse dose-dependent manner, Fig. 10 B) and virus production (Fig. 10 C) in the 
endothelial cell line EAhy rKSHV. Notably, a very recent study conducted by Peng et al. has 
shown that inhibition of Akt facilitates reactivation of KSHV from latency in the PEL cell 
line BC-3 and that RTA activity as well as subsequent lytic gene expression are increased by 
reducing Akt 1 activity (Peng et al. 2009). Together, these findings suggest that the PI3K-Akt 
signalling cascade may suppress KSHV productive replication at least in some cell lines (e.g. 
endothelial cells, B-cells) very early during the lytic cycle through Akt-mediated repression of 
RTA activity. However, I observed that Akt activation strongly increased during the delayed-
early or late phase of the lytic replication cycle in Vero rKSHV.219 (Fig. 6 A) and HEK293 
BAC36 wt cell lines (Fig. 20 A) and appeared to be partially dependent on viral DNA 
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replication (8 A). Since activating PI3K-Akt signalling is a strategy employed by several 
viruses to slow down apoptosis and prolong viral replication (Groskreutz et al. 2007; Ehrhardt 
and Ludwig 2009), it is conceivable that activation of the PI3K-Akt signalling cascade at the 
late stage of the viral lytic cycle may also support cell survival and/or viral egress during 
KSHV lytic infection.  
In summary, my results suggest that MEK/ERK pathway plays an important role during 
KSHV lytic cycle downstream of RTA expression, while activation of Akt may not be 
essential for successful virus production.  
The identification of novel kinase inhibitors that interfere with KSHV lytic replication 
may reveal additional kinases, substrates and/or signalling pathways targeted during the viral 
productive cycle and may help to characterize the function of these signalling pathways in the 
KSHV life cycle. Screening of large panels of protein kinase inhibitors and their derivatives 
will aid the development of even more specific protein-kinase inhibitors.  
Independent evidence from clinical studies suggests that lytic replication plays a pivotal 
role in KS development. The presence of replicating KSHV in peripheral blood has been 
shown to be one of the strongest predictors for the development of KS (Smith et al. 1997; 
Ziegler et al. 2003). In patients with advanced AIDS, treatment with ganciclovir, a nucleoside 
analogue that blocks lytic but not latent KSHV infection, reduces the appearance of new KS 
lesions (Martin et al. 1999). Since most of these patients have carried HIV and KSHV for 
many years, the impact of ganciclovir is not attributable simply to the reduction of early 
dissemination of KSHV to target cells. Furthermore, in vitro studies demonstrated that latent 
KSHV episomes are rapidly lost from a wide variety of proliferating cells in culture, 
including spindle cells explanted directly from KS biopsies, suggesting that ongoing lytic 
replication in a small amount of cells may be required for viral persistence and, thus, for 
initiation and maintenance of KS tumours (Aluigi et al. 1996; Lebbe et al. 1997; Grundhoff 
and Ganem 2004). Several recent studies have highlighted the crucial role of PI3K and 
MAPK pathways in KSHV infection and pathogenesis. The present study further underlines 
the essential function of the MEK/ERK cascade in KSHV lytic replication. Targeting this 
pathway, e.g. by MEK inhibitors, may inhibit viral replication and prevent subsequent 
pathogenic processes such as the production of angiogenic cytokines and growth factors. 
Thus, MEK inhibitors may have several advantages in KSHV antiviral therapy. Besides 
strong and broad antiviral activity, they may further inhibit production of contributing 
pathogenic factors such as angiogenic and inflammatory cytokines, and surprisingly showed 
very little toxicity in clinical trials for use as an anticancer agent (Cohen 2002; Wong 2009). 
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Moreover, a combined targeting of viral and cellular factors that are critical for viral 
replication may alleviate the emergence of drug-resistant virus variants. 
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4.2 Role of K1 protein in the viral lytic replication cycle 
 
Several KSHV-encoded proteins, which are expressed during the early phase of viral 
lytic replication, are capable of inducing MAPK signalling pathways and/or transcription 
factors downstream of MAPK cascades. Using siRNAs to knock down expression of these 
proteins during the lytic cycle, I obtained the most consistent results with siRNAs to KSHV 
K1 in Vero rKSHV.219 and EAhy rKSHV cells. Genetic knockout of the K1 gene in a 
bacmid containing the KSHV genome confirmed the importance of K1 protein during the 
productive cycle as virus production was severely diminished in BAC36 ΔK1 cell lines 
induced with baculovirus Orf50/RTA and Na-butyrate (Fig. 17). An involvement of K1 
during KSHV lytic reactivation had previously been suggested by Lagunoff et al. (2001) who 
showed that introduction of dominant-negative K1 mutants into BCBL-1 cells, a cultured PEL 
cell line, reduces RTA-induced lytic reactivation by 80 percent at a relatively early stage, 
prior to onset of viral DNA synthesis. In this study, stimulation with TPA could overcome the 
block imposed by K1 dominant negative mutants, suggesting that K1 and TPA might activate 
similar signalling cascades, or that other pathways activated by TPA can substitute for K1-
mediated stimulation. In contrast, another study conducted by Lee et al. (2002) shows that 
TPA-induced lytic gene expression is strongly diminished when a CD8/K1-C chimera is 
expressed in BCBL-1 cells, suggesting an inhibitory role of K1 in the lytic replication cycle. 
The authors provide evidence that K1-signalling downregulates TPA-induced activation of 
AP-1, NF-κB, and Oct-1 activities, and suggest that this may confer the observed inhibitory 
effect of K1 on viral lytic protein expression.  
My results show that K1 is required for an efficient activation of the lytic cycle in 
epithelial and endothelial cell lines. In agreement with Lagunoff et al., the present findings 
suggest that K1 expression is not indispensable for lytic cycle progression as the majority of 
K1-deletion mutants produced low numbers of infectious virus after reactivation from latency 
(Fig. 17). Rather, K1 may act as a major amplifier of lytic replication. Real-time quantitative 
PCR and Western blot analysis demonstrate that expression of immediate-early and early viral 
genes, including RTA, is reduced in ΔK1 mutants (Fig. 18, 19). These findings indicate that 
K1 is important at the early or even immediate-early phase of lytic cascade. Since RTA is 
required for expression of early viral genes and initiation of viral DNA replication, I assume 
that at least part of the block in virus production and reduced expression of early viral proteins 
is due to decreased RTA expression. However, studies conducted by Bu et al. (2008) showed 
that RTA activated only eight KSHV genes in the absence of de novo protein synthesis. Direct 
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transcriptional targets included the genes PAN, orf57/MTA, orf56/Primase, K2/vIL-6, 
orf37/SOX, K14/vOX2, K9/vIRF1 and orf52 (Bu et al. 2008). These findings suggest that the 
induction of most lytic cycle genes, including K8/bZIP and the viral CC-chemokines, requires 
additional protein expression after the expression of RTA and may involve further 
transactivators. Both cellular and viral proteins could satisfy this proposed role as RTA-
cooperating factors.  
Activation of ERK was strongly reduced in K1-deletion mutants, and Akt activation, 
although constitutively high in many clones, did not further increase during progression of the 
lytic cycle (Fig. 20 A). Activation of Akt signalling by K1 has repeatedly been shown 
(Tomlinson and Damania 2004; Wang et al. 2006). However, since my results (Fig. 8 A) 
suggest that activation of the Akt pathway occurs during the late phase of the lytic replication 
cycle, while the lack of K1 affects the expression of early proteins (Fig. 19, 20), I conclude 
that the absence of an increased Akt activity is due to reduced viral replication rather than a 
lacking direct activation of Akt by K1. In contrast to Akt, K1 does not activate ERK 
signalling (Fig. 20 D). Therefore, I suggest that the lytic cycle block observed in the absence 
of K1 occurs before the ERK pathway is activated, for example by other viral proteins (e.g. 
viral cytokines) or by cellular genes induced by K1. In this context, it is interesting to note 
that I observed a reduction of vCCL-1 and vIL-6 expression in BAC36 ΔK1 lines (Fig. 19 B), 
which have been implicated in activation of ERK/MAPK pathway.  
Investigations of RTA expression profile during reactivation from latency and 
permissive de novo infection show that RTA expression is low during the immediate-early 
phase of lytic cycle but that it strongly increases during early and late phase (Paulose-Murphy 
et al. 2001; Nakamura et al. 2003; Yoo et al. 2005). Since K1 is expressed with early kinetics 
during the productive cycle, it is unlikely that K1 affects immediate-early RTA expression. I 
rather suggest that deletion of K1 inhibits increased RTA expression at subsequent stages of 
the lytic cycle. This is in accordance with the observation that RTA is not completely blocked 
in BAC36 ΔK1 mutants. Hence I conclude that K1 signalling might, directly or indirectly, 
augment RTA expression during early phase of lytic replication. It was shown that MAPK 
pathways activate the RTA promoter activity through AP-1 during primary infection and 
TPA-induced reactivation from latency (Sharma-Walia et al. 2005; Pan et al. 2006) and that 
ectopic expression of c-Jun and c-Fos, which together form the active AP-1 complex, 
activated the RTA promoter in transient transfections and promoted expression of RTA in 
PEL cells (Wang et al. 2004c). Activation of AP-1 activity may therefore provide a possible 
mechanism how K1 augments RTA expression during lytic cycle. Interestingly, AP-1 activity 
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has also been implicated in early activation of the K8 promoter (Wang et al. 2004c). I found 
the K8 gene was to be significantly reduced in K1-deletion mutants (Fig. 18 A, 19 B). Hence, 
K1-induced activation of AP-1 might be involved in activation of the K8 promoter. 
Anti-apoptotic/pro-survival mechanisms are important during KSHV lytic cycle to 
prevent premature host cell dying and thereby to ensure efficient virus replication. It was 
shown that K1 inhibits apoptosis via Akt-mediated cell survival signalling (Tomlinson and 
Damania 2004; Wang et al. 2006). However, inhibition of PI3K-Akt signalling by LY294002 
did not significantly affect viral progeny production in Vero rKSHV.219 cells (Fig. 9), and I 
did not observe increased cell death in BAC36 ΔK1 during lytic replication (not shown).  
 
 
 
 
 
Immunofluorescence in BAC36 wt cell lines showed that only about ten percent of cells 
undergoing KSHV lytic replication (indicated by expression of K8/bZIP) also express K1 
protein (Fig. 19 B). Therefore, I suggest that K1-mediated promotion of lytic replication may 
include paracrine mechanisms. Several studies show that K1-mediated signal transduction 
AP-1
RTAvIL6  vCCL1 
vGPCR K15
TRTR
K8/bZIP
K8.1
K1 homodimer
K1
Figure 22. Schematic model of K1’s function in lytic cycle progression. Intracellular signalling of 
K1 activates several cellular proteins including AP-1 transcription factor. Active AP-1 has been shown 
to induce expression of viral RTA and K8/bZIP proteins by targeting specific binding sites in their 
promoter region. These proteins in turn transactivate expression of other viral proteins such as vGPCR 
and the viral cytokines which have been shown to positively regulate KSHV lytic replication. Thus, K1 
signalling may promote progression through the lytic cycle by upregulating expression of viral proteins 
that facilitate KSHV productive replication. 
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induces numerous cellular cytokines and growth factors, including macrophage derived 
cytokine (MCD), IL-8, IL-10, VEGF, basic fibroblast growth factor (FGF-2), IL-αβ, and 
RANTES (Samaniego et al. 2001; Wang et al. 2004b; Lee et al. 2005). It has been suggested 
that K1 activates the promoter of VEGF and probably also promoters of other cytokines in an 
AP-1-dependent manner (Lagunoff et al. 2001; Wang et al. 2004b; Lee et al. 2005). 
Activation of ERK signalling cascade by K1-induced cellular cytokines might therefore 
significantly contribute to lytic gene expression and viral DNA replication. The details of the 
signalling cascade underlying the stimulatory effects of K1 in KSHV lytic cycle remain to be 
elucidated.  
I further analysed the cellular gene expression profile of BAC36 wt– and BAC36 ΔK1-
containing HEK293 cells before and after induction of the viral lytic cycle in order to identify 
genes that are differentially regulated by BAC36 wildtype and K1-deletion mutant virus. One 
of the transcripts that were most significantly and consistently upregulated in BAC36 wt-
containing cell lines compared to BAC36 K1-deletion mutant lines encoded for G protein-
coupled receptor 6 (GPR6). GPR6 belongs to a family of G protein-coupled receptors that 
also includes GPR3 and GPR12. Receptors of this family have been shown to be 
constitutively active, stimulate cyclic adenosine monophosphate (cAMP) production via Gαs-
protein activation and activate intracellular Ca2+ mobilization (Eggerickx et al. 1995; 
Uhlenbrock et al. 2002; Ignatov et al. 2003). Although constitutive activity of these receptors 
has been known for more than a decade, their physiological roles are just beginning to be 
identified. All three GPR6, GPR3 and GPR12 have been implicated in cAMP-mediated 
neurite outgrowth (Tanaka et al. 2007). Expression of GPR3 and GPR12 in ovary is 
responsible for maintaining high cAMP concentrations required for meiotic arrest in 
mammalian and rodent oocytes (Mehlmann et al. 2004; Freudzon et al. 2005; Hinckley et al. 
2005; Mehlmann 2005). Thus, promotion of cAMP-mediated signalling may be an important 
function of these receptors. cAMP stimulates serine-threonine protein kinase A (PKA), also 
referred to as cAMP-dependent protein kinase, which in turn activates the transcription factor 
CREB (cAMP response element binding) in the nucleus. Activated CREB then binds to 
cAMP response elements (CRE) in the DNA. Studies performed by Chang et al. have shown 
that activation of cAMP signalling with a cell permeable cAMP analogue or a cAMP inducer 
activated KSHV lytic gene expression in PEL cells. Furthermore, overexpression of the PKA 
catalytic subunit upregulated RTA gene expression, enhanced activity of the RTA promoter 
and posttranslationlly promoted the trans-activating capacity of RTA for its own promoter and 
heterologous lytic promoters (e.g., the viral PAN gene) (Chang et al. 2005). Additionally, it 
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was shown that RTA binds to CREB-binding protein (CBP) (Gwack et al. 2001). CBP acts as 
a co-activator of CREB, and evidence suggests that binding of RTA to CBP activates RTA-
mediated viral transcription (Gwack et al. 2001). Increased cAMP levels via K1-mediated 
upregulation of GPR6 expression may therefore facilitate KSHV lytic replication. 
Among the cellular genes that showed a reduced expression in HEK293 BAC36 wt cell 
lines compared to BAC36 ΔK1 cell lines were TRIM15, TRIM10 and SOCS3 (4-, 2.8- and 
3.5-fold downregulated, respectively).  
Tripartite motif (TRIM) proteins comprise a family of E3 ligases with over 70 members 
implicated in a variety of cellular functions, including differentiation, apoptosis and immunity 
(Reymond et al. 2001). An increasing number of TRIM proteins have been found to display 
antiviral activities, targeting retroviruses in particular (Nisole et al. 2005; Ozato et al. 2008; 
Uchil et al. 2008). The antiviral activities affect both early and late stages of the viral life 
cycle. For example, TRIM11 and TRIM31 were demonstrated to inhibit HIV entry, while 
TRIM11 and TRIM15 reduced virus release in HEK293 cells (Uchil et al. 2008). TRIM5α 
was shown to be responsible for a species-specific post-entry restriction of N-tropic murine 
leukaemia virus (N-MLV) and HIV-1 in primate cells (Hatziioannou et al. 2004; Perron et al. 
2004; Stremlau et al. 2004; Yap et al. 2004), whereas TRIM22, also known as Staf50, has 
been shown to inhibit HIV-1 replication (Bouazzaoui et al. 2006; Barr et al. 2008). TRIM28 
restricts MLV LTR-driven transcription in murine embryonic cells (Wolf and Goff 2007; 
Wolf et al. 2008). Broad antiviral activities have further been reported for TRIM19, the 
defining component of PML bodies in the nucleus. Viruses inhibited by TRIM19 include - 
among others - influenza A virus, HIV, human cytomegalovirus and herpes simplex type 1 
(Nisole et al. 2005; Everett and Chelbi-Alix 2007). The finding that two TRIM proteins, 
including TRIM15, which has already been implicated in antiviral function (Uchil et al. 
2008), are differentially regulated between BAC36 wildtype and K1-deletion mutant lines, 
may indicate that members of this protein family also play a role in the KSHV life cycle. 
Downregulation of TRIM proteins by K1 signalling possibly facilitates certain steps in viral 
lytic replication. 
The family of suppressors of cytokine signalling (SOCS) consists of eight members 
(SOCS-1 to SOCS-7 and the cytokine-inducible SH2-containing protein (CIS)) all sharing a 
central SH2 domain and a C-terminal SOCS box (Kile and Alexander 2001). SOCS proteins 
play key roles in the negative regulation of cytokine signal transduction. Transcripts encoding 
CIS, SOCS1, SOCS2, and SOCS3 are upregulated in response to cytokine stimulation, and 
the corresponding SOCS proteins inhibit cytokine-induced signalling pathways. SOCS 
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proteins therefore form part of a classical negative feedback circuit. SOCS family members 
modulate signalling by several mechanisms, which include inactivation of JAKs, blocking 
access of the STAT proteins to receptor binding sites, and ubiquitination of signalling proteins 
and their subsequent targeting to the proteasome (Kile and Alexander 2001; Krebs and Hilton 
2001). In addition to their role as inhibitors of cytokine signalling, SOCS proteins may also 
play a role in the desensitization of cytokine signalling (Fischer et al. 2004). Mice 
conditionally deficient for Socs3 revealed SOCS3 to be a potent physiological suppressor of 
IL-6 signalling (Croker et al. 2003; Lang et al. 2003; Yasukawa et al. 2003), and it was 
demonstrated that SOCS3 desensitized murine primary bone marrow-derived macrophages to 
IL-6 signalling (Wormald et al. 2006). The present microarray data may therefore provide 
evidence for a role of K1 in continuous cytokine signalling and sensitivity of KSHV-infected 
cells to viral and cellular IL-6. Previously, it was shown that RTA and the major latent protein 
LANA interact with STAT3 and stimulate transcription of STAT-driven reporter genes 
(Gwack et al. 2002; Muromoto et al. 2006), indicating that KSHV may modify STATs 
activities to increase viral persistence and/or replication. Since it is assumed that IL-6 and 
STAT3 signalling significantly contribute to malignant progression of PEL (Yoshizaki et al. 
1989; Miles et al. 1990; Burger et al. 1994; Ishiyama et al. 1994; Aoki et al. 2003), my 
findings may further reveal a novel mechanism of K1 signalling in KSHV pathogenesis. 
However, since microarray experiments were performed in the context of the whole KSHV 
genome, gene expression profiles obtained do not allow differentiation between effects caused 
by K1 directly and subsequent K1-dependent mechanisms. Therefore, it is possible that other 
lytic proteins, which depend on K1 signalling for their expression, are responsible for the 
effects on cellular gene expression described above. 
Although analysis of the microarray data provided some promising genes for cellular 
targets of K1 signalling, further investigations are necessary to verify the differential 
regulation of genes between BAC36 wildtype and K1-deletion cell lines (e.g. using real-time 
quantitative PCR). Because of the high variations in gene expression profiles among different 
HEK293 BAC36 wt and ΔK1 lines, future experiments should include larger numbers of 
individual cell lines to improve statistical verification.  
In summary, my results suggest that the K1 protein of KSHV may stimulate viral 
protein expression and viral DNA replication during the lytic replication cycle by direct or 
indirect activation of ERK signalling cascade via autocrine and/or paracrine mechanisms. 
Furthermore, K1 signalling may stimulate the expression of cellular signalling proteins and 
interfere with antiviral processes and thereby support KSHV replication and persistence.
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